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Abstract
Some 42 million individuals worldwide are infected by the Human 
Immunodeficiency Virus (HIV) and no cure or vaccine is available. This thesis 
addresses approaches to humoral immunity to HIV-1.
In primary infection, the cytotoxic T lymphocyte (CTL) response is detected early 
and is thought to play a role in the viral decline. Neutralising antibodies (NAbs) are 
detected much later. However, non-neutralising anti-HIV-1 Env glycoprotein Abs 
(non-NAbs) are present concomitantly with the CTL response. The possible role of 
non-NAbs with complement was investigated using sequential sera and viruses 
expressing gpl20 Env (gpl20) glycoproteins amplified from blood samples from a 
cohort of newly HIV-1 infected patients. Autologous gpl20 sequences were cloned 
and expressed into a replication-competent HIV-1 backbone. The autologous Ab 
pattern was studied. In the presence o f complement, inactivation of autologous and 
heterologous HIV could be detected as early as day 9 post-onset of symptoms (POS). 
IgG were partly responsible for triggering the classical complement cascade.
In parallel, a new approach was investigated to generate a recombinant vaccine to 
HIV-1. Camelids synthesise IgG devoid of light chains. These IgG fragments (V hh) 
share the same characteristics as classical IgG but have unusually long CDR H3 
regions that can adopt more flexible conformations. The possibility of generating V hh 
fragments that mimic the neutralising CD4 binding site (CD4BS) o f HIV-1 was 
investigated. A llama was immunised with IgGl b l2  (bl2), a potent cross-neutralising 
human NAb overlapping the CD4BS o f HIV-1. The non-classical V hh repertoire was 
cloned, the resulting libraries were panned against b l2  by phage display and five 
specific anti-bl2 V hh fragments were isolated. Each o f the five fragments was tested 
in animals for the induction of an anti-HIV-1 NAb response.
These studies are discussed with reference to the control of HIV-1 infection by 
drugs and vaccines.
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Chapter 1 
Introduction to HIV
1.1 HIV history
In 1981, the Center for Disease Control reported cases of Kaposi’s sarcoma and 
Pneumocystis carinii pneumonia among young homosexual men in New York and 
California (1981). These individuals were characterised by a virtual absence of their 
CD4 T cell count, had no lymphocyte proliferative responses to soluble antigens, and 
their responses to phytoheamaglutinin (PHA) were markedly reduced (Gottlieb et al., 
1981).
• 9 -4-An RNA virus, with a Mg reverse transcriptase (RT) activity, was soon isolated 
and grown in peripheral blood mononuclear cells (PBMCs) from patients who 
developed acquired immunodeficiency syndrome (or AIDS), in France. The virus was 
called lymphadenopathy-associated virus (LAV) (Barre-Sinoussi et al., 1983). A 
similar virus, called HTLV-III, was later identified in the USA, from patients who 
presented signs o f immuno-depression and from healthy individuals (Gallo et al.,
1984). In parallel, Levy et al isolated similar viruses (that they called ARV), that 
serologically reacted with anti-LAV sera, from healthy and AIDS-stage homosexual 
men in San Francisco. The authors hypothesised that this virus could be transmitted 
sexually (Levy et al., 1984). Vilmer et al isolated LAV-viruses in two adolescent 
haemophiliac siblings and proposed that LAV could also be transmitted by transfusion 
of blood products (Vilmer et al., 1984). Cheingsong-Popov et al confirmed, in a large 
epidemiological study in the UK, that AIDS-associated viruses were exclusively 
found in homosexual men, intravenous drug users and haemophiliacs (Cheingsong- 
Popov et al., 1984).
Wain-Hobson et al discovered that LAV had the same open reading frames as the 
lentivirus meadi visna virus (M W ) and, consequently, demonstrated that LAV was a 
lentivirus and not an HTLV virus (Wain-Hobson et al., 1985). Ratner et al established 
that LAV, HTLV-III and ARV viruses were variants of the same virus (Ratner et al.,
1985), suggested earlier by Cheingsong-Popov et al (Cheingsong-Popov et al., 1984), 
and the virus was later called human immunodeficiency virus or HIV (Coffin et al., 
1986a; Coffin etal., 1986b).
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Shortly after the isolation of HIV-1 (HTLV-III/LAV/ARV), a similar T-tropic 
retrovirus was isolated from four macaques and was called simian T-lymphotropic 
virus type III or SIV (Daniel et al., 1985). Another retrovirus was also isolated from 
two individuals originally from Guinea Bissau and Cape Verde, who presented with 
AIDS-like syndromes and a low CD4 T cell count. The viruses isolated from these 
two patients could be grown in primary PBMCs, had RT activity and a similar EM 
morphology to HIV-1. They reacted serologically with a serum directed against 
SIVmac but failed to react with an anti-LAV (HIV-1) serum (Clavel et al., 1986). 
Similar viruses were found later in thirty African individuals who presented with 
AIDS syndromes. This new group of viruses was called HIV-2 (Clavel et al., 1987).
1.2 Genome organisation
All retrovirus genomes encode three polyproteins: Gag (group associated antigen), 
Pol (Polymerase) and Env (envelope). Gag is cleaved into Matrix (MA, p i 7), Capsid 
(CA, p24), spacer peptides (pi and p2), Nucleocapsid (NC, p7) and p6. The Pol 
polyprotein is generated from Gag-Pol, by a ribosomal frameshift, and is cleaved into 
the Protease (PR, plO), the Reverse Transcriptase (RT, p66 and p51) and the Integrase 
(IN, p32) by PR. The Env polyprotein is cleaved into the surface protein (SU, gpl20) 
and the transmembrane protein (TM, gp41).
HIV is a lentivirus and possesses regulatory genes: transactivator o f transcription 
(tat) and regulatory viral protein (rev). The HIV genome also encodes accessory 
proteins that are not always necessary for the successful completion o f the replication 
cycle in cell culture in vitro: Negative factor (Nef), Viral infectivity factor (Vif), Viral 
protein R (Vpr) and Viral protein U (Vpu). HIV-2 and SIV do not encode Vpu but the 
protein Vpx. The long terminal repeats (LTRs) delineate the coding sequences at the 
5’ and 3’ends. The schematic representations of HIV-1 and HIV-2 genomes are 
shown in figure 1.1.
22
HIV-1  "M
LTR gag Vif Nef
pol ■  DDLZ env LTR
Vpr Vpu
tat L J
n ........... ............
LTR gag 1 Vif Nef
pol m o o  ■ env LTR
Vpx Vpr
Figure 1.1 DNA Genomic organisation of HIV-1 and HIV-2
HIV encodes structural proteins, regulatory proteins (non-structural proteins 
that are necessary for the completion o f the replication cycle) and accessory 
proteins (non-structural proteins that are not compulsory for the completion o f 
the replication cycle in some cell lines). LTR regions are in shaded yellow, 
genes for the production o f structural proteins in blue, regulatory proteins in 
red and accessory proteins in orange. The dotted lines show the introns and the 
solid lines represent the exons. (Levy, 1998)
1.3 Classification and distribution of HIV-1 in the world
HIV-1 and HIV-2 are the two lentiviruses causing AIDS currently found in 
humans. Like other retroviruses, the RT of HIV does not contain a proof-reading 
domain and, therefore, allows nucleotide substitution, which explains the diversity o f 
the HIV genomes found all over the world. HIV-1 is classified into three groups: 
group M (for main), the group O (for outlier) and the group N (for new, non-M non- 
0). Group M represents over 95% of the HIV-1 isolates found in infected individuals 
worldwide and groups N and O are restricted to Central Africa. Group M is further 
divided into clades (or subtypes) A, B, C, D, E, F, G, H, J and K. Subtypes are 
genetically defined lineages that can be classified by phylogenetic analysis o f the 
HIV-1 M group (Gaschen et al., 2002).
Based on their Env sequences, up to 35% divergence can be observed between 
two viruses from different clades, within the group M (Gaschen et al., 2002). The 
divergence is reduced to 20% between viruses from the same clade and up to 10% 
between viruses isolated from the same individual (Perrin et al., 2003). The clades, so 
far, are geographically restricted. Subtypes A and D are predominant in Central and
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West Africa. Clade C represents the main clade in the world, being endemic in 
Southern Africa, the Horn of Africa, South America, China and India. Clade E viruses 
are found in South East Asia (UNAIDS). The clade B is predominant in Western 
Europe, Northern America, Japan, Australia and New Zealand but the number of non­
subtype B viruses within those regions of the world is increasing, as reported in 
France (Couturier et al., 2000). Most of the non-clade B viruses found in developed 
countries are detected in immigrants who contracted HIV in zones where non-B 
subtypes are endemic. However, non-B subtypes have started to be transmitted in 
Cuba, where B clades viruses used to represent the main clade (Cuevas et al., 2002). 
The clade distribution in the world is shown in figure 1.2.A.
Within the same individual, recombination of viruses from different clades can 
occur, which leads to the rise of circulating recombinant forms (CRFs). To be 
classified as such, the same recombinant has to be found in three unrelated 
individuals. Fourteen CRFs have so far been identified in the world. As an example, 
CRF01AE is now predominant in heterosexual transmissions in Thailand (Gao et al., 
1996). Without a drastic policy to stop transmission, the diversity of HIV is likely to 
become greater, which already poses a serious problem for a protective anti-HIV 
vaccine (Gaschen et al., 2002).
Between 38 and 42 million individuals are estimated to be infected with HIV, of 
whom 90% live in developing countries. HIV distribution is shown in figure I.2.B.
1.4 Origins of HIV
HIV-2 is closely related to SIVsm found naturally in sooty mangabeys Cerbocerus 
atys and probably arose from a zoonotic infection of SIVsm in humans (Hirsch et al., 
1989). HIV-1 seems to have evolved from SIVcpz found in chimpanzees Pan 
troglodytes troglodytes, that live in Central Africa, where the three groups of HIV-1 
are found and where HIV is the most diverse (Gao et al., 1999). The three groups of 
HIV-1 are thought to have arisen from three independent introductions of HIVcpz in 
humans (Gao et al., 1999). Neither chimpanzees nor sooty mangabeys seem to 
develop an AIDS-like syndrome when infected with SIVcpz and SIVsm respectively.
The common ancestor of the HIV-1 group M is estimated to date back to the first 
half of the 20th century (1931 ± 12 years), although this might not reflect the date of the 
actual zoonosis of this group (Korber et al., 2000). The timing of the ancestor of the
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Figure 1.2.A Geographic distribution of HIV clades in the world
The clade B is predominant in developed countries (USA, Western Europe, Australia, New 
Zealand and Japan). The predominant clades in developing countries are clades A and C. The 
greatest HIV diversity is found in Central Africa, where the original zoonoses are thought to 
have occurred. From the Los Alamos web site
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Figure 1.2.B Population estimated to be infected with HIV worldwide
Between 38 and 42 millions individuals are currently infected with HIV and 90%  o f HIV 
cases are reported from developing countries. From UNAIDS website
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group M confirms that the HIV epidemic was not triggered (or favoured) by a 
possible SIV contamination of oral polio vaccine preparations used in Africa in the 
late 1950’s (Berry et al., 2001; Blancou et a l, 2001; Rambaut et al., 2001). The 
introduction of the HIV-1 subtype B into the US is thought to have occurred around 
1968 (±1.4 year), around ten years before the earliest report of the infections (Robbins 
et al., 2003).
1.5 Replication cycle
The replication cycle of HIV consists of specific steps: binding of the virus onto 
the cell, entry via specific receptors allowing fusion of the viral and cellular 
membranes and release o f the virus core into the cell. The HIV RNA genome is then 
reverse transcribed into double stranded DNA that subsequently reaches the 
nucleoplasm and integrates into the host genome. The HIV genome is then treated by 
the host transcription machinery as a cellular gene. By a complex mechanism of 
alternative splicing and nuclear export, proteins and polyproteins of HIV, as well as 
intact copies of its RNA, are translocated to the cytoplasm of the cell. The cellular 
machinery translates the RNA molecules into viral proteins. The assembly of the viral 
core occurs and two copies of the RNA genome, as well as several other viral and 
cellular proteins, are encapsulated into the cores. The core and Env of HIV associate 
and the virus particle buds from the cell. The maturation of the virus is then mediated 
by PR and this results into the typical conical shape of the mature HIV core. The 
representation of the viral life cycle is shown in figure 1.3.
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Figure 1.3 Replication cycle of HIV
HIV binds to CD4 and a chemokine co-receptor, typically CCR5 or CXCR4. The binding to 
the chemokine receptor triggers conformational changes within g p l 2 0  and gp41, revealing the 
fusion peptide o f gp41 that mediates fusion between the viral and cellular membranes. The 
viral core is released into the cell, followed by uncoating that allows reverse transcription o f 
the viral genomic RNA into a double stranded DNA form. The DNA genome is then 
transported into the nucleus where it integrates into the host genome catalysed by viral 
integrase. Transcription o f  viral RNA takes place, mediated by the cellular transcriptional 
machinery. Viral RNA is alternatively spliced and the resulting viral RNA molecules are 
transported into the cytoplasm via Rev. Viral core components (yellow) are synthesised in the 
cytoplasm and the Env glycoproteins in the endoplasmic reticulum. Viral core proteins 
accumulate at the cell membrane where they encapsulate two copies o f full-length RNA and 
bud from the cell membrane. Viral protease cleaves Gag and the Env glycoproteins are 
incorporated. Mature virus particles are released and can infect new target cells
1.5.1 Entry
HIV entry is mediated by the interaction with the primary receptor CD4 
(Dalgleish et al., 1984; Klatzmann et al., 1984), which is thought to change the 
conformation of gpl20 that allows HIV to bind to a 7-Transmembrane (7-TM) protein 
that acts as a co-receptor (Alkhatib et al., 1996; Choe et al., 1996; Doranz et al., 1996; 
Dragic et al., 1996; Feng et al., 1996). The membrane of HIV then fuses with the
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cellular membrane and the viral core, containing the viral genetic material, is released 
into the cytoplasm of the cell (see sections below for more details).
1.5.2 Uncoating and reverse transcription
Once inside the cell, uncoating takes place. It is still a poorly understood 
mechanism and is likely to involve the phosphorylation of MA, interaction with 
cyclophilin A (CypA), and actions from Nef and V if (Greene and Peterlin, 2002). 
Successful uncoating generates the reverse transcription complex (RTC). The RTC 
consists of the RNA genome, tRNALys3, RT, IN, NC, Vpr, host proteins and MA 
(Fassati and Goff, 2001; Greene and Peterlin, 2002). The RTC is liberated from the 
plasma membrane and the complex interacts with actin microfilaments (Greene and 
Peterlin, 2002). Reverse transcription then occurs.
Reverse transcription is mediated by the RT, which is an RNA-dependent, DNA- 
dependent DNA polymerase in 5’ to 3’ manner. The RT of HIV-1 is constituted o f the 
heterodimer of p66 and p51. The p66 contains the RT sequence linked to the RNase H 
domain and p51 contains the RT sequence. The mechanism of reverse transcription is 
schematised in figure 1.4. Cellular tRNALys3 binds to the complementary region, 
called the primer binding site (PBS) near the 5’end of the RNA (A) and the RT 
synthesises the DNA copy of the U5 and the R regions that constitute the strong stop 
negative DNA (ssDNA) strand (B). The RNase H o f the RT degrades the 
corresponding RNA region. The first strand jump of reverse transcription then occurs 
(C) and the R region o f the DNA strong stop anneals with the R region situated at the 
3’end the RNA copy. The first jump can take place on the same RNA or on the 
second RNA copy. The strong stop acts as a primer for the polymerisation o f the rest 
of the minus DNA strand. The RNase H degrades the RNA except for two regions 
rich in purines, called the polypurine tract at the 3’end of the RNA (PPT) and the 
central PPT (cPPT). The two PPT regions then act as primers to allow the 
polymerisation o f the positive DNA strand (D). The PPT and the tRNALys3 are 
degraded by the RNase H (E). The second jump of reverse transcription occurs. The 
positive DNA strand containing the PBS anneals at the 5’end of the minus DNA 
strand and elongation o f both DNA strands is completed (F). The resulting double 
stranded DNA contains a 99 nucleotide flap situated on the positive strand of DNA 
within the cPPT.
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Figure 1.4 Reverse transcription of HIV RNA into genomic DNA
A. The binding o f  tRNA Lys3 to the Primer Binding Site (PBS) starts the reverse transcription 
catalysed by the Reverse Transcriptase (RT). The DNA minus strand from 5 ’ to 3 ’ to the R 
region is first synthesised, creating a DNA species known as the strong stop. B. The RNAse H 
domain o f the RT degrades the RNA copy o f  the nascent minus strand. C. The first jum p o f  
the reverse transcription occurs and allows the elongation o f  the minus DNA strand. D. The 
RNAse H degrades the RNA except the regions o f  the central Poly Purine tract (PPT) and the 
PPT. E. These 2 RNA regions then serve as primers for the synthesis o f  the positive strand o f 
viral DNA. F. The second jum p o f  reverse transcription occurs. The 3 ’ end o f  the positive 
DNA strand binds to the homologous PBS region at the 3 ’end o f  the negative DNA. G. The 
synthesis o f both DNA strands is completed and a 99 nucleotide DNA flap at the cPPT. The 
DNA genome o f HIV is characterised by the duplication o f  the U3 and the U5 regions, at the 
extremities o f  the genome, creating the Long Terminal Repeats (LTR), necessary for the 
integration o f  the viral DNA and the initiation o f  transcription. The brown bar represents the 
cellular tRNALys3, the blue bars the RNA, the red bars the minus DNA strand and the green 
bars the positive DNA strand
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The HIV DNA genome is bound by LTRs, where U3 and U5 regions are duplicated.
The completion of the reverse transcription generates the HIV pre-integration 
complex (PIC), which is composed of viral DNA, IN, MA, Vpr and RT (Bukrinsky et 
al., 1993b). The PIC slides towards the nucleus using the microtubule network 
(Greene and Peterlin, 2002; McDonald et al., 2002), moves through the nuclear 
envelope and the DNA genome is integrated by IN.
1.5.3 Nuclear import and integration
Unlike simple retroviruses, lentiviruses have the ability to infect non-dividing 
cells, such as macrophages and naive resting T cells, in which the integrity of the 
nuclear membrane remains intact. Moreover, the size o f the HIV-1 PIC is estimated to 
be approximately 56 nm, which is about twice the size o f the aqueous channels 
present in the nuclear envelope through which the PIC has to move to enter the 
nucleus (Cullen, 2001). The nuclear import of the PIC requires specific viral 
components, the active participation of some nuclear proteins and conformational 
changes of the PIC.
It is likely that the HIV-1 PIC enters the nucleus by several mechanisms. HIV-1 
MA has been shown to contain a highly basic region resembling a classical nuclear 
localisation signal (NLS) and could be involved in the nuclear import o f the non­
dividing PtK-1 cells (Bukrinsky et al., 1993a). However, these results have not been 
reproduced by others (Fouchier et al., 1997). IN has a nuclear targeting signal that 
allows the interaction of the PIC with cellular importin a  and importin p from the 
classical nuclear import pathway (Gallay et al., 1997). More recently, it has been 
shown that importin 7 is also involved in the nuclear import o f HIV-1 in primary 
macrophages (Fassati et al., 2003).
The central DNA flap, formed during the reverse transcription from the PPT, has 
been reported to act as a nuclear import signal (Zennou et al., 2000). Mutations in the 
cPPT inhibiting the synthesis of the DNA flap lead to the formation of linear DNA 
accumulated in the cell cytoplasm at the vicinity of the nuclear membrane.
The auxiliary HIV-1 protein Vpr is a nucleocytoplasmic shuttling protein that 
contains two nuclear import signals (Sherman et al., 2001). It interacts with 
nucleoporin hCGl, one of the components of the nuclear pore complexes (NPC) (Le 
Rouzic et al., 2002). Vpr also binds importin a and increases its affinity for the NLS 
of MA (Popov et al., 1998). Then, importin a interacts with importin p. This trimeric
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complex engages the nucleoporins and moves across the pore in a series of energy- 
dependent binding and releasing steps (Sherman and Greene, 2002). Vpr can also alter 
the integrity of the nuclear envelope by the formation of herniations, which rupture 
and permit the transit o f the PIC (de Noronha et al., 2001). Vpr also arrests infected T 
cells in the G2 phase o f the cell cycle (Jowett et al., 1995; Re et al., 1995). However, 
the importance of the role o f Vpr in vivo is still uncertain. Popov et al have shown that 
high concentrations of Vpr inhibit the PIC nuclear import and cytoplasmic lysate from 
Hela cells can rescue the nuclear import of Vpr-defective PICs in H9 cells (Popov et 
al., 1998). Vpr is not required for HIV replication in resting naive CD4 T cells but 
seems to play an important role in replication in macrophages (Sherman and Greene, 
2002). However, ypr-deleted plasmids can be successfully integrated in primary 
macrophages (Neil et al., 2001).
How Vpr, IN, MA, the DNA flap and the nuclear proteins act together in vivo is 
still unclear and the mechanisms of nuclear import could be dependent on the nature 
of the target cell.
The integration of the HIV DNA genome into the host cell chromosomal DNA is 
mediated by IN. IN catalyses the removal of the terminal dinucleotide from each 
3’end of the viral cDNA and forms an integration site by the cleavage of the 
chromosomal DNA. IN then catalyses a strand transfer reaction to link the 3’end of 
the viral DNA to the host cell DNA (Bushman et al., 1990). Host proteins are also 
required for efficient integration but their roles remain unknown (Greene and Peterlin,
2002). The integration of HIV DNA is not always successful: the DNA can circularise 
and forms 1-LTR or 2-LTR circles (Greene and Peterlin, 2002).
Schroder et al showed that the insertion o f HIV-1 does not seem to be random and 
active genes could be preferentially targeted in vivo (Schroder et al., 2002). They also 
identified hot spots of HIV integration where active genes are present. They suggested 
that integration could be promoted by increased chromatin accessibility in transcribed 
regions.
The integration of the HIV DNA genome is irreversible and creates permanent 
viral reservoirs, disseminated all over the body, which allows the generation of 
viruses that can escape suppressive treatments against HIV (see section 1. 14. 1 for 
details).
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I.5.4 Transcription
Once integrated into the host DNA, the HIV genome is treated as a cellular gene 
by the cellular transcription machinery, using the 5’LTR as a promotor. The 5’LTR of 
HIV-1 contains regulatory domains: a TATA box, three Spl domains and two NF-kB 
sites. Multiple transcription factors, such as NF-kB, bind the 5’LTR (Marcello et al., 
2004) and recruit the RNA polymerase II.
In /^/-deleted HIV genomes, transcription of HIV is initiated but elongation is 
severely impaired (Strebel, AIDS, 2003). Tat binds to the transactivation response 
region (TAR), a regulatory element situated between the positions +1 and +59 of the 
HIV RNA, downstream of the transcription elements (Feng and Holland, 1988). The 
association occurs between an arginine-rich region at the C-terminus o f Tat and a U- 
rich region at the apex of the TAR element (Strebel, 2003). This association allows 
Tat to recruit cyclin T1 to the TAR element (Wei et al., 1998). Cyclin T1 associates 
with the protein kinase CDK9 of the P-TEFb (positive transcription elongation factor 
b) complex. CDK9 phosphorylates the C-terminal domain (CTD) o f the RNA 
polymerase II (Okamoto et al., 1996; Strebel, 2003). Phosphorylation o f the RNA 
polymerase II enhances its processivity, resulting in the elongation of the transcription 
and the generation of full-length HIV RNA molecules. The association o f P-TEFb 
with the CTD could also release negative elongation factors from the RNA 
polymerase II (Garber and Jones, 1999).
Besides its indirect property o f mediating the processivity of the RNA polymerase
II, Tat has been shown to modulate chromatin remodelling (Marcello et al., 2001). 
Through specific interactions with histone acetylases such as CBP (CREB-binding 
protein), Tat promotes the acetylation of H3 and H4 histone proteins (Marcello et al., 
2004), which results in activation of transcription via the recruitment of the 
transcription machinery to the HIV promoter. In parallel, Tat itself is acetylated, 
which leads to the dissociation of Tat from the TAR element (Kieman et al., 1999), 
which could enhance the accessibility o f the cellular transcription machinery to the 
HIV promoter (Strebel, 2003).
In addition to enhancing the synthesis of full-length RNA molecules o f HIV, Tat 
was shown to repress the transcription of the major histocompatibility complex 
(MHC) class I genes (Weissman et al., 1998).
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1.5.5 Splicing and nuclear export of viral mRNAs
The HIV genome is transcribed as a single RNA molecule. Each RNA molecule is 
modified at the 5’ and the 3’ends by the addition of a CAP structure and 
polyadenylation respectively. The first molecules of RNA are totally spliced by 
cellular proteins, which leads to the generation of Nef, Rev and Tat. Tat enhances the 
synthesis o f full-length RNA molecules. Unspliced copies of RNA have to be 
exported out o f the nucleus to be incorporated into newly synthesised viral cores.
Splicing of HIV is inefficient (Cullen, 2001). Moreover, the regulatory viral 
protein Rev is a cargo transporting protein. It contains both a NLS and a nuclear 
export signal (NES). It exports unspliced RNA out of the nucleus into the cytoplasm. 
Shortly after its synthesis in the cytoplasm, Rev shuttles back into the nucleus via 
interactions between the NLS and importin P (Henderson and Percipalle, 1997). Once 
in the nucleus, the leucine-rich motif o f Rev interacts with intact copies of RNA via 
the Rev responsive element (RRE) within the env sequence (Malim et al., 1989). This 
interaction leads to the multimerisation of Rev onto the RNA (Malim and Cullen, 
1991), which masks the NLS and reveals the NES (Strebel, 2003). Rev then 
associates, in human cells, with Crml (chromosome maintenance protein 1), a protein 
that interacts with NES-containing proteins and with nuclear pore proteins (Neville et 
al., 1997). The stability o f the association between RNA-Rev and Crml is thought to 
be regulated by Ran, (a cellular GTPase) involved in providing an energy gradient for 
nuclear import and export (Strebel, 2003). The RNA-Rev-Crml-Ran complex then 
moves across the nuclear membrane. Once in the cytoplasm, Crml dissociates from 
Rev-RNA by hydrolysis o f Ran-GTP (Neville et al., 1997) and, Gag, Gag-Pol and 
intact RNA molecules are released into the cytoplasm.
1.5.6 Protein assembly
HIV-1 Env is synthesised on ribosomes as an 845-870 amino acid long precursor 
called gpl60. It is then translocated into the endoplasmic reticulum (ER), via a 
hydrophobic signal peptide situated at its N-terminus, where it is folded, oligomerised 
and glycosylated. Env is then transported to the Golgi apparatus where the 
carbohydrates moieties are modified and some are terminally sialylated (Fenouillet et 
al., 1989) and cellular furin-like proteases cleave Env into gpl20 and gp41. gpl20 and 
gp41 stay associated by non-covalent bonds and oligomerise to form trimeric spikes.
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These structures are then transported to the plasma membrane via the secretory 
pathway.
The polyprotein Gag is translated by ribosomes as a single protein. The C-terminal 
domain of CA within Gag mediates the Gag-Gag interactions, which form the 
immature core o f HIV-1. The binding of NC to two copies of viral RNA, via the \|/ 
region at the 5’end of the RNA, enhances Gag assembly (Turner and Summers, 1999). 
Vif, RT, PR and IN are incorporated into the virion. The cellular components 
tRNALys3, APOBEC3G (Cen et al., 2004) (see section 1. 12. 2) and CypA (Franke et 
al., 1994) are also incorporated into the virus particle through interactions with viral 
proteins: NC for APOBEC3G and CA for CypA. The myristoyl group present at the 
N-terminus of MA within Gag targets it to the plasma membrane in specialised 
microdomains termed lipid rafts (Scarlata and Carter, 2003).
1.5.7 Virus budding and maturation
HIV Gag polyproteins are synthesised and targeted to the plasma membrane 
where they take part in viral assembly and subsequent budding. Viral release relies on 
the late assembly domain (or L domain), which, in the case of HIV, consists of the 
PTAP motif found within the N-terminus of the protein p6Gag (Huang et al., 1995). 
The amino acid sequence o f the L domain varies between viruses (Vogt, 2000). The L 
domain motifs are functionally interchangeable between HIV and Ebola virus 
(Martin-Serrano et al., 2001) but cannot be exchanged between HIV and Murine 
Leukaemia Virus (MLV) (Martin-Serrano et al., 2004).
For efficient budding, HIV recruits the whole multivesicular bodies (MVB) 
pathway, involved in endosomal sorting and endocytosis, via the interaction between 
the PTAP motif and TsglOl (Greene and Peterlin, 2002; VerPlank et al., 2001), which 
is a part o f the ESCRT-1 complex (for the description of the complete possible 
mechanism, see von Schwedler et al., 2003). TsglOl has an E2-like domain in its N- 
terminus, found in the ubiquitination machinery (Freed, 2002; Vogt, 2000). The role 
of the ubiquitination o f Gag and the mechanism by which HIV hijacks this complex 
protein degradation machinery to its advantage is currently unclear.
Simultaneously as budding occurs (or shortly after), PR cleaves Gag into MA, 
CA, NC, p i, p2 and p6. CA adopts a conical shape, characteristic o f HIV and gpl20- 
gp41 proteins, organised in trimeric spikes, associate with the viral core via an 
interaction of MA with the cytoplasmic tail of gp41. The successful cleavage of Gag
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between CA and MA seems to be essential for new viruses to fuse with new target 
cells (Wyma et al., 2004).
Viral particles bud from lipid rafts, which are microdomains of the plasma 
membrane enriched in cholesterol and saturated lipids (Manes et al., 2003), and 
incorporate GPI-linked membrane proteins such as Thy-1, the lipid raft-specific 
ganglioside GM1 (Nguyen and Hildreth, 2000), complement regulatory proteins 
(CRPs) CD55, CD59, CD46 (Saifuddin et al., 1995), ICAM-1 and MHC class II 
(Cantin et al., 1997). Budding from lipid rafts seems to enhance the infectivity of 
HIV. It has been shown that N ef increases the synthesis and the transport of 
cholesterol to lipid rafts (Zheng et al., 2003). Full infectious HIV particles can then 
infect new cell targets and new cycles of replication can take place. A schematic 
representation o f the HIV infectious particle is represented in figure 1.5.
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Figure 1.5 Schematic representation of an infectious HIV virus particle
The infectious mature particle o f  HIV has a viral membrane bearing the trimeric spikes 
constituted by the association o f  gp41 (TM ) and gp l20  (SU). Beneath the membrane, the core 
o f the particle is formed by the polymerisation o f MA interacting with the CA that forms a 
conical structure typical o f  HIV. Within CA, two copies o f  genomic RNA, covered by NC, 
interact with CA via IN. PR, RT and Vpu are also present inside the core. The cellular 
components tRNA Lys3 and CypA are incorporated into the virus particle. Note that, in 
permissive cells, APOBEC is incorporated and in non-permissive cells, V if is incorporated
1.6 Viral entry
The first step of the infection cycle of HIV consists of one or several specific 
interaction(s) with some cellular surface structures (see 1. 6. 2. 3 for details) and one 
or several receptors. In the case o f HIV-1, gpl20 binds to CD4 (Dalgleish et al., 1984; 
Klatzmann et al., 1984) and a chemokine co-receptor (Alkhatib et al., 1996; Choe et 
al., 1996; Dragic et al., 1996; Feng et al., 1996). The second step in the infection cycle 
is the fusion of the virus into the target cell. This step is mediated by gp41, which is 
involved in the fusion mechanisms between the viral and the cellular membranes.
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1.6.1 Structure of HIV envelope
1.6.1.1 gpl20
gpl20 (or gpl05 for HIV-2) mediates the specific interactions with CD4 and the 
co-receptor. It has the highest variability in its amino acid composition amongst all 
the HIV proteins (Gaschen et al., 2002) and consists of five constant domains (C1-C5) 
intercalated by five variable regions (VI-V5) (Starcich et al., 1986; Willey et al., 
1986). The conserved regions C l, C2 and C5 interact together (Moore et al., 1994b) 
and form a central discontinuous protein backbone. The variable regions (with the 
exception of V5) have disulphide bonds at their base and form loops exuding from the 
protein backbone (Kwong et al., 1998; Leonard et al., 1990).
The structure o f the T cell line-adapted (TCLA) molecular clone HxB2 
monomeric gpl20 core was crystallised in association with the D1-D2 fragment of 
CD4 and the anti-co-receptor binding site Fab fragment 17b (Kwong et al., 1998). For 
stability reasons, HIV-1 gpl20 could not be crystallised with the carbohydrates and 
the variable regions and, therefore, the VI/V2 and V3 loops were removed by 
mutagenesis and over 90% of the carbohydrate motifs were stripped. The N- and C- 
extremities o f gpl20 were also missing. A schematic figure o f the crystal structure of 
the resulting gpl20 core is represented in figure 1.6. The overall structure o f the 
gpl20 core is heart-shaped and consists of two domains: the inner and the outer 
domain linked by a highly conserved p-sheet that forms the bridging sheet. The inner 
domain possesses helical features whereas the outer domain forms a barrel. The inner 
domain faces gp41 and the outer domain is more exposed on the surface of gpl20 
(Wyatt and Sodroski, 1998). The V1/V2 loop protrudes at the base o f the inner 
domain. The variable loops V3, V4 and V5 protrude from the outer domain, at the 
base, at the external side and at the top respectively.
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Figure 1.6 Schematic representation of the monomeric gpl20 backbone
Crystal structure o f the deglycosylated, V1/V2- and V3 loop-deleted g p l2 0  from HIV-1 
HxB2 clone in association with D1-D2 domains o f CD4 and the MAb 17b. g p l2 0  is 
organised into an inner and an outer domain. The positions o f  the variable loops (V) are 
indicated by the yellow circles. From Kwong et al, 1998
The CD4-binding site (CD4BS) on gpl20 contains a hydrophobic cavity (Kwong 
et al., 1998) that is buried within the trimeric Env structure. The amino acid residues 
involved in the CD4BS seem to be scattered along the peptide backbone o f gpl20, 
particularly on C2, C3, C5 and V5 on the monomeric gpl20 (Kwong et al., 1998; 
Levy, 1998). The conservation of some amino acid residues on gpl20 is crucial for 
the interaction with CD4 (see section 1. 6. 3) but some degree o f amino acid variation 
within gpl20 is allowed, as some interactions are mediated through main-chain atoms 
(Kwong et al., 1998). The binding of CD4 is thought to induce large conformational 
changes at the CD4BS (Kwong et al., 1998; Myszka et al., 2000).
The binding of gpl20 to CD4 reveals the co-receptor-binding site, characterised 
by a hydrophobic core surrounded by a positively charged periphery involving the 
bridging sheet and the V3 loop (Kwong et al., 1998). The role o f the V1/V2 loop in 
the co-receptor interaction is less clear since an HIV-1 mutant with V1/V2 deleted was
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still infectious (Cao et al., 1997) while a recombinant gpl20 similarly deleted for 
V1/V2 also bound co-receptors (Wu et al., 1996) The V3 loop seems particularly 
important, as a single point mutation within this region can modify cell tropism 
(Takeuchi et al., 1991) and anti-V3 loop antibodies (Abs) block gpl20-CCR5 binding 
(Trkola et al., 1996a). Other variable regions of gpl20 can be involved depending on 
the HIV strain studied (Cho et al., 1998; Smyth et al., 1998).
gpl20 is heavily glycosylated with O-linked oligosaccharides branched from a 
GalNac motif added to: serine (Ser) or threonine (Thr) amino acid residue (Bernstein 
et al., 1994). It is also modified with N-glycans that are high mannose motifs added 
on Asn-X-Ser or Asn-X-Thr sites. On average, twenty-four N-linked and eight O- 
linked glycosylation sites are found on gpl20 (Leonard et al., 1990). The 
glycosylation sites can vary in number and in position (Wei et al., 2003) according to 
the HIV isolate.
Overall, the carbohydrates represent between 40 and 50% of the molecular weight 
of gpl20 (Poignard et al., 2001) and form a protective shield against the immune 
system (see section 1. 13. 3. 3. 6 for details). Some carbohydrate motifs also modulate 
HIV infection. The overall deglycosylation of gpl20 decreases the affinity of Env for 
CD4 but does not abrogate the interaction (Fenouillet et al., 1989). In SIVmac some N- 
glycans appear to be crucial for viral infectivity (Ohgimoto et al., 1998). The absence 
of some other carbohydrates does not affect infectivity (Ohgimoto et al., 1998; Reitter 
and Desrosiers, 1998). Some glycosylation motifs could be involved in the 
modulation o f interactions with the co-receptors (Hoffman et al., 1999; Pollakis et al., 
2001; Polzer et al., 2002).
1.6.1.2 gp41
gp41 mediates the fusion between the viral and the cellular membranes. A 
schematic representation of gp41 is shown in figure 1.7. The N-terminus of gp41 
consists of a stretch o f hydrophobic amino acid residues resembling the fusion peptide 
of other fusogenic viruses, such as influenza (Colman and Lawrence, 2003), 
immediately followed by the ectodomain, composed of two hydrophobic repeat 
domains (HR1 and HR2), involved in the formation of a hairpin structure formed 
during the fusion (Colman and Lawrence, 2003). The ectodomain seems to be 
involved in the late steps of fusion, after the merging of the membranes (Bar and 
Alizon, 2004). The cytoplasmic tail of gp41 at the C-terminus, a stretch of
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approximately 150 amino acids, interacts with MA during virus assembly (Freed and 
Martin, 1996). From the homology with other type I viral proteins, gp41 is thought to 
mediate the trimeric oligomerisation o f gpl20-gp41 through interactions between the 
HR regions.
Fusion
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Cytosolic
region
NH2 COOH
512 527 546 579 628 655 684 705
Membrane 
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Figure 1.7 Schematic representation of the domains of gp41
The N-terminal fusion peptide (black square) inserts gp41 into the membrane o f  the target cell 
after the interaction with the chemokine receptor and prior to fusion. gp41 is characterised by 
the presence o f two hydrophobic repeat domains (HR1 and HR2) that associate gp41 into 
trimers. The membrane-spanning domain that crosses the viral membrane and the cytosolic 
region, at the C-terminus o f  gp41, is found within the HIV particle and interacts with 
oligomerised MA. The residues are numbered according to their position in g p l6 0 HxB2 (from 
Tan et al, 1997). The blue bars span the regions involved in the interaction with g p l2 0  (from 
Cao e ta l, 1993).
gp41 is glycosylated and has five putative N-glycosylation sites, three o f which 
have been shown to be glycosylated (Fenouillet et al., 1993). These sites are found 
within the HR2 region (Tan et al., 1997). They have been shown to be involved in the 
efficient cleavage of gpl60, possibly by shaping gpl60 into a suitable conformation 
(Cao et al., 1993; Fenouillet et al., 1993). Non-glycosylated gp41 seems to mediate 
the formation of syncytia less efficiently than the glycosylatyed form (Fenouillet et 
al., 1993) but these results are controversial (Lee et al., 1992).
6.1.3 The gpl20-gp41 interaction
gpl20 and gp41 form trimers through the non-covalent interactions of 
hydrophobic amino acid residues localised mainly in the Cl region, and less 
hydrophobic residues in the C2 region of gpl20 (Helseth et al., 1991; Wyatt et al.,
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1997). Hydrophobic amino acid residues within C3, C4 and C5 are also involved to a 
lesser extent (Helseth et al., 1991; Wyatt et al., 1997). gp41 interacts with gpl20 via a 
region involving the amino acid residues 528 to 562, overlapping HR1, and amino 
acid residues at positions 608 and 628, the latter being found within HR2 (Cao et al., 
1993).
Most of the structures exposed on the oligomeric gpl20-gp41 spike are on the 
gpl20. A large number o f the gpl20-gp41 trimers dissociate, possibly due to the weak 
association between gpl20 and gp41, and monomeric forms of gpl20 shed from the 
virions resulting in defective virus particles, which predominate in HIV cultures in 
vitro (Wyatt and Sodroski, 1998). The shedding of monomeric gpl20 in serum is 
thought to be a main target for the generation of non-NAbs, contributing to the viral 
escape from immune attack (see section 1. 13. 3. 3. 6 for details).
1.6.2 Receptor, co-receptors and surface cellular structures involved in virus
binding
1.6.2.1 CD4
CD4 was first identified as the receptor for HIV-1 (Dalgleish et al., 1984; 
Klatzmann et al., 1984) and also for HIV-2 and SIV (Hoxie et al., 1988; Sattentau et 
al., 1988). CD4 is a 55 kDa monomeric membrane glycoprotein that contains four 
extracellular immunoglobulin-like (Ig-like) domains (D1-D4), a transmembrane 
region (TM) and a cytoplasmic tail. CD4 is expressed on T helper cells (Th), a subset 
of natural killer cells (NK) and cells of the monocyte/macrophages lineage. It interacts 
with MHC class II molecules present on antigen presenting cells (APCs) (Janeway, 
2001).
The interaction between CD4 and HIV is mediated by gpl20. The primary 
interaction with gpl20 occurs at the N-terminus o f the D1 domain, that has a similar 
structure to the CDR H2 region of IgG (Arthos et al., 1989). The D4 domain appears 
to play a role in the post-binding events, possibly during fusion (Moir et al., 1996).
The affinity of gpl20 for soluble CD4 (sCD4), lacking the transmembrane domain 
and the cytoplasmic tail, varies according the HIV strain (Ivey-Hoyle et al., 1991). 
Primary isolates (Pis) o f HIV require larger amounts of sCD4 for efficient inhibition 
than TCLA strains (Kabat et al., 1994) and could have a lower affinity for CD4 than 
TCLA viruses (Daar et al., 1990).
41
CD4 is down-regulated from the cell surface by N ef in primary cells (Garcia and 
Miller, 1991). N ef mediates the endocytosis of CD4 via clathrin-coated pits (Foti et 
al., 1997). It interacts with CD4 via two leucine residues within its cytoplasmic tail 
(Peter, 1998) and dissociates CD4 from a lymphocyte-specific protein tyrosine kinase 
p56lck, which leads to the internalisation of CD4 (Arora et al., 2002). N ef also 
interacts with one o f the components involved in the formation of clathrin-coated pits, 
AP2 (Arora et al., 2002). By bringing CD4 and AP-2 together, N ef favours the 
endocytosis of CD4 and its degradation (Greenberg et al., 1997). N ef acts only on 
CD4 when it is expressed at the surface of the cell. The accessory protein Vpu 
contributes to CD4 degradation in the ER (Meusser and Sommer, 2004).
The degradation o f CD4 by HIV has two purposes. The down-regulation of CD4 
from the surface could prevent super-infection from occurring and prevent gpl20 
from associating with CD4 (Arora et al., 2002). The degradation o f CD4 results in 
enhanced viral infectivity (Harris, 1999).
1.6.2.2 The chemokine co-receptors
After the discovery o f the role of CD4 in HIV infection, Maddon et al, showed 
that the expression o f human CD4 on murine cells was not sufficient to allow HIV 
infection (Maddon et al., 1986). Feng et al showed that TCLA HIV-1 strains, 
intensively passaged in immortalised T cells lines, used the chemokine receptor 
CXCR4 (previously known as Fusin, HUMSTSR, LCR-1 or LESTR) in addition to 
CD4 to allow their entry in mouse cells (Feng et al., 1996). CXCR4 also mediates the 
entry of HIV-2 CD4-independent strains (Endres et al., 1996). Shortly after, CCR5 
and, to a lesser extent, CCR3 were found to be the main co-receptors for infection of 
HIV-1 Pis in primary PBMCs and macrophages (Alkhatib et al., 1996; Choe et al., 
1996; Dragic et al., 1996). Chemokine receptors are 7-TM G-coupled proteins 
involved in signalling that are internalised by endocytosis via clathrin-coated pits 
when bound to their chemokines. CCR5 binds to a variety of chemokines: RANTES, 
M IP-la, M IP-lp and MCP-2; whereas CXCR4 only binds to SDF-1.
Pis and TCLA strains o f HIV-1, HIV-2 and SIV were found to use a wide range of 
chemokine receptors in vitro (see Clapham and McKnight, 2002 for details), HIV-2 
being able to use a broader range o f chemokine receptors than HIV-1 in vitro 
(McKnight et al., 1998). Table 1.1 lists the co-receptors used for HIV and SIV 
infection in vitro.
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It became apparent that CCR5 and CXCR4 were the chemokine receptors that 
mediated HIV infection more efficiently in vitro. Before the identification of the co­
receptors, HIV strains were described as macrophage-tropic (M-tropic) or T cell line- 
tropic (T-tropic) (Fenyo et al., 1988; Schwartz et al., 1989). They could also be 
classified by their ability to form synticia in T cells lines. Viruses that can form 
syncytia are called syncytium-inducing (or SI viruses) and the ones that are unable to 
form syncytia are called non-syncytium-inducing (or NSI viruses) (Tersmette et al., 
1988). NSI viruses use CCR5 as their main co-receptor and SI viruses use CXCR4. 
There are exceptions to this rule (Simmons et al., 1998). Viruses showing 
predominant CXCR4 usage are called X4-tropic, viruses showing a predominant 
CCR5 usage are called R5-tropic and viruses showing a co-dominant usage of CCR5 
and CXCR4 are called dual tropic X4R5 (Berger et al., 1998).
More importantly, CCR5 and CXCR4 seem to be the co-receptors relevant in vivo. 
Although some studies have shown that some HIV strains might enter primary cells 
via an alternative co-receptor. Lee et al showed that some X4-viruses could enter 
primary thymocytes isolated from children via CCR8 (Lee et al., 2000). Similarly, 
Willey et al reported that some HIV-1 and HIV-2 strains could infect PBMCs and 
astrocytes via an unidentified co-receptor (Willey et al., 2003). In these two cases, the 
alternative co-receptors mediated infection less efficiently than CXCR4 and CCR5 
(Lee et al., 2000; Willey et al., 2003). Macrophages and dendritic cells (DCs) are 
mainly infected by R5-viruses, although some Pis infect macrophages via CXCR4 
(Simmons et al., 1998). Zhang et al showed that a panel of adult and paediatric 
clinical isolates of H IV-1, SI and NSI, used CCR5 almost exclusively, although the 
tropism was broader for some SI isolates (Zhang et al., 1998). Individuals 
homozygous for a 32 base pair deletion in the CCR5 gene (CCR5 A32), which leads 
to the production of a non-functional receptor, are highly resistant to HIV infection 
(Dean et al., 1996; Deng et al., 1996; Samson et al., 1996). Moreover, infected 
individuals heterozygous for A32 CCR5 show a slower progression towards AIDS 
(Dean et al., 1996), which suggests that HIV infects their cell targets via CCR5 in 
vivo.
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Co receptor Ligand Virus Reference
CCR1 M IP-la, MPIF-1, 
MCP-3, RANTES
HIV-2, SIV (McKnight et al., 
1998)
CCR2b MCP-1, MCP-2, 
MCP-3
HIV-1, HIV-2, SIV (Doranz et al., 1996)
CCR3 Eotaxin-1, eotaxin-2, 
MCP-3, MCP-4, 
RANTES
HIV-1, HIV-2, SIV (Doranz et al., 1996)
CCR4 MDC, TARC, 
RANTES, MIP-1 a
HIV-2 (McKnight et al., 
1998)
CCR5 M IP-la, MIP-1 P, 
RANTES, MCP-2
HIV-1, HIV-2, SIV (Alkhatib et al., 
1996; Deng et al., 
1996; Dragic et al., 
1996)
CCR8 1-309 HIV-1, HIV-2, SIV (Rucker et al., 1997)
CCR9 TECK HIV-1 (Choe et al., 1998)
CXCR2 IL8, NAP-2. ELR, 
CXCs
HIV-2 (Bron et al., 1997)
CXCR4 SDF-1 HIV-1, HIV-2, SIV (Feng et al., 1996)
CX3CR1 Fractaline HIV-1, HIV-2, SIV (Garin et al., 2003; 
Reeves et al., 1997)
STRL/Bonzo CXCL16 H IV-l, HIV-2, SIV (Alkhatib et al., 
1997)
GPR1 Unknown HIV-1, HIV-2, SIV (Farzan et al., 1997)
GPR15/Bob Unknown HIV-1, HIV-2, SIV (Farzan et al., 1997)
APJ Apelin HIV-1, HIV-2, SIV (Choe et al., 1998; 
Edinger et al., 1998)
Chem R23 Unknown HI V -l, SIV (Samson et al., 1998)
RDC1 Unknown HIV-2, SIV (Shimizu et al., 2000)
Table 1.1 Chemokine receptors that support HIV and SIV replication in vitro
The CXCR4 and CCR5 chem okine receptors are thought to be the most relevant co-receptors 
in vivo. Adapted from Clapham  and M cKnight, 2002
Viruses that harbour a predominant X4-tropism can be found in up to 50% of 
patients at the stage o f AIDS development infected with subtype B viruses. R5- and
44
X4-viruses appear to infect different subsets of CD4 T cells in vivo. R5-viruses infect 
memory CD4 T cells whereas X4-viruses infect naive CD4 T cells (Moore et al., 
2004). X4-tropism in vivo is thought to be associated with a more rapid disease 
progression (Connor et al., 1997) but X4-tropism is not a prerequisite for AIDS 
development (de Roda Husman et al., 1999; Li et al., 1999). Macaques infected with 
SIVmac usually die o f AIDS-related syndromes without a switch to X4-tropism (Moore 
et al., 2004). Moreover, the R5-X4 switch could be a phenomenon observed 
predominantly for subtype B viruses, as X4-viruses from subtype C are more rarely 
isolated from infected individuals (Ping et al., 1999). Subtype C viruses, however, 
may not have the time to evolve into X4 as subtype C-infected individuals can die 
more rapidly, due to the enhanced cytopathy of subtype C viruses compared to 
subtype B or due to the precarious health care conditions in the countries where 
subtype C is endemic.
The possibility that HIV might use alternative co-receptors in vivo for infecting 
target cells in compartmentalised tissues, such as astrocytes in the brain, where the 
expression of CCR5 or CXCR4 is undetectable, is still unclear and cannot be ruled out 
(Willey et al., 2003).
The V3 loops o f X4-viruses have an overall higher positive charge than the V3 loops 
of R5-tropic viruses.
X4- and R5-tropic viruses seem to interact with their co-receptors via different 
regions (Clapham and McKnight, 2002; Dragic, 2001). Chemokine receptors are 
proposed to form rods in the membrane with a central pore surrounded by the 7-TM 
regions. They have four domains exposed on the cell surface: the N-terminus and 
three extracellular loops: E l, E2 and E3 (Clapham and McKnight, 2002).
In the case o f CCR5, the binding sites of the chemokines and gpl20 seem to be 
overlapping but distinct (Atchison et al., 1996). The extracellular E2 loop is important 
for binding chemokines (Blanpain et al., 1999). HIV binding to CCR5 requires 
multiple interactions with several regions of CCR5 (Atchison et al., 1996; Bieniasz et 
al., 1997). The N-terminus tyrosine-rich region of CCR5 appears to be important for 
the binding of g l20  (Farzan et al., 1998; Farzan et al., 1999) and the E2 loop seems 
more involved in the fusion and the entry of the virus (Clapham and McKnight,
2002). The N-terminus o f CCR5 contains sulphated tyrosine residues that appear to 
interact directly and specifically with the V3 stem of gpl20 (Cormier and Dragic,
2002). The overall negative charge of the N-terminus of CCR5, conferred by the
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sulphated tyrosines, could interact with the positively charged V3 loop and facilitate 
the specific interactions between CCR5 and gpl20, but the charges do not seem to 
drive the specificity o f the interactions (Clapham and McKnight, 2002). The C4 
domain of gpl20, however, has been shown to directly interact with the N-terminus of 
CCR5, in a CD4-independent R5-tropic HIV-2 isolate (Lin et al., 2001), suggesting 
that the mechanisms of interaction with CCR5 might vary according to the strain 
(Rabut et al., 1998) or on the subtype studied (Thompson et al., 2002). Moreover, 
mutant strains of HI V -l, resistant to inhibition by CCR5 antagonist molecules, do not 
switch to X4-tropism in vitro (Trkola et al., 2002). In macaques, a transient and brief 
switch from R5 to X4 occurs but R5-tropism becomes again predominant (Wolinsky 
et al., 2004).
Unlike CCR5, mutations within CXCR4 do not clearly define a region that plays a 
crucial role in binding and entry o f X4-tropic viruses (Dragic, 2001). The N-terminus 
of CXCR4 seems to be required for interacting with some HIV-1 strains but not all 
(Picard et al., 1997). However, the E2 loop seems to be more important for X4-tropic 
HIV-1 (Brelot et al., 1999; Clapham and McKnight, 2002) and X4-tropic, CD4- 
independent HIV-2 isolates (Reeves et al., 1998). The E2 loop has a negative charge, 
which could interact with the highly positively charged V3 loop of X4-tropic viruses. 
The major involvement o f the E2 loop of CXCR4 at mediating the entry of X4-tropic 
HIV-1 viruses has been shown by the broad inhibitory effect of AMD3100 against 
HIV-1 (Labrosse et al., 1998). This molecule blocks HIV entry by binding residues on 
the E2 loop and the transmembrane domain TM4 of CXC4 (Labrosse et al., 1998).
Some strains o f HIV-2 and SIV can infect cells without the requirement of CD4 
(Borsetti et al., 2000; Reeves et al., 1998) but no HIV or SIV strain described so far is 
co-receptor independent (Farber and Berger, 2002). Moreover, the acquisition of 
CD4-dependence only requires a few changes on gpl20 and gp41 in CD4- 
independent SIVmac (Puffer et al., 2004). These observations have lead to the 
hypothesis that the chemokine co-receptor was the primary receptor o f these 
lentiviruses; the requirement o f CD4 for infection was acquired later in order to 
protect the virus from the attack o f the immune system (LaBranche et al., 2001; Wyatt 
and Sodroski, 1998).
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1.6.2.3 Surface cellular structures
The entry of HIV generally relies on the presence of CD4 and a chemokine co­
receptor (Clapham and McKnight, 2002). Hiv also uses several molecular structures 
present on the cellular membrane to mediate attachment, accelerate fusion or promote 
dissemination.
Mondor et al showed that the attachment o f HIV-1 to Hela cells relied on 
interactions between gpl20, from an X4-virus, and heparan sulphate proteoglycans, 
independently o f the interaction with CD4 (Mondor et al., 1998). Moreover, it appears 
that X4-tropic viruses interact directly with polyanions via their co-receptor binding 
site and their V3 loop in vitro. R5-viruses seem less dependent on interactions with 
heparan sulphates, probably due to the more neutral overall charge of their V3 loop 
(Moulard et al., 2000). The implication of the heparan sulphate for infecting CD4 T 
cells in vivo is probably less important, as they seem to express low levels of these 
motifs (Ibrahim et al., 1999). However, Bobardt et al recently showed that heparan 
sulphate and chondroitin sulphate could be exploited by HIV, regardless of the virus 
tropism, to enter and migrate through the blood brain barrier (BBB) (Bobardt et al., 
2004). The removal o f heparan sulphate proteoglycans also inhibits HIV infection in 
macrophages (Saphire et al., 2001a).
HIV seems to use molecular structures found in lipid rafts of the target cells to 
facilitate infection (Popik et al., 2002). Phospholipids, such as phosphatidylserine, 
have been shown to enhance HIV infection of macrophages (Callahan et al., 2003). 
Glycosphingolipids, such as sulphatide galactosyl ceramide (SGalCer), have also been 
shown to bind HIV virions, regardless of their co-receptor usage, (Kensinger et al., 
2004) and could be important for the infection of HIV in neuronal cells (Bhat et al., 
1991). Fusion between the cell and the HIV-1 membranes seem to be promoted by 
several ceramides (Alfsen and Bomsel, 2002; Puri et al., 1998) as well as the 
ganglioside GM3 (Hug et al., 2000), although its over-expression inhibits fusion 
(Rawat et al., 2004). The over-expression of human leukocyte elastase (HLE) on non- 
infectable cells expressing CD4 and CXCR4, has been shown to allow infection of the 
X4-tropic N L 4 .3  by co-patching CD4 and HLE, suggesting that HLE could be required 
as a fusion receptor (Bristow et al., 2003). The marker LFA-1 (leukocyte function 
associated antigen type 1) can also promote viral attachment via its interaction with 
ICAM-1, acquired in the HIV membrane during budding from lipid rafts (Giguere and 
Tremblay, 2004).
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In addition to docking and fusion, other cellular molecular structures, such as DC- 
SIGN and syndecans, can promote the transmission of HIV to other cells (in trans). 
DC-SIGN (dendritic cell-specific intercellular adhesion molecule grabbing non- 
integrin), or CD209, is a C-type lectin involved in the recognition o f carbohydrate 
structures on self-antigens and pathogens (van Kooyk and Geijtenbeek, 2003). DC- 
SIGN is present on DCs and interacts with CD4 T cells via ICAM-3 (Geijtenbeek et 
al., 2000b). It is also expressed on monocytes and peripheral blood lymphocytes. HIV 
binds DC-SIGN, by specific N-glycans on gpl20 (Hong et al., 2002; Kwon et al.,
2002), independently o f its interaction with CD4. Thus, DC-SIGN could enhance HIV 
infection o f CD4 T cells (Geijtenbeek et al., 2000a; Kwon et al., 2002). DC-SIGN 
might be one o f the motifs involved in the transmission of HIV from DCs to CD4 T 
cells in trans (Arrighi et al., 2004), as other C-lectins, such as langerin and mannose 
receptor, have been reported to bind HIV on DCs (Turville et al., 2002). DC-SIGN 
could mediate the enhancement of transmission by internalising HIV in DCs in a low 
pH endosomal compartment that can keep the virus fully infectious for a longer period 
than in a free state (Kwon et al., 2002). Turville et al, however, have shown that HIV 
could interact with other structures on DCs, such as the mannose receptor, and HIV 
internalisation could be medited by other structures (Turville et al., 2002).
DC-SIGN can also enhance HIV infection on the same cell (in cis) (Lee et al., 
2001). DCs in mucosal tissues (such as the rectum and the cervix) express high levels 
of DC-SIGN (van Kooyk and Geijtenbeek, 2003). A DC-SIGN homologue expressed 
on endothelial cells, DC-SIGNR, has also been described to enhance HIV infection in 
trans (van Kooyk and Geijtenbeek, 2003). It has been shown that N ef from R5-tropic 
viruses up-regulates the expression o f DC-SIGN in DCs (Sol-Foulon et al., 2002) and 
DC-SIGN could contribute to the dissemination of HIV after sexual transmission or 
blood contamination (van Kooyk and Geijtenbeek, 2003).
Syndecans, a class o f proteoglycans, can enhance attachment and infection of HIV 
(produced in PBMCs) to target cells, by interacting with the V3 loop and the co­
receptor binding site o f gpl20. HIV captured by non-infective cells expressing 
syndecans seems to retain infectivity longer than in a cell-free state (Bobardt et al.,
2003). This finding could be of particular importance for HIV infection in the 
vascular system as the endothelium expresses high levels of syndecans (Bobardt et al., 
2003; Saphire et al., 2001a).
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Fc receptors, in association with anti-HIV Abs, have been involved in the 
enhancement of HIV infection (see section 1. 13. 3. 3. 9 for details).
Complement receptors CR1 (CD35), CR2 (CD21) and CR3 (CD llb/C D 18) have 
been shown to enhance HIV infection of target cells (see section 1. 13. 2. 3 for 
details).
1.6.3 Binding to CD4 and co-receptor and fusion
HIV entry into target cells is mediated by gpl20 and gp41, associated in trimeric 
spikes on infectious viruses. HIV has a type I fusion envelope, which means that Env 
is synthesised as a protein precursor that is cleaved by cellular proteases and the 
subsequent SU and TM proteins associate in trimers. Other viruses fitting into this 
classification are influenza, mumps and measles viruses (Colman and Lawrence,
2003). Unlike influenza, fusion and entry of HIV seems generally to be pH- 
independent (Colman and Lawrence, 2003).
The first step o f entry generally requires the interaction of gpl20 with CD4. gpl20 
interacts with CD4 via the amino acid residues of the N-terminus o f D l. The amino 
acid residues Phe 43 and Arg 59 of CD4 interact with the residues Asp 368, Glu 370 
and Trp 427 o f gpl20 and are crucial for the CD4-gpl20 interaction (Kwong et al., 
1998; Saphire et al., 2001b). Phe 43 accounts for 23% of the CD4-monomeric gpl20 
interaction. These amino acid residues are conserved in the SU proteins of all 
immunodeficiency lentiviruses (Kwong et al., 1998). Several trimeric spikes must 
interact with CD4 and at least two gpl20 proteins per trimer need to be engaged with 
CD4 to continue entry (LaBranche et al., 2001).
The binding o f CD4 triggers conformational changes, revealing the V3 loop 
(Sattentau and Moore, 1991). These modifications expose the co-receptor binding site 
on gpl20 (Trkola et al., 1996a; Wu et al., 1996), composed o f the V3 loops and the 
bridging sheet between the V1/V2 and the V3 loop (Kwong et al., 1998). Hoffman et 
al have shown that, in the CD4-independent HIV-1 strain IIIBx, the co-receptor 
binding site is more exposed and could be in a more stable conformation than on its 
CD4-dependent counterpart IIIB (Hoffman et al., 1999).
CD4 and CCR5 are associated within lipid rafts regardless of the presence of 
gpl20 (Xiao et al., 1999). This clustering leads to a greater cooperativity between 
gpl20, CD4 and the chemokine receptors, which could optimise the fusion,
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particularly on cells expressing low levels o f CD4 and co-receptors (Gallo et al., 
2003; Popik et al., 2002).
The binding event with the chemokine receptor is a prerequisite for the initiation 
of fusion (LaBranche et al., 2001). Using a modified truncated gpl40  Env, where 
extra cysteine residues were added to obtain disulfide-stabilised trimeric-like 
structures (Binley et al., 2000), it has been suggested that gpl20 provides a clamp that 
holds gp41. The binding of gpl20 onto the co-receptor then releases the clamp, 
allowing gp41 to modify its conformation to mediate fusion (Abrahamyan et al.,
2003). The fusion peptide, at the N-terminus o f gp41, is exposed and inserts into the 
membrane of the target cell. The three HR1 regions interact to form a coiled-coil 
structure and the three HR2 domains fold back in a hairpin-like structure into the 
hydrophobic regions o f the coiled-coil to form a thermodynamically stable six-helix 
bundle (Tan et al., 1997). This brings the viral and the cellular membranes into close 
proximity, forming a hemifusion intermediate (Bar and Alizon, 2004). A fusion pore 
is then formed to allow the viral core to enter the cytoplasm of the cell. A schematic 
representation of HIV fusion with the cell membrane is shown in figure 1.8.
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Figure 1.8 Fusion between HIV and cell membranes
The viral glycoprotein g p l2 0  interacts with cellular receptors (CD4 and a chemokine 
receptor) and the envelope com plex undergoes a conformational change (A ). A pre-hairpin 
intermediate is formed in w hich the fusion peptide has inserted into the target membrane 
(B). The pre-hairpin interm ediate resolves to the fusion-active hairpin structure when the C 
and N peptides interact, pulling the cell and viral membranes into c lose  proxim ity and 
culm inating in membrane fusion (C). From D'Souza et al., 2000
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1.7 Cell targets
HIV potentially infects all human cells expressing CD4 and one o f the co­
receptors described in 1. 6. 2. 2. HIV infects CD4 T cells but not all HIV strains infect 
the same subset o f these cells. R5-tropic viruses infect memory CD4 T cells (CCR5+) 
whereas X4-tropic viruses infect naive CD4 T cells (CXCR4+). HIV also infects 
macrophages in vitro (Simmons et al., 1996) and in vivo (Miller and Shattock, 2003). 
The HIV life cycle in macrophages differs from the life cycle in CD4 T cells. In 
macrophages, viral components are assembled in late endosomes and, consequently, 
macrophage-derived HIV viruses express unique markers in their membranes 
(Pelchen-Matthews et al., 2003).
HIV-infected CD8 T cells, that express CD4, have been isolated from patients at 
the AIDS stage (Cochrane et al., 2004; Livingstone et al., 1996). Immature DCs have 
been infected in vitro by X4 and R5 isolates (MacDougall et al., 2002) but mature 
DCs are refractory to HIV infection (Miller and Shattock, 2003). Monocyte-derived 
Langerhans cells (LCs) are also susceptible to HIV infection (Kawamura et al., 2003). 
Astrocytes have been shown to be infected by HIV in vitro (Willey et al., 2003).
1.8 Transmission
HIV can be horizontally transmitted by sexual contact, blood-blood contact and 
vertically from mother to child during birth and breast-feeding. In the developed 
world, the risk groups are mainly men having sex with men and intravenous drug 
users who share needles. With the systematic screening o f blood products, 
haemophiliacs no longer represent a risk group. In the developing world, heterosexual 
contact is the main route o f transmission, and, hence, represents the main mode of 
transmission worldwide.
Sexually transmitted diseases increase the probability of HIV infection (Miller,
1998), which suggests that the presence of cells from the mucosal immune system 
mediates or enhances infection. Greenhead et al showed that HIV infection was 
enhanced in vaginal tissues incubated in the presence o f PHA and interleukin 2 (IL2) 
(Greenhead et al., 2000). Moreover, HIV is not detected in vaginal epithelial cells and 
does not seem to be transcytosed (Greenhead et al., 2000). LCs and y8 T cells (see 
section 1. 13. 2. 2 for details) are found in the mucosal epithelium and macrophages 
while T cells reside in the lamina propria beneath the epithelial layers. The 
mechanisms of infection and successful dissemination in sexual transmission of HIV
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are unclear. LCs are DC-SIGN negative and CD4, CXCR4 and CCR5 positive (Miller 
and Shattock, 2003). LCs and macrophages seem to be the prime targets during HIV 
transmission (Miller, 1998). LCs are infected by SIV in vivo (Miller, 1998). In the 
male genital system, LCs are mainly found in the foreskin. The removal of the 
foreskin has been shown to reduce the risk of HIV infection, which suggests that these 
cells are involved in transmission (Auvert et al., 2001; Miller, 1998). LCs could also 
transmit HIV to HIV-specific CD4 T cells (Sugaya et al., 2004).
In addition to LCs, DC-SIGN expressing DCs are found within the lamina propria 
of the vagina. Although the in vivo infection of DCs by HIV remains unclear, they 
could be involved in the early dissemination of HIV (Miller and Shattock, 2003).
It is still unclear if  HIV transmission occurs by cell-free virus or infected cells 
(Levy, 1998; Miller, 1998). Cell-free HIV can infect target cells (see section 1. 6. 3) 
but can also be transmitted from cell to cell via the virological synapse (Jolly et al.,
2004), which is a cytoskeleton-dependent, stable adhesive junction across which the 
viral core is transmitted by directed transfer, occurring between an infected cell and a 
permissive non-infected cell (Jolly and Sattentau, 2004).
1.9 Clinical symptoms of HIV and AIDS
HIV infection is characterised by two phases: the acute infection and the chronic 
infection, leading to AIDS. The course of HIV is represented in figure 1.9.
1.9.1 Acute infection
HIV acute infection is generally associated with flu-like symptoms one to four 
weeks after infection. The symptoms consist of headache, retro-orbital pain, muscle 
aches, sore throat, fever, swollen lymph nodes, rash affecting the trunk, weight loss, 
fatigue and night sweats. In some cases, oral and (or) genital candidiasis, nausea, 
vomiting, diarrhoea and central nervous system disorders, such as encephalitis, can 
occur (Kahn and Walker, 1998; Levy, 1998). Fever, fatigue and rash represent the 
most common symptoms observed in acute infection (Kahn and Walker, 1998). The 
symptoms of acute infection may last from a few days to more than ten weeks, but the 
duration is usually fourteen days (Kahn and Walker, 1998). The non-specific nature of 
the symptoms associated with HIV infection makes the diagnosis difficult to assess. 
Therefore, recent “risky” behaviour has to be known.
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Figure 1.9 Representation of the viral load, the CD4 T cell count, the emergence 
of CTL response, the anti-HIV IgG and the development of neutralising anti- 
HIV Abs
After transmission, in acute infection, the HIV viral load (red line) arises to reach a peak 
concomitant with a decrease in the CD4 T cell count (green line), the detection o f  a specific 
CD 8  T cell response (blue line) and anti-HIV Abs (black line). The HIV-infected individual 
usually presents with flu-like symptoms. The viral load then drops to a set point, detected 
between three and six months post-infection, and is predictive o f  the evolution o f  the disease. 
An increase in the CD4 T cell count occurs concomitantly with the drop in viral load. The 
HIV-infected individual becomes asym ptom atic and HIV infection enters the chronic phase. 
NAbs are usually detected after the establishm ent o f the viral set point. Despite the 
persistence o f a specific immune response through the infection, the CD4 T cell count 
progressively decreases and the viral load increases. When the CD4 count is below 200 
cells/pl, the individual enters the AIDS phase and is susceptible to opportunistic diseases. The 
AIDS stage occurs on average ten years after contracting the infection without any anti-viral 
treatment. The viral load re-augm ents and is comparable to levels reached before the set 
point. From Levy, 1998
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Concomitantly, a peak o f viraemia is observed and the number of HIV RNA copies 
can reach 108/ml in plasma (Levy, 1998). The number of CD8 T cells rises, the CD4 T 
cell count decreases, hence the CD4/CD8 ratio is inverted (Levy, 1998).
Infection studies in humans and in rhesus macaque monkeys infected with a 115- 
tropic SHIV show that there is a rapid and profound CD4 T cell depletion in the 
gastrointestinal tract within three weeks of infection as CD4+ CCR5+ T cells represent 
the main CD4 T cell population (Douek et al., 2003; Moore et al., 2004). The overall 
loss of CD4 T cells is less severe in the plasma, as CD4+ CCR5+ T cells represent a 
minority CD4 T cell subset. In contrast, in macaques infected with a X4-tropic SHIV 
virus, the opposite phenomenon occurs: the gastrointestinal CD4 T cell population 
declines more slowly than in the peripheral blood, where the CD4 T cell population is 
almost eradicated within the first few weeks of infection (Harouse et al., 1999; Moore 
et al., 2004).
During the onset o f symptoms (or shortly after), the number o f CD4 T cells 
recovers, without reaching the initial level before infection, and the viral load in the 
plasma decreases by 100- to 1000-fold to reach a set point, which is an indicator to 
progression towards AIDS (Mellors et al., 1996). In parallel, Abs are detected but are 
primarily directed against p24Gag, then against Env and do not neutralise autologous 
and heterologous viruses (Aasa-Chapman et al., 2004; Richman et al., 2003; Wei et 
al., 2003). During acute infection, HIV disseminates and viral reservoirs are 
established (see section 1.9) (Douek et al., 2003).
1.9.2 Chronic infection and AIDS
Following acute infection, HIV infection enters an asymptomatic chronic phase 
that lasts on average ten years without any anti-viral treatment. NAbs are detected 
(Aasa-Chapman et al., 2004; Richman et al., 2003; Wei et al., 2003) as well as a CTL 
response but both branches o f the immune system fail to clear the virus. The 
CD4+/CD8+ ratio continues to be inverted, the CD4 T cell population progressively 
declines, at a rate o f 25 to 60 cells/pl per year, and viraemia eventually rises to levels 
similar to prior to seroconversion (Levy, 1998). In some cases, the decline o f CD4 T 
cells occurs more rapidly and could be associated with a switch from R5 to X4- 
tropism (Connor et al., 1997).
When the CD4 T cell count is below 200 cells/pl in plasma, the infected 
individual enters the AIDS stage of the disease and opportunistic infections, such as
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cytomegalovirus (CMV) and Pneumocystis carinii as well as AIDS-related 
malignancies, such as Kaposi Sarcoma, non-Hodgkin’s lymphoma, anal and cervical 
cancers, usually appear (Levy, 1998). Neurological pathologies, such as dementia, can 
be detected in some patients. The emergence o f opportunistic diseases is due to the 
exhaustion o f the immune system, incapable of fighting pathogens.
1.9.3 Cell death and CD4 T cell dynamics
HIV infection is mainly characterised by the progressive depletion of CD4 T cells. 
Death of HIV-infected cells results from apoptosis or necrosis. Apoptosis is an active 
cell suicide mechanism, involved in the clearance o f autoreactive T cells and the 
establishment o f self-tolerance. Apoptosis requires the expression o f cell markers, 
such as Fas receptor (CD95), p55 tumour necrosis factor (TNF) receptor and TRAIL 
receptors, which activate caspases, which in turn activate endonucleases involved in 
the fragmentation o f the DNA genome (Alimonti et al., 2003; Janeway, 2001). 
Apoptosis is also characterised by mitochondrial leakage and the release of caspase 
activators (Alimonti et al., 2003). Apoptosis is regulated by the presence of anti- 
apoptotic regulatory molecules, belonging to the Bel family, which act mainly on the 
caspases (Badley et al., 2000). Apoptotic cells do not trigger an inflammatory 
response, unlike necrotic cells. Necrosis is associated with swelling o f cytoplasmic 
compartments, extensive vacuolisation and leakage o f the cytoplasm.
HIV-infected CD4 T cells fail to proliferate and undergo apoptosis in vitro and ex 
vivo (Groux et al., 1992; Perfettini et al., 2004; Plymale et al., 1999) and apoptosis has 
been observed in neurons (Ryan et al., 2004). The half-life of infected CD4 T cells 
varies between twelve and thirty-six hours (Alimonti et al., 2003). Fas and FasL cell 
expression is up-regulated in HIV-infected T cells. The regulation o f TNF receptors is 
also altered and TRAIL/APO 2 expression could be dysfunctional (Badley et al., 
2000).
Viral proteins have been shown to have a direct apoptotic effect on infected and 
non-infected cells, (Alimonti et al., 2003; Badley et al., 2000). Tat, Env and N ef have 
been shown to induce apoptosis by upregulating the expression of Fas (Alimonti et al.,
2003) but HIV could also induce direct killing by a Fas-independent mechanism 
(Gandhi et al., 1998). Vpu has been shown to induce apoptosis with an X4-tropic 
virus (Akari et al., 2001) but Vpu from Pis could have a protective role against 
apoptosis in PBMCs (Komoto et al., 2003). Vpr could have an effect on mitochondrial
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permeability and PR could directly cleave and activate caspase 8 and the anti 
apoptotic Bcl2 (Badley et al., 2000). Soluble gpl20 can cross-link CD4 and CXCR4 
and induce apoptosis by enhanced susceptibility to Fas killing (Banda et al., 1992).
However apoptosis might not be the main cell death-inducer. Several studies 
suggest that necrosis is the main cell death mechanism in HIV-infected cells Bolton et 
al showed that cell death o f laboratory HIV-infected cell lines was independent of 
caspases (Bolton et al., 2002), and appeared more necrotic (Lenardo et al., 2002). 
Similarly, a study by Plymale et al showed that laboratoty-adapted cell lines, infected 
with HIV, died more o f necrosis than o f apoptosis (Plymale et al., 1999).
HIV-infected cells are subject to killing by CD8 T cells (see section 1. 12. 3. 2) 
and macrophages. Non-infected T cells could be also killed by HIV-infected 
macrophages, contributing to the CD4 depletion (Badley et al., 2000).
During the chronic phase o f infection, there is a high level o f CD4 T cell 
activation (Douek et al., 2003), which could lead to the death of activated CD4 T cells 
in the periphery. The circulating CD4 T cells have a shorter half-life and, despite the 
CD4 activation, the number o f circulating CD4 T cells is not increased (Hellerstein et 
al., 1999). As HIV infection progresses, a decline o f quantity and the quality of the 
CD4 T cells occurs (Douek et al., 2003; Fleury et al., 2000). HIV also affects the 
thymus, the main organ for T cell production, in both children and adults and 
suppresses thymocyte proliferation (Dion et al., 2004). HIV also perturbs and inhibits 
the production o f haematopoietic lineages other than CD4 T cells (Douek et al.,
2003).
HIV infection o f macrophages impairs their functions. Fey receptor signalling is 
impaired, resulting in the alteration o f the mechanisms of phagocytosis and cytokine 
secretion (Verani et al., 2005). It also induces phenotypic and functional perturbations 
of B cells (Moir et al., 2001). Peripheral lymphoid organs are altered, the follicular 
dentritic cell (FDC) architecture is progressively destroyed and the lymphoid tissue is 
replaced by fibrotic tissue and fatty infiltration (Kacani et al., 2001).
1.10 Viral reservoirs
The initial infection is followed by the dissemination of HIV to various parts of 
the body, which form viral reservoirs. Blankson et al define a viral reservoir as a cell 
type or an anatomical site in which there is accumulation of replication-competent
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viruses, characterised by slower turnover properties than actively replicating viruses 
(Blankson et al., 2002).
The main targets for HIV are CD4 T cells (Dalgleish et al., 1984; Klatzmann et 
al., 1984). Not all CD4 T cells are equally infected by HIV. The predominant 
population of infected T cells consists of memory CD4 T cells, with naive CD4 T 
cells being more refractory to infection by R5-tropic viruses (Stebbing et al., 2004). 
HIV-specific memory CD4 T cells are more susceptible to HIV infection than other 
memory CD4 T cells, as they contain more HIV DNA at all stages of the infection 
(Douek et al., 2002). A small proportion of the infected cells can become quiescent 
and form a pool o f resting cells, thus, forming a viral reservoir (Blankson et al., 2002; 
Stebbing et al., 2004). This reservoir is long-lived, with a half-life o f 44 months, even 
after seven years o f anti-viral drug suppression (Siliciano et al., 2003). The existence 
and the persistence o f reservoirs in HIV infection makes the total eradication of HIV 
impossible, even in patients treated with anti-viral drugs (see section 1. 14. 1).
HIV also infects macrophages. Macrophage-derived viruses have also been 
reported to be less infectious (Domadula et al., 1999). Post-mortem analysis o f 
kidney, brain and liver tissues, isolated from AIDS patients, revealed that HIV was 
mostly found in infiltrated macrophages (van't Wout et al., 1998). Only a small 
proportion o f macrophages is infected by HIV, but the percentage increases in patients 
suffering from opportunistic infections. Macrophages represent a viral reservoir as 
they may be involved in the second phase o f decay observed during anti-viral therapy 
(see section 1. 14. 1).
Monocytes have been reported to be infected by HIV in vitro at low levels and 
could represent a viral reservoir in patients treated with anti-viral drugs (Sonza et al.,
2001). Blankson et al, however, suggested that monocytes have a turnover too rapid 
to be truly classified as a viral reservoir (Blankson et al., 2002).
A subset o f NK cells express CD4 and CCR5 and can be efficiently infected by 
HIV (Fleuridor et al., 2003) (see section 1. 13. 2. 1). Viral DNA can be detected in 
CD4 positive NK cells from patients on anti-retroviral therapy and replication- 
competent virus can be isolated (Valentin et al., 2002). This NK population could also 
represent a reservoir in vivo (Blankson et al., 2002; Stebbing et al., 2004).
Infection of activated CD8 T cells has been reported in patients with AIDS 
(Livingstone et al., 1996) as they can express CD4 in vitro (Cochrane et al., 2004). 
But the frequency o f infected memory CD8 T cells is very low in patients (Stebbing et
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al., 2004) and the contribution o f infected CD8 T cells as a reservoir needs further 
investigation (Blankson et al., 2002).
Lymph nodes, where resting memory CD4 T cells can be detected in the same 
frequency as in the peripheral blood, are considered to be viral reservoirs (Blankson et 
al., 2002). FDCs are also associated with HIV and are thought to be a source of 
infectious viruses (Kacani et al., 2001). The thymus is also infected by HIV (Dion et 
al., 2004) but has yet to be characterised as a reservoir (Blankson et al., 2002; 
Stebbing et al., 2004).
1.11 Genetic factors and progression of HIV/AIDS
In the absence o f anti-viral therapy, 90% of the individuals who have contracted 
HIV have died (or will die) o f AIDS (O'Brien and Nelson, 2004). All individuals from 
risk groups, however, are not all equal regarding infection dynamics or in their 
progression towards AIDS. The evolution of HIV in a patient is, o f course, modulated 
by their immune response but genetic factors also have to be taken into account.
Mutations affecting the level of chemokine receptor expression can have a potent 
effect on HIV infection. Based on studies comparing either infected versus non­
infected individuals or normal, slow or rapid progressors, gene polymorphisms have 
been associated with prevention o f infection, delay or acceleration towards AIDS in 
vivo (Liu et al., 2004; O'Brien and Nelson, 2004).
As mentioned in 1. 6. 2. 2, individuals who present a genetic mutation within the 
CCR5 gene (usually referred as A32), in both alleles, resulting in a truncated CCR5 
receptor that is not expressed at the cell surface, are highly resistant to HIV infection 
(Dean et al., 1996). The homozygous mutation is found in 1% of the Caucasian 
population (O'Brien and Nelson, 2004). These individuals, however, are not entirely 
resistant to infection, as they can be infected by HIV viruses causing a rapid depletion 
of the CD4 T cells in their blood (O'Brien et al., 1997; Theodorou et al., 1997). The 
heterozygous mutation confers partial protection and the progression towards AIDS is 
delayed (O'Brien and Nelson, 2004). Recently, a study by Gonzalez et al reported that 
the number of copies o f CCL3L1, the gene encoding the most potent chemokine 
ligand of CCR5 (RANTES), directly influences the susceptibility to HIV infection 
and disease progression (Gonzalez et al., 2005). The CCR2 V64I variant is associated 
with a delay in AIDS progression (Smith et al., 1997). This mutated CCR2 receptor
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could associate with CXCR4, which could prevent the R5-X4 switch (O'Brien and 
Nelson, 2004).
DC-SIGN is a prime target in the transmission and the dissemination of HIV. DC- 
SIGN interacts with mannose residues by its transmembrane domain. The 
transmembrane domain has o f repeats o f twenty-three amino acids residues (Liu et al., 
2004). Polymorphisms of DC-SIGN  exist but are rare and are characterised by the 
number of repeat motifs within the transmembrane domain. A study has shown that 
some exposed seronegative individuals expressed DC-SIGN with a decreased number 
of repeats (six repeats against seven or eight repeats) whereas all infected individuals 
synthesised the consensus number o f the DC-SIGN sequence (seven repeats). This 
may suggest that some degree o f protection could be associated with a decreased 
number o f repeats within DC-SIGN (Liu et al., 2004). Considering that this 
polymorphism was found only in less than 1% of the cohort studied, these findings 
will have to be confirmed. Martin et al recently reported that a single nucleotide 
polymorphism (SNP), present within the promoter of DC-SIGN was slightly over 
represented only in parenterally exposed Caucasian Americans (Martin et al., 2004). 
An SNP found within the coding sequence o f APOBEC3G  gene could be associated 
with rapid progression towards AIDS (An et al., 2004).
Polymorphisms within promoters modulating the synthesis level o f chemokines 
such as RANTES, SDF-1, the ligands for CCR5 and CXCR4 respectively (see table 1. 
1), have been linked to protection or disease progression (Martin et al., 1998). The 
polymorphisms could result in higher or lower levels o f chemokine synthesis.
SNPs within the genes for MCP1, MCP2 and eotaxin, have been found more 
frequently in highly-exposed HIV-1 seronegative Caucasian Americans (Modi et al.,
2003). These SNPs were found mostly within non-coding regions o f the genes. The 
mechanism of protection against HIV infection is not clear, and could be associated 
with a modulation in the recruitment o f target cells at the site o f inflammation (Modi 
et al., 2003).
The alleles of the MHC class I genes, known as the human leukocyte antigen 
(HLA) loci and controlling the CD8 T cell response, play a major role in the control 
of HIV viraemia and in the prevention of infection. Not all HLA types handle HIV in 
the same manner (for a complete review, see Nolan et al., 2004).
The HLA-B57 haplotype has been strongly associated with delay in HIV 
progression (Altfeld et al., 2003). Altfeld et al reported that this haplotype in
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individuals presenting symptoms o f HIV acute infection was under-represented 
compared to the general population. They showed in acute infection that HLA-B57 
responses were dominant and had a broader and stronger effect than the responses 
restricted to all the other haplotypes combined (Altfeld et al., 2003). The other 
haplotypes linked to delay in disease progression are HLA-B27 and HLA-B18 (Nolan 
et al., 2004). The haplotypes HLA-B35, HLA-B22 and HLA-B8 have been linked to a 
more rapid disease progression (Nolan et al., 2004).
NK cells are lymphoid cells, involved in the innate immune response against 
viruses by releasing granules such as perforin and granzymes into infected cells (see 
section 1. 11.2). The genotype o f the receptors at their surface, called KIR, has been 
involved in the modulation o f killing HIV-infected-CD4 T cells. Flores-Villanueva et 
al showed that the HLA-Bw4 locus ligand for the NK inhibitory receptor, was linked 
to protection from AIDS (Flores-Villanueva et al., 2001).
Polymorphisms found within the mannan binding lectin (MBL), one o f the three 
pathways o f complement (see section 1. 13. 2. 3), was associated with a slower (Maas 
et al., 1998) or a more rapid progression (Garred et al., 1997) towards AIDS.
Individuals, who possess one or more of the genetic polymorphisms associated 
with delay in disease progression, will see their life expectancy increased without the 
need for anti-viral treatments. Whether these genetic advantages can allow the 
infected individuals to live with HIV asymptomatically, without any CD4 T cell 
decline until they die o f  non HIV-related illnesses is premature to assess as the 
epidemic started twenty years ago.
1.12 Innate non-immune responses to HIV
Until recently, the immune system was thought to be the most potent arm of 
defence against the spreading o f incoming mammalian retroviruses. However, the 
picture of innate complex intracellular networks capable of blocking the life cycle of 
some retroviruses in vitro (targeting pre- and post-RT steps) is now emerging 
(Bieniasz, 2004; Schmitz et al., 2004). This newly investigated field might lead to a 
better understanding o f the early events of the retrovirus life cycle following entry 
and, more importantly, to the generation of new classes of anti-HIV drugs.
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1.12.1 Post-entry restrictions targeting CA
Fvl can block the replication o f MLV type N or B, between the RT and the 
integration viral steps, due to the presence of the f v l  alleles in some strains of 
laboratory inbred mice (Lee and KewalRamani, 2004). Fvl sensitivity is determined 
by MLV CA at position 110. Similarly, a broader, saturable pre-RT blocking agent, 
termed Ref 1, was described for MLV-N and equine infectious anaemia virus (EIAV) 
in human cell lines. A comparable pattern of pre-RT restriction, also mediated by 
saturable factor(s) was also discovered against HIV-1 and HIV-2, in several 
mammalian cells, particularly in those from monkeys (Bieniasz, 2004). The potency 
of this restriction, named Lvl (for Lentivirus restriction 1) seems to be dependent on 
the presence of CypA in the target cells (Towers et al., 2003). Both Refl and Lvl also 
act on CA of HIV or SIV.
The protein TRIM5a, originally isolated from a rhesus monkey cDNA library 
(Stremlau et al., 2004), seems to be at the centre of the blockage(s) mediated by Lvl 
and by Refl (Hatziioannou et al., 2004; Keckesova et al., 2004; Yap et al., 2004). The 
physiologic role o f TRIM 5a is unknown but it contains a RING domain characteristic 
of proteins with ubiquitin ligase activity (Stremlau et al., 2004). It is likely that 
TRIM5a constitutes only a piece in the restriction jigsaw. TRIM1 was also found to 
have a moderate effect on Refl (Yap et al., 2004). Moreover, Owens et al have 
mapped amino acid residues in two distinct regions of CA involved in the Lvl 
restriction (Owens et al., 2004), which suggests that several cellular proteins might 
orchestrate in synergy to conduct the Lvl restriction. Whether the same cellular 
machinery or the same cellular mechanisms act for both Refl and Lvl restrictions 
remain to be clarified (Bieniasz, 2004; Lee and KewalRamani, 2004).
In parallel, Vyakamam et al, reported a post-entry block to R5-tropic viruses in 
memory CD4 T cells (Vyakamam et al., 2001). Schmitz et al also described a post-RT 
restriction, named Lv2, for an HIV-2 molecular clone on several human cell lines, 
involving Env and CA (Schmitz et al., 2004). The cellular components and the 
mechanism mediating this new restriction remain to be identified; although new data 
seem to infer that the Lv2 restriction might be linked to an endocytic pathway 
(Marchant et al, submitted).
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1.12.2 APOBEC3G and V if
Lvl, Lv2 and R efl restrictions have been described to (probably partly) explain 
why some retroviruses cannot replicate in some cell lines expressing their specific 
receptors (and co-receptors) and to explore new avenues in the requirements for a 
successful retroviral zoonosis. Some cellular proteins exist to counteract the infection 
of retroviruses in their natural host. It is the case for APOBEC3G, previously termed 
CEM15 (Sheehy et al., 2002), that specifically hinders the successful generation of 
infectious viruses. APOBEC3G belongs to a multi-gene family o f cytidine 
deaminases. In non-permissive cell lines, APOBEC3G is incorporated into virions 
(Harris et al., 2003) by interacting with Gag (Cen et al., 2004) and targets the RT step 
of the second generation o f H IV -1 by altering the viral sequences during the synthesis 
of the minus DNA strand by changing the C into a U. The complementary viral strand 
will therefore incorporate an A, instead of originally a G (Harris et al., 2003; Mangeat 
et al., 2003; Zhang et al., 2003). The introduction of U into DNA can direct the 
nascent DNA to degradation by endonucleases. APOBEC3G also inhibits the 
completion of the HIV cycle by targeting preferentially C/TCC sequences, which will 
be mutated into a stop codon, leading to the generation of inactive truncated proteins. 
APOBEC3G has also been shown to deaminate endogenous retroviruses, preventing 
their retrotranspositions (Esnault et al., 2005).
HIV-1 inhibits this anti-viral activity by the direct interaction o f APOBEC3G with 
one of its accessory proteins, V if (Sheehy et al., 2002). In non-permissive cells, Vif 
prevents the encapsidation o f APOBEC3G (Mariani et al., 2003) and mediates the 
binding of APOBEC3G with an ubiquitin ligase complex, which subsequently 
ubiquitinates APOBEC3G and targets it to degradation by the proteasome (Mehle et 
al., 2004). Despite the presence o f V if in virions, G-A substitutions are frequently 
high in the HIV genome. This observation has let to the hypothesis that the anti-viral 
action of APOBEC3G is not totally inhibited by V if and the consequent diversity of 
the HIV genome might aid escape from the adaptive immune response (Bieniasz,
2004).
Other cytidine deaminases also have anti-viral editing properties such as 
APOBEC3F (Liddament et al., 2004) and, perhaps more interestingly, AID 
(activation-induced cytidine deaminase) that is involved in the Ab-gene 
diversification (Gu and Sundquist, 2003). Bishop et al reported that APOBEC1 and 
APOBEC3B could inhibit HIV even in the presence o f V if (Bishop et al., 2004).
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These proteins have also been shown to play a similar role with other viruses such as 
MLV, EIAV (Gu and Sundquist, 2003) and hepatitis B (Bieniasz, 2004).
1.12.3 The m urrl gene
The murrl gene, involved in copper regulation, inhibits HIV replication in resting 
CD4 T cells (Ganesh et al., 2003). M urrl is involved in the degradation of NF-kB, as 
inhibition of m urrl by specific short interfering RNA (siRNA) up-regulates NF-kB 
activity in laboratory cell lines and enhances HIV replication in primary resting CD4 
T cells. NF-kB is a transcription factor involved in HIV transcription by binding to 
one of the transcription boxes o f the 5’LTR (see section 1. 5. 4). M urrl does not 
directly down-regulate the synthesis o f NF-kB but inhibits the degradation o f IkB. 
When NF-kB is associated with IkB, NF-kB is sequestered in the cytoplasm and 
cannot translocate into the nucleus. IkB is ubiquitinated and is degraded by the 
proteasome, NK-kB is released and can translocate into the nucleus. M urrl acts 
(directly or indirectly) on the proteosome complex pathway and prevents the 
degradation o f IkB (Ganesh et al., 2003). By having an effect on the proteasome 
pathway, the authors speculated that murrl could also affect the budding of HIV in 
resting CD4 T cells, providing a second block in the replication cycle.
1.13 Immune responses to HIV and immune escape
When infecting an individual, HIV will trigger a potent adaptive immune 
response, mediated by both CTLs and Abs (see sections 1. 13. 3. 2 and 1. 13. 3. 3). 
HIV can actively escape immune control, by exerting a direct stress on the immune 
system itself, such as down-regulating key markers involved in the coordination of a 
potent and focused neutralising response (such as MHC class I and II molecules) via 
the direct action o f the viral proteins, such as N ef (Piguet et al., 2000; Stumptner- 
Cuvelette et al., 2001), Tat (Howcroft et al., 1993), Vpu (Kerkau et al., 1997) and Rev 
(Bobbitt et al., 2003). HIV can also escape from the pressure o f the adaptive immune 
response by nucleotide substitutions within its genome, resulting in the generation of 
escape mutants, (generally) without a severe cost to viral fitness.
1.13.1 The viral proteins Nef, Tat and Vpu
Antigen presentation to CD8 T cells triggers cytolytic attack against cells infected 
by microbes - an essential mechanism in fighting viruses - as they are intracellular
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parasites. HIV has developed strategies to inhibit MHC Class I presentation to reduce 
CTL attack. HIV down-regulates MHC Class I by interfering with the transcription of 
the genes, via Tat (Carroll et al., 1998), by degrading the synthesis o f the proteins in 
the ER, via Vpu (Kerkau et al., 1997) and by acting on the presence of the MHC Class 
I molecules on the surface o f the infected cell, via N ef (Piguet et al., 2000; Stumptner- 
Cuvelette et al., 2001).
1.13.1.1 MHC Class I and Tat
Tat stimulates the synthesis of full-length RNA molecules of HIV (see section 1. 
5. 4) but also influences the expression of some cellular genes and appears to repress 
the transcription o f the MHC Class I genes (Howcroft et al., 1993), by modulating the 
acetylation o f TFIID, involved in the transcription of MHC Class II genes (Kamp et 
al., 2000). Tat also represses the activity of the P2 microglobulin promoter (Carroll et 
al., 1998).
1.13.1.2 MHC Class I and Vpu
Vpu has a role in degrading CD4 in the ER and has been shown to induce the loss 
of newly synthesised endogenous MHC Class I a-chains in the ER (Kerkau et al.,
1997).
1.13.1.3 Nef
N ef is a protein that is not required for the efficient replication o f HIV in vitro in 
constitutively activated cells (Arora et al., 2002). Nef, however, seems to play a 
crucial role for replication in vivo as viral replication in primary non-activated cells is 
enhanced by N ef (Arora et al., 2002). It has also been associated with HIV 
pathogenesis, as «£/-truncated genomes o f HIV have been found in long-term non- 
progressors (LTNPs) (Learmont et al., 1999).
As well as down-regulating CD4 (see section 1. 6. 2. 1), N ef contributes to the 
immune escape by down regulating MHC Class I (Schwartz et al., 1996). The down- 
regulation of MHC class I by Nef, partially protects infected primary cells from the 
CD8 T cell attack (Collins et al., 1998), providing HIV with a powerful tool for 
escaping the immune system. N ef down-regulates the MHC class I molecules by 
interacting with their cytoplasmic tail (Williams et al., 2002) and targeting them 
towards the trans Golgi network (TGN) involving an interaction with PACS-1, a
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protein able to form vesicles for trafficking (Piguet et al., 2000), and the recruitment 
of other proteins involved in endocytosis (Blagoveshchenskaya et al., 2002). Not all 
MHC allotypes are down-regulated: the HLA-A and HLA-B seem to be the only 
target of Nef-mediated down-regulation, the expression of HLA-C and HLA-E on the 
cell surface does not seem to be affected by N ef (Cohen et al., 1999; Williams et al., 
2002). The residual expression o f MHC class I molecules on the surface of infected 
cells could be a sufficient disguise to (partially) escape the attack from the NK cells 
(see section 1. 13. 2. 1).
N ef also impairs the MHC Class II presentation (Stumptner-Cuvelette et al.,
2001). Unlike MHC class I, MHC class II is only present on APCs, such as 
macrophages, B lymphocytes and DCs. Peptide presentation, within the context of 
MHC Class II, is therefore altered but N ef also up-regulates immature forms of MHC 
Class II (Stumptner-Cuvelette et al., 2001).
N ef has also been shown to down-regulate other surface molecules such as CD la, 
on immature DCs (Shinya et al., 2004), involved in antigen presentation to CD8 T 
cells and NKs, and CD28, critical for the induction of CTL responses (Swigut et al., 
2001).
1.13.2 The innate immune response
Despite the active involvement o f HIV at escaping the immune system, barriers do 
exist in vivo against HIV infection. One of the hurdles that the virus can encounter is 
the innate immune response, which consists mainly of NK cells, y5 T cells and 
complement.
1.13.2.1 Natural killer cells
NK cells are large granular lymphocytes, which play an important role in the 
innate and adaptive immunity. They represent a subset of T cells expressing a very 
restricted, unmodified T cell receptor (TCR) specific for glycolipid antigens 
(Unutmaz, 2003). The TCR on NK cells recognizes the non-polymorphic MHC class 
I-like molecule CD Id, which presents non-peptide antigens (Unutmaz, 2003).
When activated, NK cells synthesise large amounts of cytokines (such as IFNy, 
TNFa, IL1, IL5, IL8, IL10) and chemokines (M IPla, M IPlp, RANTES). Hence, they 
can regulate immune function and haematopoiesis. They also destroy infected cells by 
releasing cytolytic substances such as perforin, serine-like proteases, granzyme A and
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B and chondroitin sulphate proteoglycans (Jacobs et al., 2005). The action of NK cells 
can be triggered by IgG bound to the FcyRIII (CD 16), a process called antibody- 
dependent cellular cytotoxicity (ADCC), in the context of adaptive immunity, or by 
the down-regulation o f the MHC class I on APC, in the context o f the innate 
immunity. NK cells are regulated by a complex network of stimulatory and inhibitory 
receptors, present on their surface.
The ability o f NK cells to control HIV replication in vivo is unclear. Low NK cell 
numbers are associated with a more rapid disease progression (Jacobs et al., 2005; 
Kottilil et al., 2003) and some polymorphisms within some o f the receptors have been 
shown to have an impact on the progression towards AIDS (see section 1. 11). NK 
cells could also represent a barrier against HIV infection. Some highly exposed HIV- 
seronegative drug users have NK cells with enhanced chemokine level and cytolytic 
properties compared to control seropositive drug users and seronegative individuals 
(Scott-Algara et al., 2003). These findings suggest that NK cells can be successful at 
fighting HIV.
Some other studies, however, suggest that HIV inhibits the anti-viral actions of 
NK cells. NK cells can be divided into two subsets: CD4 negative and CD4 positive 
cells. The CD4 positive subset also expresses large amounts o f CCR5 and can be 
efficiently infected by R5-tropic strains o f HIV-1 (Fleuridor et al., 2003; Motsinger et 
al., 2002; Valentin et al., 2002), which leads to the selective depletion o f NK cells in 
infected individuals in the course o f infection and seriously impairs innate immunity 
against HIV (Motsinger et al., 2002).
When infected with HIV, NK cells seem to have their cytolytic properties 
impaired and are unable to lyse MHC class I down-regulated HIV-infected CD4 T 
cells or DCs (Bonaparte and Barker, 2003; Tasca et al., 2003). This inhibition of the 
cytolytic properties could be mediated by Tat (Poggi et al., 2002; Tasca et al., 2003), 
which may inhibit a kinase involved in calcium flux, resulting in the blocking of 
granzymes release (Poggi et al., 2002). Tat is unlikely to be the only agent inhibiting 
the release o f cytolytic substances, as the in vivo administration o f IFNa can restore 
some cytolytic activity in HIV-infected NK (Portales et al., 2003).
Despite their inability to lyse MHC Class I down-regulated HIV-infected cells, 
NK cells could control HIV viraemia, via the release of CC chemokines. HIV-infected 
NK cells have a direct effect on viral replication by releasing RANTES, M IPl-a and
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M IPl-p that bind to CD4 T cells from HIV-infected individuals in vitro and ex vivo 
(Fehniger et al., 1998; Kottilil et al., 2003).
ADCC is mediated when IgG binds to CD 16 on NK cells. Forthal et al reported 
that HIV-negative NK cells could inhibit autologous and heterologous HIV strains in 
association with non-NAbs, during the episode of acute infection in vitro (Forthal et 
al., 2001). Moreover, ADCC and viral load could be correlated in some studies 
(Ahmad et al., 2001; Forthal et al., 2001), and ADCC was found to be prognostic in 
HIV infection (Ahmad et al., 2001).
1.13.2.2 y8 T cells
A small proportion o f T cells express the y8 TCR receptor instead o f the a|3 TCR 
receptor. This particular subset represents a major T cell population in the skin, the 
intestinal epithelium and the pulmonary epithelium. Most of the y8 T cells consist of 
the V82 chain in combination with the Vy9 segment. A minor subset of y8 T cells 
expresses the V81 chain (Boullier et al., 1997). Unlike ap T cells, they do not appear 
to circulate extensively and remain fixed in the tissues. The ligand recognised by y8 T 
cells is unknown but these cells do not seem to be restricted by the MHC molecules 
and may bind to antigens like Ig. They might eliminate damaged cells as well as 
intruding pathogens in the mucosa (Janeway, 2001).
The y8 T cell subset is elevated in HIV-infected individuals and mainly consists of 
V81, both in peripheral blood and in mucosa (Boullier et al., 1995; Poles et al., 2003). 
The V81 subset, isolated from HIV-infected patients, can also produce anti-viral 
cytokines such as TNFa and IFNy (Boullier et al., 1997; Lichterfeld et al., 2004). V82 
T cells from uninfected individuals, can also secrete M IP-la, M IP-lp, RANTES and 
SDF-1 and can inhibit HIV infection in vitro (Poccia et al., 1999). But this subset 
might become anergic in HIV-infected individuals (Poccia et al., 1996). Macaques 
immunised with recombinant SIV gpl20 and p27 then anally infected with SIV, 
however, have an increase in the y8 T cell subset in the rectal mucosa. Furthermore, 
y8 T cells, from immunised monkeys, inhibit HIV infection by secretion o f CCR5 
chemokines (Lehner et al., 2000).
1.13.2.3 Complement
Complement consists o f more than 30 serum proteins organised in three cascades: 
the classical pathway, the alternative pathway and the MBL (for details, see the
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introduction o f Chapter 4). The triggering o f the cascades leads to C3 deposition on 
pathogens, a process called opsonisation, and the generation of the membrane attack 
complex (MAC). By-products o f the cascades, such as C3a, C4a and C5a, are called 
anaphylatoxins and are involved in inflammation, which results in the increase of 
smooth muscle contraction and vascular permeability. Complement also attracts 
phagocytic cells and neutrophils at the site o f inflammation via interactions between 
anaphylatoxins and complement receptors CR1, CR2 and CR3. Complement is also 
involved in the clearance o f immune complexes (Nash et al., 2001). Complement 
proteins are mainly synthesised by hepatocytes. Extra-hepatic sites of complement 
protein synthesis have been described, such as cells of the monocytic/macrophages 
lineage, fibroblasts, adipocytes, epithelial and endothelial cells. The brain is the 
second most important site o f complement protein production (Stoiber et al., 2003).
HIV activates all three complement pathways. The classical pathway can be 
triggered by HIV (Senaldi et al., 1989) in the presence (Spear et al., 1993b) or the 
absence of Abs by the direct binding o f C lq  on gp41 (Ebenbichler et al., 1991; Susal 
et al., 1994). MBL is also activated by the presence o f mannose residues on gpl20 
(Haurum et al., 1993). The alternative pathway has been also shown to be activated 
(Stoiber et al., 2001; Tacnet-Delorme et al., 1999).
Complement could have a dual role in vivo by inhibiting both HIV replication and 
by enhancing viral spread. Schmitz et al have shown that complement consumption, 
by cobra venom, in monkeys lead to an increase in viral load during primary viraemia 
(Schmitz et al., 1999b). Moreover, complement can enhance the protection mediated 
by the post-exposure administration of a NAb in mice (Gauduin et al., 1998b).
Complement-mediated enhancement of opsonised HIV has been reported in vitro 
in DCs via CR3 (Bajtay et al., 2004) as well as in epithelial cells (Bouhlal et al., 
2002). Complement could also mediate the binding o f HIV to erythrocytes (Horakova 
et al., 2004), playing a role in HIV dissemination. Complement also mediates binding 
of virions to B cells via CR2, which then may transmit HIV to CD4 T cells (Jakubik 
et al., 2000; Moir et al., 2000). FDCs, which constitute one o f the main sources of 
infectious viruses during chronic infection (Schacker et al., 2000; Stoiber et al., 2001), 
can trap HIV virions, mainly via interactions between C3d and CR2 (Kacani et al., 
2001).
Complement protein C3 synthesis is up-regulated in HIV-infected astrocytes 
(Speth et al., 2001) and could represent the source of increased levels of this protein in
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the cerebrospinal fluid o f HIV-infected patients (Stoiber et al., 2001). Complement, 
therefore, could be implicated in the neurodegeneration observed in some HIV- 
infected patients (Speth et al., 2001; Stoiber et al., 2001).
1.13.3 The adaptive immune response
1.13.3.1 The CD4 T cell response
CD4 T cells have a pivotal role in the induction o f a specific adaptive immune 
response. They function as T Helper (Th) cells that recognise antigens in an MHC 
class II context, present on APCs, and become effector cells that secrete various 
cytokines important in the stimulation of CD8 T cells, B cells and macrophages. Th 
cells can be differentiated into Th I cells or Th2 cells, based on the panel of secreted 
cytokines. Th I cells secrete IL2, IFN-y, TNF-P, GM-CSF and IL3 and stimulate a 
CTL response. Th2 cells secrete IL3, IL4, IL5, IL10 and IL13 and stimulate an Ab 
response (Janeway, 2001).
A specific CD4 response to HIV can be detected in acute infection (Pitcher et al., 
1999). This CD4 response inhibits HIV in vitro by producing M IP-la, M IP-lp and 
RANTES (Abdelwahab et al., 2003). This response, however, could be rapidly 
impaired as HIV preferentially infects HIV-specific CD4 T cells (Douek et al., 2002).
A robust CD4 response has been detected in LTNPs (Pitcher et al., 1999), and 
HIV-specific CD4 responses correlate inversely with the viral load (Kalams and 
Walker, 1998). This suggests that a functional CD4 response could be pivotal in the 
control of HIV in vivo. Pitcher et al, however, have shown that the CD4 T cell 
response against HIV could be detected in normal progressors (NPs), by IFN-y 
production, which suggests that the protective role of CD4 T cells against HIV could 
be indirect and could influence the CTL or the Ab response (Pitcher et al., 1999).
1.13.3.2 The CTL response
CTLs are generated by the immune activation of cytotoxic T cells (Tc cells). They 
are MHC Class I restricted and, therefore, can recognise and eliminate almost any 
infected cell accessible to them. CTL proliferation results from the stimulation with 
IL2 synthesised by the CD4 positive Th I cells that have been stimulated by APCs in a 
MHC Class II context. Contact between CTLs and cell targets are mediated by an 
interaction between the TCR on the CD8 T cells and the MHC Class I on the cell
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targets. Following this initial contact, the integrin receptor LFA-1 on the CTLs 
interacts with adhesion molecules ICAM on the target cells. The cell-cell contact 
triggers the release o f pore-forming proteins called perforin and serine proteases 
called granzymes into the cytoplasm of the target cell, which triggers DNA 
fragmentation. CTL cells express Fas ligand on their surface, and an interaction with 
Fas leads to the apoptosis o f the target cell. After the death o f the infected cells, the 
CTLs are released and can bind other target cells. CTLs can also control infections by 
releasing anti-viral cytokines such as IFNy and TNFa (Janeway, 2001).
Anti-HIV CTLs are detected in almost all patients (Betts et al., 2001). The main 
CTL targets are mostly peptidic sequences from proteins Gag, Pol and Env, but CTLs 
also target Vif, Nef, Rev, Vpu and Tat (Addo et al., 2002; Altfeld et al., 2001; Borrow 
et al., 1994). The breadth o f the CTL response varies among individuals and a broad 
and potent anti-HIV CD8 T cell activity is correlated with a low viral load and a 
slower progression towards AIDS (Borrow et al., 1994; Chouquet et al., 2002).
Anti-HIV CTLs can be detected in acute infection in humans (Borrow et al., 1994; 
Cao et al., 2003; Safrit et al., 1994) and in SIVmac-infected macaques (Mothe et al.,
2002). The CD8 T cell response against HIV thought to be the main immune effector 
in the viral decline observed during acute infection, preceding the detection o f NAbs 
(Borrow et al., 1994; Cao et al., 2003). In macaques, the depletion o f CD8 T cells 
leads to an uncontrolled viral load and a faster progression towards AIDS (Schmitz et 
al., 1999a). Moreover, an inverse correlation can be measured between plasma viral 
load and CTL activity, which suggests that CTLs play an important role in the 
containment of HIV in vivo (Ogg et al., 1998).
Anti-HIV CTL responses can be also detected in all stages o f infection, even in 
the AIDS phase. In acute infection, up to 10% of the circulating CTLs are specific to 
HIV with the percentage decreasing to 1-2% in the chronic stage (Islam et al., 2001; 
McMichael and Rowland-Jones, 2001). The nature of the CTL response can differ in 
the acute and the chronic infection. Goulder et al showed, in a cohort of Caucasian 
patients, that the CTL response against a Gag-derived peptide was detected in almost 
all studied patients during the chronic phase of infection but was absent from the 
overall CTL response in the acute phase, which was directed against other peptides 
from other HIV proteins (Goulder et al., 2001a). The same observation was reported 
by Mothe et al, in macaques, where the CTL response was directed against Tat, Rev
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and N ef in acute infection and against Gag, Pol and Env during the chronic stage 
(Mothe et al., 2002).
Although it is clear that CTLs are important to control HIV in vivo, the 
mechanism(s) responsible remain to be determined (McMichael and Rowland-Jones,
2001). The cytolytic properties o f CD8 T cells, in peripheral blood as well as in 
lymphoid tissue, seem to be impaired in the acute and chronic phases of infection 
(Appay et al., 2000; Dagarag et al., 2003; Lieberman et al., 2001) due to low levels of 
perforin (Haridas et al., 2003; McMichael and Rowland-Jones, 2001). The circulating 
anti-HIV CTLs are CD27+, are CD45RA' and therefore present the phenotype of 
immature CD8 T cells. The maturation o f memory CD8 T cells specific to HIV is 
skewed (Champagne et al., 2001) and they are unable to lyse HIV-infected cells 
(Haridas et al., 2003; McMichael and Rowland-Jones, 2001).
CTLs could inhibit HIV by the release o f cytokines such as IFNy, and TNFp 
(Appay et al., 2000; Jassoy et al., 1993), M IPl-a, M IP-ip (McMichael and Rowland- 
Jones, 2001), as well as by the production o f RANTES, which competes with HIV for 
CCR5 binding and down-regulates CCR5 (McMichael and Rowland-Jones, 2001). 
RANTES also up-regulates Fas ligand expression on CD8 T cells and, thus, can 
enhance killing o f HIV-infected cells (Hadida et al., 1999). CD8 T cells can inhibit 
HIV replication by secreting the CD8 anti-viral factor (CAF), that regulates the 
5’LTR of HIV integrated genome by a Stat I-dependent mechanism and prevents the 
initiation of transcription (Chang et al., 2002; McMichael and Rowland-Jones, 2001).
Despite a strong induction o f the CD8 T cell response in HIV infection, CTLs fail 
to eradicate infection. HIV and SIV can escape the CTL response by changing amino 
acid residues within peptides recognised by the CD8 T cells, during acute infection 
(Cao et al., 2003; O'Connor et al., 2002; Price et al., 1997), as one amino acid change 
within a peptide can lead to a complete loss of recognition by the CD8 T cells specific 
to the peptide (McMichael and Rowland-Jones, 2001). Draenert et al have shown that 
mutations flanking the Gag peptide recognised by CD8 T cells, in the HLA-B57 
context, resulted in altered antigen presentation thus favouring CTL escape by HIV 
(Draenert et al., 2004). Furthermore, Bobbit et al have shown that some Rev mutants 
could decrease the export o f Gag RNA from the nucleus, which would result in a 
reduction of Gag protein synthesis and and a reduction in the sensitivity against anti- 
Gag CTLs (Bobbitt et al., 2003). Moreover, they found similar Rev mutants in 
individuals who presented an HIV population that had escaped the CTL response,
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suggesting that Rev could partially inhibit the anti-HIV CD8 T cell response in vivo 
(Bobbitt et al., 2003). The presence o f a broad protective anti-HIV CTL response does 
not protect from superinfection (Altfeld et al., 2002).
CTLs need to be primed by CD4 T cells to undergo maturation. CD4 T cells are 
infected by HIV and their number drastically decreases as infection progresses. 
Therefore, in the context of HIV infection, the CTL response might be less and less 
efficient with time, as fewer and fewer CD4 T cells stimulate CD8 T cells 
(McMichael and Rowland-Jones, 2001). N ef and Vpu also down-regulate CD4, 
contributing to an altered collaboration between CD4 Th I and CD8 T cells. They also 
initiate the degradation o f MHC Class I, crucial in the initiation of CTLs.
Although CD8 T cells have an important role in controlling HIV infection, they 
also might favour the CD4 T cell depletion in HIV-infected individuals and could play 
a role in aggravating the disease (Douek et al., 2003). Moreover, Silvestri et al have 
shown that SIV infection in sooty mangabeys, its natural host, is characterised by an 
attenuated CD8 T cell response (Silvestri et al., 2003).
1.13.3.3 The humoral response
The first Ab response detected during primary infection is targeted against Gagp24, 
the most abundant HIV protein. Abs against all other HIV proteins are detected later 
(Levy, 1998). The purpose o f an Ab response in vivo is to prevent further 
dissemination o f  an infectious agent. In the case o f HIV, protective Abs will interfere 
with receptor binding and fusion with the cell membrane, both mechanisms being 
mediated by gpl20 and gp41. These Abs are called NAbs and are directed against 
gpl20 and gp41. The paragraph 1. 13. 3. 3 will only describe NAbs, as they have been 
extensively studied.
1.13.3.3.1 IgA
IgA represent the predominant Ig in external secretions such as saliva, tears, breast 
milk and mucus o f the bronchial, genito-urinary and digestive tracts. Specific IgA 
targeted against CCR5, capable o f neutralising HIV-1 and HIV-2 in vitro, have been 
found in saliva and genital fluids from HIV-2 infected individuals (Lizeng et al.,
2004) or from highly-exposed seronegative individuals (Barassi et al., 2004; Lizeng et 
al., 2004). IgA isotypes o f 2F5 (see section 1. 13. 3. 3. 7) could also potently
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neutralise Pis in vitro (Wolbank et al., 2003). IgA could therefore play a role in 
preventing infection in some exposed individuals.
1.13.3.3.2 Evolution of the neutralising anti-HIV response in infected individuals
Although the anti-gpl20 IgG response develops during acute infection, between 
four and twenty-five days post onset o f symptoms (POS) (Aasa-Chapman et al., 2004; 
Moore et al., 1994a), NAbs, that give 90% neutralisation, are usually detected 
between two and nine months o f infection against autologous isolates (Aasa-Chapman 
et al., 2004; Moog et al., 1997; Pellegrin et al., 1996; Richman et al., 2003). The 
presence of an earlier NAb response has been occasionally reported (Lewis et al., 
1998). Neutralisation may depend on the cell target as Ruppach et al have reported 
early autologous virus neutralisation in macrophages but not in lymphocytes 
(Ruppach et al., 2000). Neutralisation against heterologous isolates arises later (Aasa- 
Chapman et al., 2004; Moog et al., 1997; Pellegrin et al., 1996; Richman et al., 2003), 
is initially restricted to a few isolates, then broadens (McKnight et al., 1992) and is 
still detectable in sera from AIDS patients (Groopman et al., 1987; Weiss et al., 1985). 
Much o f the Ab response, in humans and chimpanzees, is elicited against 
discontinuous, conformation-sensitive epitopes (Moore and Ho, 1993; Steimer et al., 
1991), as the Ab binding is lost when sera are tested against denatured monomeric 
gpl20 (Moore and Ho, 1993). The neutralisation potency o f an Ab cannot be 
predicted by its binding property to monomeric gpl20 (Moore et al., 1995). The first 
Abs that are detected during primary infection are mainly directed against the CD4BS 
and, later the V3 loop (Moore et al., 1994a).
1.13.3.3.3 Role of neutralising antibodies in vivo
The protective role o f CD8 T cells against SHIV has been shown in vivo (Schmitz 
et al., 1999a), but the involvement o f NAbs in the control o f viraemia in vivo has yet 
to be fully demonstrated. Indirect evidence that NAbs can contribute to the 
containment of viral replication in vivo is, however, mounting.
In longitudinal studies, HIV variants from late time points are more resistant to 
neutralisation than viruses isolated from earlier time points. This suggests that NAbs 
are the selection pressure for the emergence of these variants (Albert et al., 1990; 
Richman et al., 2003). The neutralisation-sensitive TCLA IIIB isolate adopts a 
resistant phenotype to sCD4 and MAbs in an infected patient (Beaumont et al., 2001).
73
adults and children LTNPs have sera with higher neutralising titres and a broader 
cross-neutralisation pattern (Geffrn et al., 2003; Pilgrim et al., 1997). Binley et al 
reported the existence o f a strong NAb response in a treatment-nai've patient infected 
for at least sixteen years with undetectable viral loads and a weak CTL response 
(Binley et al., 1998). Moreover, Igarashi et al have shown that the half-life of SHIV 
was drastically reduced in vivo from 20 min (13-26 min) to 5.5 min (3.9-7.2 min) in 
monkeys that had previously developed a NAb response against the virus (Igarashi et 
al., 1999). Overall, these observations suggest that NAbs play a role in controlling 
viraemia and could delay the progression towards AIDS. However, Ab-mediated 
neutralisation is usually tested in the absence o f complement and therefore, the 
protective role o f non-NAbs in association with complement cannot be ruled out (see 
Chapters 3 and 4).
1.13.3.3.4 Neutralising epitopes
Numerous neutralising epitopes have been reported for HIV-1: on the CD4BS 
(Burton et al., 1991; McKeating et al., 1993; Trkola et al., 1995), the chemokine 
receptor binding site, that is CD4 binding-induced (Fouts et al., 2002; Moulard et al., 
2002; Thali et al., 1993; Wyatt et al., 1995), motifs on the V3 loop (Gomy et al., 
1992; Javaherian et al., 1989), on the VI/V2 structure (Fung et al., 1992; Gomy et al., 
1994; McKeating et al., 1993; Warrier et al., 1994) and on the carbohydrate motif 
recognised by 2G12 (Trkola et al., 1996b). Neutralising epitopes are also present on 
the ectodomain o f gp41 (Muster et al., 1993; Zwick et al., 2001b). Despite the 
description o f various neutralising MAbs, Pis are weakly neutralised in vitro (Moore 
et al., 1995).
1.13.3.3.5 TCLA versus PI neutralisation sensitivity
It is now clear that the neutralisation sensitivity differs between TCLA and PI 
isolates. Pis are more refractory to sCD4 inactivation (Daar et al., 1990) and NAb- 
mediated neutralisation than TCLA viruses (Gauduin et al., 1996; Parren et al., 1998; 
Wu et al., 1996). Therefore, neutralisation studies using TCLA viruses do not reflect 
the neutralising potencies o f Abs in vivo. The increased neutralisation sensitivity of 
TCLAs cannot be explained by the co-receptor usage (Montefiori et al., 1998; Trkola 
et al., 1998). The growth in immortalised cell lines could lead to the selection of viral 
genotypes with, possibly, altered Env conformations that allow more efficient entry
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but at the expense o f exposure to NAb neutralisation (Poignard et al., 1996b). Pis 
exhibit a two- to three-fold higher level of gpl20 than TCLAs. Pis may have a higher 
Env spike density, which would have an influence o n  the inactivation by sCD4 and 
perhaps by NAbs (O'Brien et al., 1994). Karlsson et a l , however, found no correlation 
between the amount o f gpl20 carried by various viruses from several clades and 
neutralisation (Karlsson et al., 1996).
1.13.3.3.6 Neutralising antibody escape
HIV infection can occur with a cell-free virus but also by cell-cell contact, using a 
virological synapse (Jolly et al., 2004), which could partially protect the virus from 
NAbs and contributing to escape mechanisms (Jolly and  Sattentau, 2004).
HIV can also support amino acid variation, particularly within Env, due to the lack 
of proof-reading activity in the RT and, therefore, can adapt to the pressure exerted by 
the immune response. Poignard et al reported that a large amount o f monoclonal 
NAbs did not control replication o f two Pis (SF162 and JRFL) in SCID-huPBL mice, 
as escape mutants arose in the targeted epitope within a week after HIV infection 
(Poignard et al., 1999). Moreover, mutations within a particular region o f Env can 
drastically influence the overall neutralisation sensitivity o f a virus (Bouma et al., 
2003; Park et al., 1998). Mutations within gp41 can also enhance or decrease the 
neutralising properties o f NAbs directed against gpl20 (Kalia et al., 2005). 
Furthermore, single point mutations can also modify the entire neutralisation profile 
of a virus (Watkins et al., 1996).
Neutralisation resistance could be due to Env conformations burying and hiding 
the neutralising epitopes (Kwong et al., 2002), as anti-co-receptor Fab fragments 
(such as 17b and X5) are more potent at neutralising HIV than whole IgG molecules 
(Darbha et al., 2004; Labrijn et al., 2003). Variable loops are the most divergent parts 
of gpl20 and their presence could influence the neutralisation potency o f NAbs. 
Deletion o f the V I/V 2 loop in HxB2 makes the virus more sensitive to NAbs (Cao et 
al., 1997). Similarly, immunisation of rabbits with the oligomeric SF162 Env deleted 
in the V2 region leads to the generation of a greater and a broader NAb response 
(Barnett et al., 2001), which also suggests that the V2 loop can protect conserved 
neutralising epitopes, such as the CD4BS and the V3 loop from NAbs (Krachmarov et 
al., 2005),. MAbs isolated from rats immunised with IIIB deleted for the V I, V2 and 
V3 loops neutralise a broader range of clade B and non-clade B isolates (Jeffs et al.,
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2002). Moreover, the VI/V2 loop exchange between SF162 and JRFL leads to the 
swap of neutralisation sensitivity between these two isolates (Pinter et al., 2004; 
Stamatatos and Cheng-Mayer, 1998).
Buried neutralising epitopes within gpl20 can create an unfavourable energy 
requirement for the NAbs to bind Env (Kwong et al., 2002). The gp41-gpl20 
interaction is weak, and monomeric gpl20 is the predominant antigen for B cell 
stimulation. Hence, the majority of Abs present in patients’ sera will bind 
preferentially to monomeric gpl20 rather than trimeric spikes on infectious viruses 
(Poignard et al., 1996b).
gpl20 is organised into a neutralising face, a non-neutralising face and an 
immunologically silent face protected by a glycan shield. Both o f the latter faces are 
exposed on the oligomeric spike protecting the neutralising face (Wyatt and Sodroski,
1998). The removal o f glycans within the V1/V2 structure (Cole et al., 2004; Johnson 
et al., 2003; Quinones-Kochs et al., 2002) or within the V3 loop (Koch et al., 2003; 
McCaffrey et al., 2004; Polzer et al., 2002) increases the neutralisation of some 
viruses. Glycosylation could represent the main Ab escape mechanism in vivo. A  
study by Wei et al showed that Env escape mutants had changes primarily in their N- 
glycosylation patterns (Wei et al., 2003).
The acquisition o f CD4 as a receptor has perhaps allowed HIV to increase its 
resistance against NAbs. Thomas et al have shown that HIV-2 CD4-independent 
isolates were much more sensitive than CD4-dependent HIV-2 strains and that the 
neutralisation sensitivity was epitope-independent (Thomas et al., 2003). Similarly, 
the artificially engineered CD4-independent strain o f HIV-1 IIIBx is more sensitive to 
neutralisation by sera than its CD4-dependent counterpart (Edwards et al., 2001).
Although HIV can escape Ab-mediated neutralisation, a study by Derdeyn et al 
showed that viruses transmitted to a new person were sensitive to neutralisation by the 
sera of the transmitting partner. This may suggest that NAbs would exert a fitness cost 
on the vims (Derdeyn et al., 2004). Eliciting a sterilising Ab response by an 
immunogen will be a difficult challenge. However, eliciting a NAb response that will 
force the vims to escape at severe fitness cost might be sufficient to delay disease 
progression.
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1.13.3.3.7 Cross-neutralising human antibodies
Although it is feasible to elicit a NAb response, it is usually isolate-specific and 
weakly cross-neutralising (Weiss et al., 1985). Nevertheless, some cross-clade 
neutralising MAbs (Binley et al., 2004), mapping to both gpl20 and gp41, have been 
isolated from LNTPs.
The NAb IgGl b l2  (refered as b l2  for the rest o f this thesis) was isolated by 
screening by phage display an Ab library amplified from the bone marrow of an 
asymptomatic HIV-1 patient. It overlaps the CD4BS of HIV-1 and neutralises HIV-1 
Pis from various clades (see introduction chapter 5 for details). The Ab IgGl 2G12 
(refered as 2G12 for the rest o f this thesis) binds to a discontinuous, purely mannose 
al-»a2-dependent epitope, on the outer face o f gpl20, defined by the C2, C3, C4 
domains and the V4 loop (Sanders et al., 2002; Scanlan et al., 2002; Trkola et al., 
1996b). The Fab X5 was isolated by screening by phage display an Ab library from a 
seropositive patient with a high titre NAb serum, using a gpl20-CD4-CCR5 complex 
(Moulard et al., 2002). It overlaps the binding site of 17b and binds to a highly 
conserved CD4-induced epitope, close to the CD4BS (Darbha et al., 2004; Moulard et 
al., 2002). It can neutralise cell-free virus entry as well as cell-cell fusion (Moulard et 
al., 2002).
The IgGl 2F5 and 4E10 NAbs (refered to as 2F5 and 4E10 for the rest o f this 
thesis) bind to distinct epitopes on gp41 (Purtscher et al., 1996). The binding of 2F5 is 
correlated with the presence o f the sequence ELDKWA, which is highly conserved 
amongst isolates from different clades. The epitope might also be conformation- 
dependent (Parker et al., 2001). 2F5 and 4E10 inhibit the fusion process o f HIV with 
the cell membrane and their neutralisation potency is enhanced in a hydrophobic 
environment, which might present the neutralising epitope in the right conformation 
(Ofek et al., 2004). The actual neutralisation mechanisms are not fully understood. 
2F5 seems to bind to Env in its native conformation and not to the pre-hairpin 
intermediate, prior to CD4 binding (Barbato et al., 2003).
It is interesting to note that 2F5, X5 and b l2  have longer than average CDR H3 
regions; 18 amino acid residues for b l2  (Saphire et al., 2001b) and 22 amino acid 
residues for 2F5 and X5 (Ofek et al., 2004). The crystallisation of X5 has revealed 
that the CDR H3 region adopts a similar prominent structure to b l2  (Darbha et al.,
2004). Longer CDR H3 regions might result in more flexible loops that allow Abs to
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bind tightly to structures, buried within gpl20, that IgG with average CDR H3 regions 
fail to reach (Saphire et al., 2001b).
When these NAbs are used as cocktails, HIV neutralisation is enhanced in vitro 
(Binley et al., 2004; Zwick et al., 2001b) and can block virus transmission from DCs 
to T cells (Frankel et al., 1998). Although some promising strategies are currently 
designed to specifically elicit b l2  as the single anti-CD4BS Ab (Pantophlet et al., 
2003b; Pantophlet et al., 2004), it will be challenging to elaborate an immunogen that 
will exclusively trigger the synthesis o f these MAbs. They, however, can be used in 
topical applications for preventing HIV infection (see section 1.14. 5).
1.13.3.3.8 Mechanisms of neutralisation
Non-neutralising and NAbs cannot be distinguished in their ability to bind 
monomeric gpl20 (Moore et al., 1995). However, it seems that only NAbs have the 
ability to bind oligomeric gpl20 on virions with sufficient affinity (Poignard et al.,
2003). Therefore, NAbs could neutralise HIV infectious virions irrespective of the 
nature of their epitopes by entirely coating the virion (Poignard et al., 2003). Studies, 
however, have revealed that some NAbs neutralise HIV by interacting in an epitope- 
specific manner. Neutralising anti-CD4 Abs against TCLA viruses favour the 
dissociation o f gpl20 from the virions, leading to the generation o f non-infectious 
viruses (Poignard et al., 1996a). b l2  competes with CD4 on the gpl20 CD4BS for 
interacting with the crucial phenyalanine residue at the bottom of the CD4BS pocket 
of gpl20 (Saphire et al., 2001b). Choe et al showed that some anti-CD4 induced Abs 
neutralised HIV by successfully competing with the sulphated regions o f CCR5 
involved in interactions with the virus (Farzan et al., 1998) via sulphate motifs on 
their CDR H3 regions (Choe et al., 2003). The crystal structure o f 2G12 reveals a V h 
domain exchange. Hence, V h interacts with V l ’ and V h ’ interacts with V l . This 
domain exchange forms an extensive multivalent binding surface composed of the 
two conventional sites (V h/V l ’ and V h ’/V l) and a homodimeric V h/V h ’ interface 
(Calarese et al., 2003).
1.13.3.3.9 Antibody-dependent enhancement
HIV is capable o f escaping Ab neutralisation but also could use Abs to its own 
advantage to enhance its infectivity. Antibody-dependent enhancement (ADE) of HIV 
has been reported in vitro (Sullivan, 2001) but the in vivo relevance has yet to be
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demonstrated. A recent report has shown that infected macaques, previously 
immunised with an attenuated strain of SIV, progressed to AIDS more rapidly than 
non-immunised animals. The sera from the immunised animals showed enhancement 
of HIV infection on MT2 cells (Staprans et al., 2004). The mechanisms for ADE are 
still unclear. The FcyRIII receptor could be involved in mediating HIV enhancement 
using sera from AIDS patients (Homsy et al., 1989). However, neutralisation studies 
using early non-neutralising sera, on macrophages which synthesise high levels of 
FcyRIII receptors, did not show enhancement of infection but showed increased 
neutralisation compared to PBMCs (Ruppart et al, J Virol, 2000). The binding of 
some Abs could also induce conformational changes in gpl20 and activate the 
binding process (Sullivan, 2001).
1.14 Anti-HIV treatments
1.14.1 HAART
The currently available anti-viral drugs HIV target RT and PR. Nucleoside 
analogues lack 3’OH extremities and prematurely abort viral DNA elongation. 
Targets of RT include non-nucleoside reverse transcriptase inhibitors (NNRTIs) that 
bind at or close to the RT catalytic domain and block enzyme activity. The anti-PR 
drugs mimic viral peptide substrates but have non-cleavable structures that block the 
catalytic activity o f the PR.
Highly active anti-retroviral therapy (HAART) includes several drugs. This 
treatment can reduce viral replication to undetectable RNA levels in plasma. HAART, 
however, does not eliminate viral reservoirs, as the treatment interruption is followed 
by viral rebound (Jubault et al., 1998). Furthermore, episomal intermediates can be 
detected in PBMCs from treated patients who show undetectable viral load in their 
plasma (Sharkey et al., 2000). Siliciano et al have estimated that over 70 years of 
consecutive therapy would be required to eradicate the memory CD4 T cell reservoir 
alone (Siliciano et al., 2003). The penetration rate o f anti-viral drugs is weaker in 
semen than in blood (Taylor et al., 1999), which suggests that drug-resistant viruses 
might appear in the genital tract, independently of viral evolution in the peripheral 
blood. Drug-resistant viruses can be successfully transmitted to new individuals 
(Hecht et al., 1998), which could result in the emergence of the circulation of these 
variants in a population (Hecht et al., 1998).
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The HAART regimen has serious side effects and can sometimes be lethal to some 
individuals who develop acute liver or renal failure months after the commencement 
of therapy (Clark et al., 2002; Murphy et al., 2003; Scherpbier et al., 2003) Structured 
treatment interruptions (STIs) could overcome this problem. STIs consist of 
alternating periods o f medication and non-medication. The STI approach can lead to 
better control SIV and HIV replication, even months after the interruption of the 
treatment (Lori et al., 2000a; Lori et al., 2000b). This which could be due to the 
induction of a more protective immune response.
Despite the inability o f HAART treatment to totally eradicate HIV infection, as 
well as the serious side effects, the wide prescription of these drugs to a population 
could seriously decrease HIV incidence and contribute to the control o f the epidemic 
(Blower et al., 2000).
1.14.2 sCD4 and sCD4-IgG
sCD4 has been shown to inactivate TCLA isolates of HIV in vitro (Deen et al., 
1988; Traunecker et al., 1988) by gpl20 shedding (Moore et al., 1990) and could be a 
potential anti-HIV treatment. However, the half-life is sCD4 in humans is short, 
between 30 and 120 min (Capon et al., 1989), and sCD4 does not decrease viral loads 
of patients in vivo (Daar et al., 1990). Pis are also more resistant to sCD4 inactivation 
in vitro (Ashkenazi et al., 1991; Daar et al., 1990) and the difference in sensitivity 
between TCLA and PI seems to be due to CD4-gpl20 affinity.
A hybrid molecule was designed, consisting o f the Fc portion of an IgG and the 
D1+D2 domains o f CD4 and was called immunoadhesin or sCD4-IgG. This molecule 
has a half-life extended by 200-fold in rabbit serum compared to sCD4, comparable to 
the half-life of human IgG (Capon et al., 1989). The intravenous injection of sCD4- 
IgG prevented infection with IIIB in chimpanzees (Ward et al., 1991) and sCD4-IgG 
was successfully transferred across the placenta (Bym et al., 1990). Based on the 
same principle, a tetravalent form of D1-D2 of CD4 fused to the heavy and light 
chains of an IgG, called PRO 542, was designed (Allaway et al., 1995). This 
compound inhibits entry o f X4- and R5-tropic HIV isolates from several clades in 
vitro (Trkola et al., 1995). Phase three clinical trials undertaken in children show that 
PRO 542 decreases viral loads in vivo by up to 7-fold and its administration does not 
cause serious side effects (Shearer et al., 2000). Another study, in HIV-infected 
adults, has shown that PRO 542 can decrease the viral load of patients up to 5-fold.
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Moreover, the inhibitory effect o f this molecule is stronger in patients with advanced- 
stage disease than with early-stage disease (Jacobson et al., 2004). Although HIV 
treatment by sCD4-IgG does not result in undetectable viral loads, it could be used as 
an alternative therapy.
1.14.3 Chemokine receptor antagonists
The relevant chemokine co-receptors for transmission in vivo are CXCR4 and 
CCR5 (see section 1. 6. 2. 2). Their respective ligands, SDF-1 and RANTES, compete 
with HIV for binding to the chemokine receptors. They down-regulate their 
chemokine receptors at the cell surface and, therefore, decrease the number of target 
cells for HIV. Some variants o f RANTES are currently tested as HIV inhibitors 
(Shattock and Moore, 2003).
Several small molecule co-receptor antagonists have been described. The 
compounds AMD3100, T22 and ALX40-4C inhibit HIV entry on CXCR4 in vitro but 
their prescription in vivo may be toxic, as CXCR4 deletion (which might be provoked 
by CXCR4 downregulation) perturbs foetal development in mice and, therefore, the 
prescription o f anti-CXCR4 compounds might lead to severe side effects (Moore and 
Stevenson, 2000). The anti-CCR5 compounds, such as TAK-779 (Dragic et al., 2000), 
AD101 (Tsamis et al., 2003) or CMPD 167, might not raise a toxicity problem, as 
individuals who not synthesise CCR5 do not suffer from obvious immunological 
defects. Recently, an antagonist molecule that inhibits X4- and R5-tropic viruses has 
been reported (Princen et al., 2004).
In the short-term, the treatment with small chemokine antagonists results in the 
inhibition of the replication o f HIV in vitro and in the reduction o f the viral load in 
vivo (Wolinsky et al., 2004). In the long-term, it results in the emergence o f resistant 
viral mutants (Trkola et al., 2002) which retain the same tropism as the sensitive virus, 
even in the presence o f the inhibitor in vitro (Farber and Berger, 2002; Trkola et al.,
2002), and in vivo, although a brief and transient tropism switch is first observed 
(Wolinsky et al., 2004).
1.14.4 The anti-fusion peptide T20
T20, also known as D P-178 and enfuvirtide (Cervia and Smith, 2003), interferes 
with fusion between HIV and the cell membranes. T20 is a hydrophobic peptide 
corresponding to the 36 amino acid residues of the HR2 domain o f gp41. T20 binds to
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HR1 and locks gp41 into a structural intermediate that prevents gp41 from entering a 
fusion-active state. T20 is effective against HIV from all clades (Cervia and Smith,
2003). R5-tropic viruses are less sensitive to T20 than X4-tropic viruses (Derdeyn et 
al., 2000), due to a greater affinity for the co-receptor, which could increase the 
kinetics of fusion (Reeves et al., 2002). Phase three clinical trials have shown that T20 
can reduce viral load between 0.8 and 1 log in patients failing HAART (Cervia and 
Smith, 2003). Unlike HAART, T20 is well tolerated. However, the hydrophobicity of 
T20 makes it difficult to inject. T20-resistant viruses emerge in vivo and mutations are 
found in gp41 (Lu et al., 2004; Wei et al., 2002) but T20-escape mutants seem to lose 
fitness (Lu et al., 2004). T20 is however very costly. The annual prescription of T20 
would cost $20, 000 per patient, which makes this drug unavailable to developing 
countries.
1.14.5 Microbicides and passive administration of neutralising antibodies
In developing countries, the majority o f HIV transmission occurs from man to 
woman. Condoms are the most reliable anti-HIV barriers but they require the consent 
of the male partner, which does not always happen. Therefore, cheap and reliable 
microbicides that can protect women from infection need to be developed (Shattock 
and Solomon, 2004). Microbicides are topical formulations that can block HIV 
infection when applied vaginally or rectally (Shattock and Solomon, 2004). Although 
an anti-HIV vaccine that will trigger a sterilising immune response is likely to still 
take many years, a topical microbicide that will prevent HIV infection altogether 
seems to be a more promising approach (Moore, 2005).
Non-specific microbicides have been tested to prevent HIV infection. The 
surfactant nonoxynol 9 disrupts viral particles and inhibits HIV in vitro (Greenhead et 
al., 2000). It also attacks the vaginal epithelium, which results in the increase of 
infection (Shattock and Solomon, 2004). Other non-specific microbicides, such as 
gramicidin (a peptide antibiotic with anti-viral activity) and PRO 2000 (a sulphonate 
polymer), have been shown to inhibit cervical X4-tropic HIV infection in vitro 
(Greenhead et al., 2000), possibly by modulating charge interactions between the V3 
loop of gpl20 and polyanions present on the target cells in cervical tissues (Shattock 
and Moore, 2003).
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CXCR4 and CCR5 antagonists, sCD4-IgG and a modified version o f the natural 
ligand for CCR5 (PSC-RANTES) can also inhibit HIV or SHIV infection of cervical 
tissue when used topically (Hu et al., 2004; Lederman et al., 2004).
The application o f a single NAb or a cocktail of NAbs can prevent mucosal 
transmission of SHIV (Baba et al., 2000; Ferrantelli et al., 2004; Veazey et al., 
2003a).
Preventing HIV infection by the use o f topical application o f anti-HIV compounds 
in monkeys is possible. Considering that microbicides should be primarily made 
available to poor countries, some compounds (such as RANTES), however, cannot be 
exploited, as they are too costly. The development of cheap molecules is now one of 
the focuses in anti-HIV treatments, along with the development o f an anti-HIV 
vaccine (Moore, 2005).
1.14.6 Other drug targets
Anti-HIV treatments target viral entry, reverse transcription and the proteolytic 
maturation o f the virus. Nevertheless, new insights into the mechanisms of the 
replication cycle, as well as the characterisation o f cellular proteins that interact with 
HIV, have given new hopes for tackling HIV replication in vivo.
HIV infectivity seems to be dependent upon the interaction between CA and 
CypA during (or shortly after) uncoating (Franke et al., 1994). Cyclosporin A, which 
counteracts the action o f CypA, has been shown to inhibit HIV replication in vitro 
(Billich et al., 1995). The problem is that cyclosporin A blocks CD4 T cell activation, 
is an immunosuppressive drug and cannot be prescribed to HIV-infected individuals. 
The development o f non-immunosuppressive cyclosporin A analogues could be a 
promising avenue in anti-HIV treatments (Billich et al., 1995).
Zhou et al have reported a new compound capable of inhibiting HIV budding by 
delaying the cleavage between CA and p2, which impairs virus maturation (Zhou et 
al., 2004).
A new group o f compounds that have anti-IN properties are new anti-HIV drugs 
in development. They contain a diketo acid moiety (Condra et al., 2002). They act by 
blocking strand transfer during the reverse transcription and by preventing HIV DNA 
integration (Hazuda et al., 2000).
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1.15 Vaccines
Attenuated HIV strains can elicit a protective immune response but they can revert 
to a cytopathic state and causes an infection and AIDS in monkeys (Burton and 
Moore, 1998; Whitney and Ruprecht, 2004).
The classical approaches for vaccine design have been unsuccessful in triggering 
protection in immunised animals. Nevertheless, new approaches are now under 
investigation.
1.15.1 Envelope-based immunogens
Monomeric gpl20 proteins from the clade B isolates MN and GNE8 have been 
used as immunogens in order to elicit NAbs that could inhibit HIV infection in 
clinical trials. Despite a strong anti-gpl20 IgG response, the elicited Abs did not 
neutralise HIV in patients and no significant difference in the number of acquired 
infections was observed between the immunised and the placebo groups (Gilbert et 
al., 2005). Pantophlet et al reported the characterisation o f the monomeric JRFL 
gpl20, modified by extra N-glycosylation and mutated around the CD4BS by alanine 
substitutions that affect the binding o f non-NAbs (Pantophlet et al., 2003a; Pantophlet 
et al., 2003b). This modified gpl20 only binds b l2  and not the non-neutralising anti- 
CD4 MAbs (Pantophlet et al., 2003b). This new monomeric Env could be used as a 
vaccine for specifically eliciting b 12-like NAbs.
Oligomeric Envs, from clades A, B, and the subtype O have been generated and 
characterised (Jeffs et al., 2004) and could confer a better Ab protection than with the 
immunisation with monomeric gpl20.
1.15.2 CTL vaccine
For some viruses, such as influenza, respiratory syncytia virus (RSV) and 
lymphocytic choriomeningitis virus (LCMV), CTLs alone can protect animals from 
death (McMichael et al., 2002a). Although it is not clear which branch(es) of the 
adaptive immune system will confer protection against HIV infection, several 
observations argue that an anti-HIV vaccine strategy based on CTLs alone might 
decrease HIV incidence. CTLs play an important role in controlling HIV infection in 
vivo (see section 1. 12. 3. 2 for details). Some highly-exposed non-infected sex 
workers have a strong and broad CTL response in the blood and genital mucosa 
(Rowland-Jones et al., 1998).
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A CTL vaccine design consists in the immunisation with DNA encoding HIV 
proteins and administration o f IL2. Canary pox virus (Belshe et al., 2001; Evans et a l, 
1999), vaccinia virus (Barouch et al., 2001), Venezuelan equine encephalitis virus 
(Davis et al., 2002) and adenovirus (Shiver et al., 2002) genomes have been tested for 
induction o f anti-SHIV CTL response in vitro or for protection in monkeys.
For example, the injection o f DNA encoding the sequence o f codon-optimised 
Gag, followed by boosts o f adenovirus encoding the same Gag sequence in rhesus 
macaques elicited a strong CTL response that did not prevent from SHIV 89.6P 
infection but did control viraemia. A normal CD4 T cell count was maintained and the 
vaccinated monkeys did not show any signs of AIDS-related syndromes six months 
after virus challenge. Mock-vaccinated (or non-vaccinated) monkeys were not 
protected against SHIV infection. They had a weak CTL response, a dramatic 
decrease in their CD4 T cell count and rapidly showed health deterioration (Shiver et 
al., 2002).
Although the principle o f an anti-HIV CTL vaccine approach seems promising, 
problems exist. CTL-induced vaccines do not prevent infection but control viral 
replication better. HIV superinfection can occur in HIV-infected individuals who have 
a broad CD8 T cell response (Altfeld et al., 2002). Thus, the same problem could 
occur in vaccinated individuals. Moreover, CTL viral escape has been reported in 
vaccinated animals, that initially controlled SIV infection (Barouch et al., 2002). Loss 
of viral replication control can occur by only one amino acid substitution within an 
epitope recognised by CD8 T cells (McMichael et al., 2002a) and can lead to 
uncontrolled viraemia, decline in the CD4 T cell count and onset of AIDS-related 
symptoms (Barouch et al., 2002). Furthermore, the Gag KK10 CTL escape mutant (in 
the HLA-B57 context) can be successfully transmitted by mother-child transmission 
(Goulder et al., 2001b). This could cause a problem in terms o f protecting an overall 
population (Goulder and Watkins, 2004). From this observation, Goulder and Watkins 
suggest that all CTL responses could not be equally effective at controlling HIV 
viraemia in vivo and, like Abs, vaccines might trigger immuno-dominant CTLs at the 
cost of more protective responses (Goulder and Watkins, 2004). The aim of a 
protective anti-HIV CTL vaccine might not be simply to induce as many CTL 
responses as possible in vaccinated individuals (Goulder and Watkins, 2004). The 
issue of targeting the best peptides might be complicated by the co-existence of 
various HIV clades in countries where CTL vaccines are needed the most (McMichael
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et al., 2002b). Developing a vaccine that, firstly, will target the peptides where 
mutations would occur at a severe fitness cost, and, secondly, that will contain the 
peptides found within all the HIV clades, predominant in a specific area, seems more 
problematic than originally planned.
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1.16 Scope of this thesis
In HIV infection, NAbs are usually detected between two and nine months POS 
(Aasa-Chapman et al., 2004; Richman et al., 2003) and, therefore, are unlikely to play 
a role in the decline o f viral load observed during acute infection. Non-neutralising 
anti-gpl20 Abs, however, can be detected within days POS (Aasa-Chapman et al., 
2004; Moore and Ho, 1993). I first investigated if early non-neutralising sera as well 
as neutralising sera could also inactivate autologous and heterologous viruses in 
association with complement (Chapter 3). In chapter 4 , 1 investigated the mechanisms 
of CMI, the nature o f the pathway, as well as the Ab isotype involved. I also tested 
CMI using anti-gpl20 MAbs and sCD4-IgG and investigated the influence of the 
virus-producing cell line on CMI.
Finally, I re-examined the anti-idiotypic approach to generate an anti-HIV vaccine 
(Chapter 5). For this project, the cross-NAb b l2  was used. A new anti-idiotypic 
strategy detailed in this thesis took advantage of a peculiarity o f the camelid family 
(llamas) that naturally synthesise single chain non-classical IgG devoid of light chains 
(Hamers-Casterman et al., 1993). These non-classical IgG (referred to as V hh) have 
long CDR H regions that can adopt non-canonical conformations (Muyldermans, 
2001) and therefore could potentially mimic the b l2  binding site on HIV-1. Specific 
anti-bl2 V hh fragments were isolated from a V hh library generated from a llama 
immunised with Fab fragments o f b l2 . Five V hh fragments were tested for their 
specificity to b l2  and were subsequently used as immunogens in rats and rabbits in 
order to determine if  they could elicit a strong, b l 2-like NAb response.
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Chapter 2 
Material and Methods
2.1 Buffers and solutions
PBST
TBS
TBST
TEA
TMT/GS
Extraction buffer
HRP substrate
SDS-PAGE 12%
PEG/NaCl 20% polyethylene glycol 6000 (w/v), 2.5 M NaCl
PBS 137 mM NaCl, 3 mM KC1, 10 mM Na2H P 04, 2 mM K2H P04
pH 7.4
PBS, 0.05% Tween (v/v)
20 mM Tris-HCl, pH 7.6, 120 mM NaCl 
TBS, 0.05% Tween (v/v)
100 mM Triethylamine
TBST, 20% goat serum (v/v), 4% skimmed powder milk (w/v) 
20% sucrose (w/v), 1 mg/ml lysozyme, 30 mM Tris pH 6.8 
1 mg/ml 3,3',5,5'-Tetramethylbenzidine (Sigma, UK) in 100 mM 
sodium acetate, 10 pi o f hydrogen peroxide per 50 ml 
for a 10 ml gel, 3 ml 40% acrylamide, 0.4 M Tris-HCl pH 8.8, 
0.1% SDS (v/v), 0.05% ammonium persulphate (v/v), TEMED, 
15pl
40 mM Tris-HCl pH 7.8, 20 mM sodium acetate, lm  M 
EDTA
Loading buffer 6X 0.25% bromophenol blue (w/v), 0.25% xylene cyanol FF (w/v), 
30% glycerol (v/v)
2% Bacto-tryptone (w/v), 0.5% yeast extract (w/v), 10 mM NaCl
2.5 mM KC1, 10 mM MgCl2, 10 mM M gS04, 20 mM glucose 
1.6% Bacto-tryptone (w/v), 1% yeast extract (w/v), 0.5% NaCl 
(w/v)
2TY, ampicillin 100 pg/ml 
2TYAmp, 1% glucose (w/v)
2TYAmp, kanamycin, 50 pg/ml
TAE
SOC
2TY
2TYAmp
2TYAmpGlc
2TYAmpKan
2TYAmpXgalIPTG 2TYAmp, 0.5 M IPTG, 80 pg/ml X gal
2.2 Description of bacterial strains, mammalian cell lines and antibodies
2.2.1 Bacterial strains
E.coli strain
Genotype
F ’traD36 laclq A(lacZ) M15pro+B+/supE A(hsdM-mcrB)5 (rk-mk-
TG1
M crB') thi A(lac-proAB)
F-, ompT, hsdSp(rp-mp), dcm, gal, (DE3) ton A
BL21
F- mcrA D(mrr-hsdRMS-mcrBC)f801acZDM15 DlacX74 deoR recAl
TOP 10® R
araD139(ara-leu)7697 galU glK rpsL(Str ) end A l nupG
Table 2.1 Description of bacterial strains
2.2.2 Mammalian cell lines
Cell line
Description Reference
293T Human embryonic kidney (Graham et al., 1977)
H9 Human CD4+ T cell (Popovic et al., 1984a)
NP2/CD4/CXCR4 Human (Soda et al., 1999)
glioma/ CD4/CXCR4
NP2/CD4/CCR5 Human glioma/CD4/CCR5 (Soda et al., 1999)
Table 2.2 Cell lines
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2.2.3 Antibodies and sera
Antibody M apping and properties Reference
447-52D Human IgG3. Binds to GPXR on V3 loop o f MN. 
Neutralises some TCLAs and Pis
(Gomy et al., 1992)
M N215 Human IgG l. Binds to RIHIGPGRAFYTTKN on (Schutten et al.,
the V3 loop o f MN. Neutralises some TCLAs 1995)
268-D Human IgG l. Binds to HIGPGR on V3 loop of 
MN. Neutralises some TCLAs
(Gomy et al., 1991)
GP68 Human IgG l. Binds to CD4BS. Neutralises some (Schutten et al.,
TCLAs (IIIB) 1993)
654-D Human IgG l. Binds to CD4BS of LAI. Neutralises 
IIIB
(Laal et a l , 1994)
b l2 Human IgG l. Binds to CD4BS. Neutralises (Burton et a l.
TCLAs and Pis from different clades 1991)
b6 Human IgG l. Binds to CD4BS of IIIB. Neutralises (Parren and Burton,
some TCLAs 1997)
A32 Human IgG l. Binds to C1-C4, to a CD4-induced 
epitope. Does not neutralise
(Wyatt et a l , 1995)
17b Human IgG l. Binds to a CD4-induced epitope. 
Neutralises some TCLAs, weakly some Pis. Is 
more potent as a Fab fragment
(Thali et a l ,  1993)
670-D Human IgG l. Binds to PTKARR on C5. Does not (Zolla-Pazner et
neutralise a l ,  1995)
697-D Human IgG l. Binds to 
ISTSIRGKVQKEYAFFYKLD on V2 loop o f IIIB. 
Neutralises some Pis
(Gomy et a l, 1994)
2G12 Human IgG l. Binds to a carbohydrate-dependent (Buchacher et a l.
epitope. Neutralises some TCLAs and Pis 1994)
Table 2.3 Antibodies
The MAbs b l2 , b6, A32, 17b, 2G12 were kindly provided by Dr. R. Pantophlet 
and Prof. D. R. Burton (Scripps, USA). The others MAbs were provided by NIBSC 
(Potters Bar, UK).
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The anti-HIV-1 QC sera 1, 2, 4, 5 and 6 were harvested from anonymous HIV- 
infected British patients. The sera were selected for the WHO programme on 
standardisation o f neutralisation when described by McKeating et al (McKeating et 
al., 1989).
2.3 Mammalian cell culture 
2.3.1 Maintenance of cell lines
Adherent cell lines were passaged in Dulbecco’s modified Eagle medium 
(DMEM) (Invitrogen, UK) supplemented with 5% (v/v) foetal calf serum (FCS) 
(Invitrogen, UK). Suspension cell lines were maintained with Roswell Park Memorial 
Institute (RPMI) (Invitrogen, UK) supplemented with 10% FCS (v/v). All cell lines 
were grown at 37°C in an humidified atmosphere with 5% CO2 (v/v) except for 293T 
cells, which were grown in a humidified atmosphere with 10% CO2 .
2.3.2 Passage of cells
Every four or five days, adherent cells were washed with trypsin diluted in 
versene (0.5% trypsin v/v in 0.02% versene v/v) and left for 5 min at 37°C until the 
cells detached from the flask, 1/10th o f the trypsinised cells was diluted in DMEM- 
FCS and was seeded in a new flask. Non-adherent cells were diluted 1:5 in RPMI 
every four or five days.
2.3.3 Storage of cells
Exponentially-grown adherent cells were trypsinized as described in 2. 3. 2 and 
then centrifuged at 900 g for 10 min at RT. The cell pellet was resuspended in 90% 
FCS-10% DMSO (Sigma, UK) and the cells were aliquoted in cryovials. The vials 
were then carefully wrapped in paper and progressively frozen at -20°C between four 
and twelve hours, at -40°C and -80°C between four and twelve hours and finally 
stored in liquid nitrogen.
2.3.4 Transfection of mammalian cells
The day prior to transfection, 293T cells were split 1:2 or 1:3, depending on the 
confluence of the cells, and were plated in a 6-well tray at the density of 4xl05 
cells/well. The following day, DMEM 10% FCS was replaced by fresh medium. For 
each well, 6 pi of Fugene® (Roche, UK) was premixed with 2 pg of total DNA in 200
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pi of serum-free Optimem (Invitrogen, UK). The mix was incubated at RT for 20-30 
min and was added dropwise to the cells. After an overnight incubation at 37°C, the 
medium was replaced and harvested 24-36 hours later.
2.4 Primary cell culture
2.4.1 Preparation of PBMCs from buffy coats
Buffy coats, provided by the blood Bank (Brentwood blood transfusion centre, 
London) were diluted 1:1 (v/v) in sterile PBS. 45 ml of diluted buffy coat were then 
carefully layered onto 15 ml o f lymphoprep (Nycomed, Norway). The preparation 
was centrifuged at 1500 g for 30 min at RT (no brake). The layer containing the white 
blood cells was carefully harvested, washed with sterile PBS twice then recoverd by 
centrifugation at 900 g for 10 min at RT. The cells were incubated at RT for 10 min 
with 10 ml of red blood cell lysis buffer (Sigma, UK). After centrifuging at 900 g for 
10 min at RT, the cells were diluted 1:100 in serum-free RPMI and counted using a 
haemocytometer. The cells were resuspended at the concentration of 106 cells/ml in 
RPMI-10% FCS containing PHA (Murex, UK) at the final concentration of 20 U/ml 
and grown for three days at 37°C in a humidified atmosphere with 5% CO2. The cells 
were centrifuged at 900 g for 10 min at RT and then resuspended at the concentration 
of 106 cells/ml in RPMI-FCS supplemented with recombinant human IL2 (Roche, 
Germany) at the final concentration o f 20 U/ml. Every three days, the cells were 
counted and adjusted at 106 cells/ml in RPMI-FCS-IL2.
2.4.2 Preparation of macrophages from buffy coats
The preparation o f macrophages from buffy coats is the same as for PBMCs 
described in 2. 4. 1 until the incubation o f the cells with red blood cell lysis buffer. 
After centrifugation, 108 cells, in RPMI-5% human serum (HS), were plated onto a 14 
cm2 tissue culture dish (Falcon, UK), previously coated for two hours with 5 ml of 2% 
bovine skin gelatine (Sigma, UK) at RT. The cells were incubated for two hours at 
37°C to adhere to the plates and were washed gently once in their own medium, once 
in fresh medium and then left overnight in RPMI-10% HS at 37°C.
The following day, the medium was removed, the cells were washed with PBS 
and incubated with 5 mM EDTA in PBS for 10 min at 37°C. After another wash, the 
PBS/EDTA solution, containing the cells, was centrifuged at 900 g for 10 min at RT, 
the cell pellet was washed twice with PBS and the cells were resuspended in 20 ml of
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RPMI. 5x l06 cells were seeded in a 25 cm2 tissue culture flask in RPM I-10% HS for 
two hours at 37°C. The cells were washed with RPM I-10% HS and were incubated at 
37°C until they differentiated into macrophages bearing the distinctive “fried egg” 
morphology (seven days).
2.5 HIV strains
2.5.1 Description of viral strains
Virus
strain
History
Phenotype Source Clade Status References
IIIB TCLA SI PBMC B AIDS (Gallo et al., 
1984)
RF TCLA SI PBMC B AIDS (Popovic et 
al., 1984b)
SF2 TCLA SI Brain B AIDS (Levy et al., 
1984)
BaL PI NSI Brain B AIDS (Gartner et al., 
1986)
SF162 PI NSI Brain B AIDS (Cheng-Mayer 
et al., 1989)
SL2 PI NSI PBMC B Asympt (Simmons et 
al., 1996)
2044 PI SI PBMC B AIDS (Simmons et 
al., 1998)
Table 2.4 HIV isolates
2.5.2 Growth of viral stocks
2.5.2.1 From suspension cells
Laboratory-adapted, X4-tropic strains o f HIV were grown in the H9 cell line. A 
viral stock was thawed and incubated at 37°C for one to three hours with 
approximately 106 cells previously centrifuged at 900 g for 10 min at RT. The cells 
were then resuspended in 5 ml o f RPMI-FCS for 3 or 4 days at 37°C in a humidified 
atmosphere with 5% C 0 2. The infected cells were then centrifuged again and 
incubated at 37°C for between one and three hours with 5xl06 fresh non-infected
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cells. The cells were resuspended in 12 ml of RPMI-FCS for further three or four days 
until syncytia were visible under the microscope. The cells were centrifuged and the 
supernatant, containing the viral particles, was aliquoted and snap frozen in liquid 
nitrogen. Pis of HIV were grown in PBMCs in the same manner.
2.5.2.2 From macrophages
Eight days after preparation of the macrophages (described in 2. 4. 2), the medium 
was removed from the cells and incubated with 8xl05 TCID50 macrophage-derived 
stock of BaL (kind gift o f Beatrice Kramer, UCL) for two hours at 37°C, after which 
the volume was increased to 6 ml. Seven days after the infection, half of the medium 
was harvested and replaced with fresh RPMI-10% HS every three days. The harvested 
medium was aliquoted and stored in liquid nitrogen.
2.5.3 Titration of viral stocks
All HIV titres were assessed on NP2/CD4/CXCR4 cells or NP2/CD4/CCR5 cells 
depending on the main co-receptor usage of the HIV strain.
The day previous to the experiment, cells were split (as described in 2. 3. 2) and 
104 cells were seeded per well in a 48-well plate and kept at 37°C in a humidified 
atmosphere with 5% CO2. The day of the experiment, a vial containing the viral stock 
was thawed and was serially diluted 1:10 (v/v) in DMEM-FCS. 200 pi of the serial 
dilutions of the virus were incubated onto the cells plated the day before for between 
one and four hours at 37°C in a humidified atmosphere with 5% CO2. The medium 
was then discarded the cells were washed once with medium and incubated with 500 
pi of DMEM-FCS per well. The plates were incubated for three days at 37°C in a 
humidified atmosphere with 5% CO2.
2.5.4 Estimation of viral infection
Medium from the HIV-infected cells was discarded and the cells were incubated 
with an equal mix of ice-cold 100% methanol/acetone (v/v) for approximately 10 min 
at RT. The cells were then washed with PBS and incubated for one hour at RT with an 
equal mix of two anti-p24 monoclonal antibodies, ADP 365 and ADP 366 (AIDS 
Reagent Program, NIBSC, UK), diluted at 1:40 in PBS-1% FCS. After three washes 
with PBS-FCS, the cells were incubated with a goat anti-mouse polyclonal serum 
conjugated to p-galactosidase (Southern Biotechnology associates Inc, USA) diluted
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in PBS-FCS at 1:400 for one hour at RT. After two washes in PBS-FCS and a final 
washing with PBS, the cells were incubated with |3-galactosidase substrate (X-gal in 
PBS containing 3 mM potassium ferrocyanide, 3 mM potassium ferricyanide and 1 
mM MgCh) for two or three hours at 37°C. The cells infected with HIV-1 developed 
a blue colour. Individual or grouped cells were counted as a focus-forming unit (ffu).
2.6 Extraction and storage of complement
50 ml of blood were harvested from individuals (who gave written consent) and 
was stored at 4°C until complete clotting. The tubes were then centrifuged at 900 g at 
4°C and the upper phase containing the serum was carefully harvested, aliquoted and 
stored at -80°C until further use. Some aliquots of fresh serum, as well as all HIV- 
positive sera, were incubated at 56°C for two hours to completely inactivate 
complement. Alternatively, sterile solutions of EDTA or EGTA were added to fresh 
human serum at the final concentration of 2.5 mM for 5 min at RT.
2.7 The Jenner patient cohort and the processing of the samples
The study subject is detailed in Aasa-Chapman et al (Aasa-Chapman et al., 2004). 
The development of the antibody response was monitored in seven HIV-positive men 
who have sex with men (MM4, MM8, MM 19, MM22, MM23, MM27 and MM28). 
All the subjects presented at the Mortimer Market clinic (UCL, London) with various 
symptoms. The characteristics of each patient are presented in table 2.5 below.
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Patient Age3 Acute
infection
symptoms'3
Likely
exposure0
Time
point
gpl20d*
VLe’
(copies/ml)
CD4T
cell
count
W )
MM4 41 F, L, ST, 
A, D, NS
-35 17 160,000 780
MM8 33 F, L, NV, 
D, H, Ph
-21 12 5,927,000 290
MM19 31 Uf -4 13 5,678,900 400
MM22 U U -21 14 8,311,000 360
MM23 27 F, R, NS, P -2 9 11,105,300 330
MM27 32 F, NV, D,
D
-20 28 437,800 570
MM28 30
r
NS, R, L -4 6 4,337,100 560
Table 2.5 Characteristics of the Jenner patients
a Age at which the patients were diagnosed with HIV-1 infection
b F, Fever. L, Lethargy. ST, Sore throat. A, Anorexia. D, Diarrhoea. NV, Nausea/vomiting. 
NS, Night sweats. H, Headaches. P, Pharyngitis. Ph, Photophobia. R, Rash 
c Days prior to the onset o f symptoms
d Days from the onset o f  symptoms at which gpl20 sequences were amplified by PCR and 
cloned into the HxB2 MCS-A-£«v g p l2 0  vector to generate infectious viruses.
'T he viral load (VL) was determined by a Chiron 3.0 kit (Emeryville, USA) 
f Unknown
* The VL, CD4 T cell count and the gpl20 amplifications were performed from samples 
harvested on the same day
Acute HIV-1 infection was diagnosed by the detection of HIV genomes in the 
presence or absence of an evolving HIV-1 Ab profile which subsequently became 
fully positive. All subjects remained treatment naive throughout the study with the 
exception of MM22, who commenced therapy 26 days after diagnosis. Blood samples 
were obtained weekly for the first month, monthly for three months and then at three 
months intervals. The study protocol was approved by the Camden and Islington NHS 
Trust Ethics Committee and written consent was obtained from all subjects.
Blood samples was centrifuged at 900 g for 10 min at 4°C, the supernatant, as well 
as the blood pellets, were stored at - 80°C until further use.
2.8 Neutralisation and CMI assays
2.8.1 Neutralisation assays
Virus (100 ffus) was incubated with two-fold serial dilutions of HIV-positive sera, 
HIV-negative sera as negative controls, (from 1:10 or 1:20 final concentration) or 
MAbs in 100 pi of DMEM-FCS. MAbs were used at the final concentration of 10 
pg/ml or at the final dilution of 1:10 when the concentration was unknown. The mix
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was placed for one hour at 37°C and was incubated on NP2/CD4/CCR5 or 
NP2/CD4/CXCR4 cells, plated in 48-well plates, for between one hour and four hours 
at 37°C. The cells were washed with DMEM-FCS and incubated with 500 pi of 
DMEM-FCS per well and the plates were incubated for three days at 37°C in a 
humidified atmosphere with 5% CO2. The cells were fixed and the viral infections 
were estimated as described in 2. 5. 4. The neutralisation percentage was calculated 
with the formula:
100 x ^  ~ (avera&c with patient sera)
(average FFU with seronegative serum)
2.8.2 CMI assays
Two-fold serial dilutions (from 1:10 or 1:20 final concentration) of heat- 
inactivated sera from HIV-1 infected individuals were incubated with 100 ffus of HIV 
and with human serum, source of complement, Guinea pig complement reconstituted 
in PBS (Sigma, Poole, UK) and EGTA- or EDTA-treated serum, at the final 
concentration of 10% (v/v) in a total volume of 100 pi. The mix was then pre­
incubated for one hour at 37°C and then incubated on NP2/CD4/CCR5 or 
NP2/CD4CXCR4 for one to four hours at 37°C. The cells were washed once with 
DMEM and incubated with fresh medium for three days at 37°C. The cells were fixed 
and viral estimates were determined as described in 2. 5. 4. The percentage reduction 
of infection was calculated with the formula:
100 x ^  _ (average FFU with patient sera)
(average FFU with seronegative serum)
2.8.3 Inhibition of bl2 neutralisation in vitro
The Vhh fragments were diluted in PBS respectively at 10, 5, 1, 0.5, 0.1 and 0.01 
fold in excess to b 12 molecular ratio. b l2 was diluted at the concentration of 50 pg/ml 
in PBS. 10 pi of V hh fragments were pre-mixed with 10 pi of bl2 and the equivalent 
of 100 ffus of HIV-1 in a total volume of 200 pi. After one hour incubation at 37°C in 
5% CO2, the mix was plated on NP2/CD4/CCR5 or NP2/CD4/CXCR4 cells for 
between one and three hours at 37°C in 5% C02. The cells were then washed with 
DMEM medium and incubated for three days.
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2.8.4 Statistical analysis
The statistical analyses of the results of the neutralisation and the CMI assays 
were undergone using the Student’s /-test. Wilcoxon test (a variant of the Student /- 
test) and the Mann-Whitney U test (a non parametric version of the Student /-test), ,as 
well as ANOVA test (a test comparing the variances) could also have been applied for 
the statistical analysis. However, both Wilcoxon and Mann-Whitney tests can be less 
sensitive than the Student t-test and the ANOVA test is only relevant when three 
groups or more can be compared. For each experiment described in this thesis, the 
comparison is between two groups (with compared to without complement and with 
or without Abs).Therefore, the Student /-test was chosen as it allows statistical 
analysis on small samples. The /-test compares the actual difference between two 
means (with or without Abs for neutralisation assays or with or without complement 
for CMI assays) in relation to the variation within the data (expressed as the standard 
error between experiments). The null hypothesis chosen for the tests was that the 
means of the two samples (inactivation data in the absence or the presence of 
complement or neutralisation with or without sera) were not significantly different 
from each other. The two samples to be compared are not randomly selected: the 
second sample is the same as the first after some treatment has been applied. So the 
populations are paired. An example of the /-test value is shown in appendix 1.
The number of replicates was six per experiment. The p value of p<0.05 shows 
that the probability that the two means are significantly different from each other 
(with a 95% certainty). For each comparison on each graph, the statistical significance 
is shown by a star.
2.9 DNA manipulation
2.9.1 Generation of chimeric HIV-1 viruses
gpl20 sequences of HIV-1 Envs from the infected patients were first cloned in 
pGEM® vector and then sucloned into the backbone of the HIV-1 molecular clone 
HxB2, containing all the genetic elements of HIV-1 but lacking the sequence of 
gpl20. The clones were then transfected in 293T cells and the resulting chimeric 
viruses were tested for their infectivity.
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2.9.1.1 Primers
Primer
Position Sequence
988L+0 6089-6122a 5 GTA GCA TTA GCG GCC GCA ATA ATA ATA GCA 
ATAG
943S+0 6084-6104a 5 CAA TAG (CT) AG CAT TAG TAG TAG
626Ld+0 6326-6347a 5 GTG GGT CAC CGT CTA TTA TGG G
125Yd'0 7716-7742v 5 CAC CAC GCG TCT CTT TGC CTT GGT GGG
6O9RE’0 7790-7816a 5 CCC ATA GTG CTT CCG GCC GCT CCC AAG
628L'0 8065-80863 5 TCA TCT AGA GAT TTA TTA CTC C
Sp6® pGEM® 5’g a t t t a g g t g a c a c t a t a g
T7® pGEM® 5 TAATACGACTCACTATAGGG
E80+® 6564-6585a 5 CCA ATT CCC ATA CAT TAT TGT G
625L® 3017-30273 5’g g a  TAT a a t  c a g  t t t  a t g  g g
A589'® 6286-63073 s’CAG AGT GGG GTT AAT TTT TAC AC
621® 6651-66733 5 GTA CAT TGT ACT GTG CTG ACA TT
E110® 6708-67313 5 CTG TTA AAT GGC AGT CTA GCA GAA
619® 6716-67353 5 TGG CAG TCT AGC AGA AGA AG
307d‘® 7021-7038a 5 CTG GGT CCC CTC CTG AGG
325h'® 7222-72403 5 GGG CAT ACA TTG CTT TTC C
015s+® 6917-69363 5’ACA TTG TAA CAT TAG TAG AG
MPE25® PUR4676 5 TTT CTG TAT GGG GTT TTG CTA
M13® PUR4676 5 GAG CGG ATA ACA ATT TCA CAC AGG A
Table 2.6 Primers
0 Primers used for amplifying gpl20 
® Primers used for sequencing gpl20 
0 Primers used for sequencing V hh fragments 
a The position is given according to HxB2 alignment
The primers annealed to regions of gpl20 as shown below. For clarity, the primers 
used for gpl20 sequencing are not indicated.
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gp 120 gp41
609R E
- 6 2 8 L
2.9.1.2 Amplification of gpl20 sequences
Total DNA was ex tracted  from  the first blood sam ple  availab le from  each HIV-1 
infected patient (see table 2.5) using the w hole blood p rep  kit (Q iagen) according to 
the m anufacturer’s instructions. T he g p l2 0  DNA frag m en ts w ere am plified  by nested 
PCR as described by A asa-C hapm an e t a l, (A asa-C hapm an et al., 2004). For the first 
PCR, 1 pm ol o f  prim ers 9 8 8 L f , 943S +, 609R E ’and 628L ', 2.5 units o f  proof-reading 
Long Expand D NA po lym erase (R oche, G erm any) in k it supplied  P C R  buffer 3 and 
25 pM o f  each dN T Ps w ere used. The D NA w as am plified  for 30 cycles using the 
following conditions: 92°C for 45 sec, 44°C for 45 sec and  68°C for 3 m in 30 sec.
A second PC R  w as perform ed using 5 pi from  th e  firs t PC R  in th e  follow ing 50 pi 
PCR mix: 1 pm ol o f  prim ers 626L dt and 125Yd', 25 pM  o f  each dN T P s and 2.5 U o f  
Long Expand D N A po lym erase (R oche, G erm any) in PCR  b uffer 3. The gp l2 0  
sequences w ere am plified  accord ing  to  the sam e cond itions described  for the first 
PCR.
After com pletion o f  the second PCR, 15 pi o f  each  PC R  w ere m ixed with 6X 
loading buffer and run on a 0 .8%  agarose gel in IX  T A E  at 100 V fo r approxim ately 
30 min. The gel w as then v isualised  under UV light and  the bands corresponding to
1.5 Kb fragm ents w ere excised and purified using th e  Q iaqu ick  ex traction  kit (Qiagen, 
UK).
2.9.1.3 Cloning of gpl20 sequences in pGEM vector®
The g p l2 0  fragm ents w ere cloned into pG E M -T  v ec to r system  I (Prom ega, UK) 
by m ixing 10 pi o f  the purified  g p l2 0  D N A  fragm ents w ith  1 pi o f  th e  vector and 5 U 
o f ligase (Prom ega, U K ) in ligation buffer, in acco rdance w ith the  m anufacturer’s 
instructions. The ligation m ix w as incubated at RT for tw o  hours. H a lf  o f  the m ix was 
used for transform ation in T op 10 E .co li.
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2.9.1.4 Cloning of gpl20 sequences in the HxB2 backbone virus
gpl20 DNA fragments were cloned into MCS-A-Env gpl20  that allows 
incorporation of heterologous gpl20 sequences from amino acid 38 (seven amino 
acids after the signal peptide) to six amino acids prior to the gpl20/gp41 junction 
(McKeating et al., 1996).
The following day, individual white colonies (containing gpl20 sequences cloned 
in pGEM®) were picked using sterile cocktail sticks and grown overnight in 2 ml of 
LBAmp (37°C, 250 rpm). The plasmids from each culture were extracted from the 
bacteria using the Qiagen miniprep kit (Qiagen, UK) according to the manufacturer’s 
instructions and were eluted in 50 pi of elution buffer. Half of the purified plasmids 
and the vector containing the complete genome of HxB2 were then digested with 5 U 
of the restriction enzyme M lul (Roche, UK) for one hour at 37°C and then with 5 U of 
BstEII (Promega, UK) for one hour at 65°C. The digested plasmids and pHxB2-MCS- 
A-Env gpl20  were loaded onto a 0.8% agarose gel and the DNA fragments were 
purified again using the Qiaquick kit (Qiagen, UK). They were then eluted in 20 pi of 
elution buffer.
The ligation mix containing 3 pi o f the vector HxB2 and 3 pi of the inserts were 
incubated with 5 U o f ligase (Promega, UK) in ligation buffer for Vi hour at RT and 
overnight at 4°C. The mix was briefly frozen at -20°C to inactivate the ligase. Half of 
the ligation was used for transformation in Top 10 bacteria (Invitrogen, UK).
2.9.2 Preparation o f  Vhh libraries
2.9.2.1 Llama immunisation and generation of Vhh libraries
This work was performed by Hans de Haard and colleagues in the Netherlands. 
Briefly, a llama was immunised six times with decreasing amounts of Fab b 12. After 
verification o f the anti-bl2 Ab response by ELISA, 15 ml of blood were harvested, 
the B cells were extracted and the total RNA was isolated by acid guanidium 
thiocyanate extraction. Synthesis of cDNA was performed from total RNA, using 
random dNTP hexamers. V hh sequences were amplified as described by Dolk et al 
(Dolk et al., 2005). Long-hinge and short-hinge Vhh fragments were amplified by 
PCR from the cDNA using Taq polymerase, primers LAM 07 (5 AAC AGT TAA 
GCT TCC GCT TGC GGC CGC GGA GCT GGG GTC TTC GCT GTG GTG CG) 
and Vh-2B (5 AGG TSM ARC TGC AGS AGT CWG G) where S is C or G, M is A 
or C, R is A or G and W is A or T) for the short-hinge fragments and LAM 08 (AAC
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AGT TAA GCT TCC GCT TGC GGC CGC TGG TTG TGG TTT TGG TGT CTT 
GGG TT) and VH-2B for the long-hinge fragments. The fragments of both long hinge 
and short hinge were then digested with PstI and Hindlll (Roche, Germany) and 
cloned separately in phage display vector pUR 4676 encoding the sequences of a myc 
tag and a His-tag in order to fuse them at the 3’ end of the V hh DNA. The two 
libraries were then cloned in TGI E.coli by electroporation. The size of each library 
was estimated and subsequently stored at -80°C in 2TYAmpGlc 20% glycerol (v/v) 
until further use.
2.9.3 Bacterial transformation
2.9.3.1 Preparation of calcium chloride-competent E.coli
The calcium chloride-competent bacteria were prepared as described in Molecular 
Cloning (Sambrook et al., 1989). The day prior to the preparation, single colonies of 
the BL21 strain of E. coli, grown on minimal medium plus agar, were resuspended in 
5 ml of 2TY and grown overnight at 37°C and shaken at 200 rpm. An aliquot of the 
overnight culture was then resuspended in 50 ml of fresh 2TY medium at 200 rpm at 
37°C until the bacterial culture reached the exponential growth (which is reached 
when the OD 600 nm is between 0.4 and 0.8). The bacteria were pelleted for 10 min 
at 3200 g at 4°C and incubated for 30 min on ice in cold sterile 500 mM CaCh in half 
and then in 1/15th of the initial culture volume. The treated cells were then kept at 4°C 
between twelve and twenty-four hours before usage.
2.9.3.2 DNA transformation
3 pi of the ligation mix described in 2. 9. 1. 1 for the cloning of gpl20 and 50 ng 
of plasmid DNA encoding the V hh fragments were added to 15 pi of commercially 
available chemically competent Top 10 cells for the gpl20 cloning or 100 pi of freshly 
made BL21 cells for the V hh protein expression. The DNA-bacteria mixture was then 
incubated on ice for 30 min. The bacteria were then heat-shocked at 42°C for 90 sec 
and then immediately placed on ice. 100 pi of SOC medium was promptly added to 
the cells and incubated at 37°C for 30 min. 100 pi of the mix was plated on 
2TYAmpXgalIPTG for cloning gpl20 into pGEM vector®, 2TYAmp for gpl20 
cloning into HxB2 and 2TYAmpGlc for transformation of plasmids containing the 
Vhh sequences. The plates were incubated at 37°C overnight for the V hh expression 
and at 30°C for the gpl20 cloning.
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2.9.4 Colony screening
2.9.4.1 Screening by PCR and enzyme restriction
For the V hh selection, single colonies were picked using sterile cocktail sticks and 
resuspended in a 50 pi PCR mix containing: 25 pmol of primers MPE 25 and M13, 1 
pmol dNTPs, 2.5 mM MgCh and 1 unit of Taq polymerase (Promega, UK) in 10X 
MgCh-free PCR buffer (Promega, UK). The PCR conditions were as follows: 1 min 
at 94°C, then 1 min at 94°C, 30 sec at 55°C, 1 min at 72°C for 30 cycles and a final 
step at 72°C for 1 min.
30 pi of each PCR reaction was digested for 1 hour at 37°C using 2 U of the 
frequent cutting restriction enzyme Hinfl (New England Biolabs, USA). The 
restriction pattern of each clone was then checked on a 2.5% agarose gel.
2.9.4.2 Plasmid purification and enzyme restriction
From the same plates, colonies were picked using sterile cocktail sticks, 
resuspended in 5 ml of 2TYAmp for gpl20 cloning and 2TYAmpGlc for Vhh 
expression, and were grown overnight at 37°C for VHH or at 30°C for gpl20 cloning 
and shaken at 200 rpm. The bacterial cultures were then centrifuged at 3200 g for 10 
min at 4°C and the plasmid extraction was performed using Qiagen mini-prep kit 
(Qiagen, UK) according to the manufacturer’s instructions. The plasmids were eluted 
in 50 pi of elution buffer and 10 pi of each PCR reaction were digested as described 
in 2. 9. 2. 1.
2.9.5 Sequencing reactions
For the V hh selections, 0.5 pg of plasmid DNA was sequenced on both strands 
using 0.6 nmol of MPE25 or M13. For the gpl20 cloning, 1.2 pg of plasmid DNA 
was sequenced on both strands using 0.6 nmol of the primers described in 2. 9. 1. 1. 
Sequencing reactions were performed by the Windeyer Institute sequencing service 
using the Abi PRISM big dye terminator v 3.1 sequencing kit (Applied Biosystems, 
USA). The sequences were analysed using Sequencher software (Gene Codes 
corporation, Michigan).
2.10 Selections of the Vhh libraries
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2.10.1 Growth of the libraries
20 |il of the library glycerol stocks or 100 pi of an overnight grown TGI culture, 
were inoculated in 5 ml of 2TYAmpGlc and were grown at 37°C and shaken at 200 
rpm until log phase was reached, determined by the OD of the culture at 600 nm.
2.10.2 Phage rescue
The coding sequences of the V hh fragments are fused by their 3’end to the coat 
protein pVIII encoded by the filamentous phage M l3. The pUR4676 plasmid has a 
filamentous phage backbone but the genes encoded for the phage arms have been 
deleted. To promote the production of full phage encoding the Vhh fragments on their 
surface, helper phage (carrying the missing genes) was added to the log phase culture 
in a 20:1 ratio (helper phage/bacteria) and the culture was incubated for 30 min at 
37°C (no shaking). The bacteria were then centrifuged at 3200 g for 15 min and the 
bacterial pellet was then resuspended in 50 ml of 2TYAmpKan. The culture was 
incubated at 37°C at 200 rpm and shaken overnight.
2.10.3 Phage precipitation
The overnight bacterial culture was centrifuged at 3200 g for 10 min at 4°C. The 
supernatant was incubated with l/5th of the volume of the overnight culture of cold 
sterile PEG/NaCl for one hour on ice with occasional shaking. The phage were 
centrifuged at 3200 g for 30 min at 4°C. The supernatant was discarded and the phage 
pellet was carefully resuspended in 1 ml of cold sterile PBS. The phage were 
centrifuged for 5 min at 9000 g to spin down the cell debris. The phage-containing 
supernatant was precipitated again with PEG/NaCl and incubated for one hour on ice. 
The phage were pelleted and resuspended in 1 ml of sterile PBS. Phage were serially 
diluted 1:10 in PBS and phage diluted at 10'10 and 10'12 were used to infect an E.coli 
culture to determine the phage titre. For long-term storage, phage were kept in PBS- 
10% sterile glycerol at -20°C.
2.10.4 Selections
All selections were performed in 96-well Maxisorb plates (NUNC, UK). The 
purified NAb bl2 (kind gift from Prof. D.R Burton), as well as purified polyclonal 
human IgG, were used at 5 and 10 pg/ml in PBS to coat a maxisorb plate overnight at 
4°C. After blocking the plate with PBST-2% skimmed powder milk (w/v) at RT for
104
one hour, several phage inputs from each library (detailed in Chapter 5), diluted in 
PBST-2% skimmed powder milk, (pre-incubated with polyclonal human IgG from a 
HIV seronegative donor for 30 min at RT on a rotating wheel) were incubated on the 
plate for two hours at RT. After twenty washes with PBST and PBS, the phage were 
eluted either with virus lysate, gpl40 (or PBS as a negative control) for 2 V2 hours at 
37°C and (or) with 100 pi of TEA (100 mM triethylamine). The eluted phage were 
then neutralised with 50 pi o f 1 M Tris buffer pH 7.5 for 10 min at RT. Half of the 
neutralised phage were used to infect 350 pi of an exponentially grown TGI E.coli 
culture for 30 min at 37°C. Serial dilutions of the infected bacteria were then plated on 
2TYAmpGlcAgar. The rest of the bacterial culture was pelleted and resuspended in 5 
ml of 2TY AmpGlc and grown overnight shaking at 37°C. The bacterial culture was 
centrifuged, the pellet was resuspended in 2TYAmp/20% glycerol and stored at -80°C 
until further use.
2.10.5 Clone screening
2.10.5.1 Master plate
Enriched libraries obtained after successive rounds of selection were serially 
diluted and plated on 2TYAmpGlcAgar to have distinct clones. Colonies were 
randomly picked with sterile cocktail sticks into a 96 V-bottom plate (NUNC) in 
2TYAmpGlc and were grown shaking at 100 rpm at 37°C until log phase was 
reached. Sterile glycerol was added to the wells at the final concentration of 20% and 
the master plate was stored at -80°C until further use.
2.10.5.2 Soluble expression and ELISA
5 pi from each well of the master plate were inoculated in 150 pi of 2TYAmpGlc 
in a 96 V-bottom plate. The plate was incubated at 37°C and shaken at 100 rpm until 
log phase was reached. It was then centrifuged at 900 g for 15 min, the medium was 
discarded, and the bacterial pellets were resuspended in 2TYAmpIPTG. The plate was 
incubated overnight at 37°C and shaken. After another centrifugation, 50 pi of each 
supernatant was tested for the detection of specific bl2 binding by ELISA.
A maxisorb plate was coated overnight either with b 12, polyclonal human IgG or 
BSA, diluted at a concentration of 5 pg/ml in PBS, overnight at 4°C. After washing 
with PBST, the plate was incubated for one hour at RT with PBST-2% skimmed
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powder milk (w/v). After further washing with PBST, 50 pi of supernatant were 
mixed with 50 pi of PBST-2% skimmed powder milk and were incubated for two 
hours at RT. The plate was washed with PBST and an anti-myc Ab directly 
conjugated to HRP (Abeam, Cambridge, UK), diluted at 1:2000 in PBST-2% powder 
milk, was added and incubated for one hour at RT. The plate was washed with PBST 
then pure H2O and 100 pi of HRP substrate were added. After the development of a 
blue color, the enzymatic reaction was stopped by the addition of 50 pi of 1 M HC1. 
The plate was read at 450 nm using a plate reader.
2.11 Expression and purification of Vhh fragments
2.11.1 Induction of protein expression
15 pi of the glycerol stock of each clone were inoculated in 5 ml of 2TYAmpGlc 
and were grown overnight at 37°C shaking. 500 pi of the overnight culture were used 
to inoculate 50 ml of fresh 2TYAmp-0.1%glc and were incubated at 37°C until log 
phase was reached. The 50 ml culture was added to 450 ml of fresh 2TYAmp- 
0.1%glc complemented in IPTG (0.1 mM final concentration) and the cultures were 
then grown overnight at 37°C shaking. The cultures were centrifuged at 3200 g for 20 
min, the supernatants discarded and the bacterial pellets were stored at -20°C.
2.11.2 Periplasmic extraction and purification of Vhh fragments
The bacterial pellets were thawed and resuspended in l/20th of the culture volume 
in the extraction buffer and incubated on ice for 30 min. The bacteria were centrifuged 
at 9000 g for 30 min and each supernatant was then applied onto 2 ml of Ni-NTA 
superflow column (Qiagen) previously equilibrated with PBS. Each supernatant was 
mixed with the column overnight at 4°C. Each column was washed at least five times 
with 15 ml of PBS-5 mM imidazole for one hour and the Vhh fragments were eluted 
from the column with 2 ml of PBS-250 mM imidazole overnight at 4°C on a rotative 
wheel. Each eluant was then placed in a dialysis cassette (Pierce, UK) and was 
dialysed for 36 hours in PBS at 4°C with regular changes of PBS. After the dialysis, 
the VHH fragments were aliquoted in 100 pi volumes. BSA was added at the final 
concentration of 1 mg/ml and they were kept at -80°C until further use.
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2.11.3 Protein gel electrophoresis
The production and the purification of the Vhh fragments were checked by 
Coomassie staining on SDS-PAGE 12% gels and by Western blotting using the anti- 
His-HRP described in 2. 10. 5. 2. The concentration of the purified Vhh fragments 
was determined by comparison with BSA on a Coomassie gel.
2.12 Characterisation of Vhh fragments by ELISA
Purified Vhh were tested against sCD4 and ant-HIV-1 Abs 17b and 2G12 (listed 
in table 2.5) by ELISA using the same protocol as described previously.
2.13 Detection of the anti-gpl20 Ab response by ELISA
A 96-well plate was coated with the anti-gpl20 Ab D7324 (Aalto Bioreagents Ltd, 
Ireland) at 10 pg/ml in PBS overnight at 4°C. The plate was washed four times with 
TBST and was blocked for one hour at RT with TBS-4% skimmed powder milk. 
After two washes with TBST, 50 pi of gpl20, diluted at 0.2 ng/pl in TBS-1% 
skimmed powder milk (w/v), were incubated in each well for two hours at RT. For 
each tested serum, a blank was included omitting the gpl20. The plate was washed 
four times with TBST. Sera, included a mix of QC sera 1, 2 and 4 used as a positive 
control and a seronegative serum used as a negative control, were serially diluted 
from a 1:100 dilution in TMT-GS and incubated on the plate for one hour at RT. The 
plate was washed four times with TBST and 100 pi of goat anti-human Ig conjugated 
to AP (Immunochemical direct, USA), diluted at 1:2000 in TMT-GS, was added in 
each well. After six washes with TBST, lOOpl of luminescent AP substrate (Labtech, 
UK) was added and the plate was incubated in the dark for one hour at RT. 
Luminescence was measured in a Lucy 1 luminometer at 405 nm and analysed using 
Stingray software.
2.14 IgG purification
IgG from patients’ samples were purified by binding to protein G using MAb trap 
kit (Amersham, UK) according to the manufacturer’s instructions. Plasma samples 
were centrifuged for 1 min at 9000 g, diluted 1:1 with binding buffer (Amersham, 
UK) and applied onto the protein G column previously equilibrated with binding 
buffer. After washes, the IgG were eluted and renatured with neutralising buffer
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(Amersham, UK) according to the manufacturer’s intructions. All the collected 
fractions, fall through (FT) fractions, washes and eluants were then tested for the 
presence of protein with Biorad Protein Assay solution (Biorad, Germany). The 
collected fractions were diluted 1:10 in PBS, as well as serial dilutions of BSA of 
known concentration, and 40 pi of Biorad protein assay solution was added. Fractions 
containing proteins would develop a blue color, of which the intensity is proportional 
to the amount of proteins present in the fractions.
2.15 KLH conjugation to Vhh fragments and to gpl20
This work was performed by Dr Peter Delves and colleagues (UCL, London). 
KLH (Sigma, UK) was resuspended in 0.9 M NaCl to a final concentration of 40 pM. 
KLH was then mixed with purified the Vhh fragments, diluted in 0.9 M NaCl, at a 
ratio Vhh/KLH 40:1. Glutaraldehyde was then added to the Vhh-KLH mix at the 
final concentration of 0.2% (v/v) and the mix was rotated on a wheel for one hour at 
4°C. Glutaraldehyde was added again to reach a final concentration of 0.4% (v/v) and 
the mix was again rotated on a wheel for one hour at 4°C. Glutaraldehyde was 
inactivated by the addition of 50 pi of 0.2 M ethanolamine in 0.5 M bicarbonate pH
9.5 per ml of conjugate and the mix was rotated for further 30 min at 4°C.
The KLH-Vhh fragments were then purified from ethanolamine and free 
glutaraldehyde by applying the mix onto 2x Hi Trap G25 columns (Pharmacia, UK) 
on an HPLC system previously equilibrated with 0.9 M NaCl in PBS. The first peak 
was collected. The protein concentration was estimated by BCA microplate protocol 
(Sigma, UK). The same protocol was used for the conjugation of gpl20 to KLH.
2.16 Immunisation regimes
Four rats and one rabbit were used for the immunisation of each Vhh fragment. 
The adjuvants used for the rabbits and the rats were MPL-TDN-CWS (Sigma, UK) 
and MPL-TDM (Sigma, UK) respectively. MPL is constituted of lipids from the 
bacterium S. minnesota and TDM is composed of an analogue of trehalose dimycolate 
from bacillus. CWS are cell wall skeleton from mycobacteria.
For each immunisation, the recommended dose was 25-125 pg in 500 pi per rat 
and 50-250 pg in 1 ml per rabbit, according to the manufacturer’s instructions. For the 
rats, 200 pi of antigen mixed with adjuvant were injected at two sites subcutaneously 
and 100 pi intraperitoneally. For the rabbits, 50 pi of antigen mixed with adjuvant
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were injected at six sites intradermally, 200 pi were injected intramuscularly into each 
hind leg, 100 jxl were injected subcutaneously, in the neck region and 200 pi 
intraperitoneally. The amounts of antigen injected in each animal are detailed in tables 
2. 7 for the rats and 2. 8 for the rabbits.
Prime First Boost
A3 26 pg 61 pg
B4 39 pg 42 pg
D3 52 pg 77 pg
D7 67 pg 61 pg
F10 10 pg 34 pg
OC 23 pg 65 pg
Table 2.7 Amount of antigen injected for immunisation of the rats
The rats were sacrificed after the first boost o f antigen.
Prim e First Boost Second boost gpl20a
A3 104 pg 243 pg ND 150 pg
B4 155 pg 170 pg 211 M-g 150 pg
D3 210 pg 310 pg Bled -
D7 268 pg 243 pg Bled -
F10 39 pg 135 pg 135 pg 150 pg
OC 94 pg 260 pg Bled -
Table 2.8 Amount of antigen injected for immunisation of the rabbits
* The gpl20 used for the boost o f the recombinant monomeric gpl20 from the X4-tropic 
isolate IIIB (NIBCS, UK).
ND: Not Done
- The rabbits immunised with the KLH -V H H  D3, D7 and OC were sacrificed after the second 
boost o f antigen.
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Chapter 3
Role of anti-HIV-1 Antibodies and complement during the
course of infection
3.1 Introduction
HIV infection in individuals is characterised by two phases; the acute and the 
chronic phases. D uring the acute phase, non-specific sym ptom s appear (see 
introduction, section 1. 9), the plasm a viral load increases and the C D 4 T cell count 
declines. Tw o to four w eeks after the onset o f  sym ptom s, the CD4 T  cell count 
increases w ithout reaching the initial level prior to infection and the viral load drops 
to a set point around six m onths post-infection (Levy, 1998). The infection then 
becom es chronic and is characterised by a gradual depletion in CD4 T  cells. W hen the 
CD4 T  cell count is below  200/p.l, the individual is declared to be at the AID S stage 
(Levy, 1998).
The arm (s) o f  the im m une system  responsible for the drop in viral load rem ain(s) 
unclear. CTLs are probably im plicated, as CTL activity is detected in acute infection 
(Borrow  et al., 1994) and C D 8  T  cell depletion in m onkeys leads to an uncontrolled 
viraem ia (Schm itz et al., 1999a). A lthough som e N A bs in the acute phase have been 
reported (Lew is et al., 1998), they are unlikely to be involved as they are generally 
detected after the drop in viral load (A asa-Chapm an et al., 2004; R ichm an et al., 
2003). A n ti-gp l20  Abs, how ever, are detected concom itantly w ith CTLs, during 
prim ary infection by ELISA  (A asa-C hapm an et al., 2004; M oore et al., 1994a).
N on-neutralising an ti-g p l2 0  A bs from the acute infection, could, how ever, play a 
role in viral decline as they can inactivate HIV with N K  cells in v itro  (Forthal et al., 
2001). The isotype o f  the Ab response against HIV-1 proteins, including g p l2 0 , is 
restricted prim arily to  IgG l (K halife et al., 1988). IgG l (IgG3, IgG4 and less potently 
IgG2) can activate the classical pathw ay o f  com plem ent. The classical pathw ay has 
been shown to be activated by neutralising anti-H IV  sera on laboratory-adapted 
viruses (Spear et al., 1992). C om plem ent-m ediated inactivation (CM I), how ever, has 
not been tested on viruses and sequential autologous sera isolated during the acute 
phase o f  infection, w here A b-neutralisation is not detected.
This chapter investigates w hether non-neutralising an ti-g p l2 0  Abs, detected early 
during the acute phase, can inactivate viruses with autologous and heterologous g p ! 2 0
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in the presence o f  com plem ent. CM I is higher in the presence o f  non-neutralising sera 
than in presence o f  neutralising sera.
N on-neutralising an ti-g p l2 0  Abs, in association w ith com plem ent, could, 
therefore, play a role in the viral decline observed in acute infection.
I l l
3.2 Results
For each CM I assay, a S tudent M est w as used to evaluate i f  there was a significant 
difference betw een data obtained in the presence and in the absence o f  com plem ent. 
The probability (p value) chosen w as 0.05 in order to evaluate as accurately as 
possible sm all differences. W hen the p value was above 0.05, no statistically 
significant CM I w as observed under the experim ental conditions used.
3.2.1 CMI of HIV-1 in the presence of heterologous cross-neutralising sera
3.2.1.1 TCLA strains
TCLA X 4-tropic strains IIIB, SF2 and RF were tested with QC serum  2 and IIIB 
and RF w ere tested w ith QC serum  5 in the absence or the presence o f  com plem ent to 
determ ine CM I (see p 91 for details on the QC sera). In the experim ents described in 
C hapters 3 and 4, CM I represents the inactivation o f  HIV in the presence o f  
(neutralising or non-neutralising) sera and com plem ent. The results are shown in 
figure 3.1 (QC serum  2) and in figure 3.2 (QC serum 5).
Serum QC 2 alone neutralised IIIB, SF2 and RF by 90%  at the reciprocal dilutions 
o f  80, 320 and 40 respectively. CM I increased the 90%  neutralisation titre by 2-fold 
only for IIIB. CM I w as only observed for reciprocal dilutions 80 and 160. For SF2 
and RF, CM I did not increase the 90%  neutralisation titres.
A sim ilar result w as observed for QC serum  5 with IIIB. CM I also increased the 
90%  reciprocal neutralisation titre by 2-fold and was 320. CM I w as only observed for 
reciprocal dilutions 320 and 640. For RF, CM I did not increase the 90%  neutralisation 
titre. CM I w as also tested for Pis.
3.2.1.2 Pis
Pis R 5-tropic strains SF162 and SL2 w ere tested for CM I w ith QC sera 2 and 5 in 
the absence and the presence o f  com plem ent. The results are show n in figure 3.3.
Serum QC 2 alone neutralised SF162 by 90%  at the reciprocal dilution o f  80. For 
SL2, 90%  neutralisation w as not observed. CM I increased the neutralisation titre for 
SL2, at the reciprocal dilutions o f  20, 40 and 80. CM I did not increase the 
neutralisation titre for SF162 except at the reciprocal serum  dilution o f  160.
Serum QC 5 alone neutralised by 90%  SF162 and SL2 at the reciprocal dilutions 
o f  160 and 20 respectively. CM I did not increase the 90%  neutralisation for either 
SF162 or SL2.
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Figure 3.1 CMI of IIIB, SF2 and RF with the heterologous neutralising serum QC 2
Viruses were incubated with serial dilutions o f  the heterologous cross-neutralising serum QC 
2 in the presence (orange bars) or the absence (green bars) o f  complement. Percentage 
inactivation was calculated from viral inputs, represented by the incubation o f  virus with 
complement or heat-inactivated complement. Error bars represent the standard error from 
three independent experiments. The indicated star (*) represents a statistically significant 
difference (/-test, p<0.05) between data obtained in the presence and in the absence o f 
complement under the experimental conditions used. The arrows span the dilutions where 
significant difference is observed
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Figure 3.2 CMI of IIIB and RF with the heterologous neutralising serum QC 5
Viruses were incubated with serial dilutions o f  the heterologous cross-neutralising serum QC 
5 in the presence (orange bars) or o f  the absence (green bars) o f  complement. Percentage 
inactivation was calculated from viral inputs, represented by the incubation o f  virus with 
complement or heat-inactivated complement. Error bars represent the standard error from 
three independent experiments. The indicated star (*) represents a statistically significant 
difference (/-test, p<0.05) between data obtained in the presence and data in the absence o f 
complement under the experimental conditions used. The arrows span the dilutions where 
significant difference is observed
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Figure 3.3 CMI of SF162 and SL2 with the heterologous sera QC 2 (A) and QC 5 (B)
Viruses were incubated with serial dilutions o f  the heterologous cross-neutralising sera QC 2 
(A) and QC 5 (B) in the presence (orange bars) or the absence (green bars) o f  complement. 
Percentage inactivation was calculated from viral inputs, represented by the incubation o f  
virus with complement or heat-inactivated complement. Error bars represent the standard 
error from three independent experiments. The indicated star (*) represents a statistically 
significant difference (/-test, p<0.05) between data obtained in the presence and in the 
absence o f  complement under the experimental conditions used. The arrows span the dilutions 
where significant difference is observed
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The presence of complement can only enhance HIV neutralisation by 2-fold in the 
presence of some cross-neutralising anti-HIV-1 sera for some isolates and for 
dilutions where 90% neutralisation was not observed.
Sequential sera from a cohort of patients recently infected with HIV-1 are 
available to our laboratory (for details of the patients, see Chapter 2, table 2. 5). By 
cloning the gpl20 sequences from samples, harvested soon after the diagnosis of 
HIV-1 infection, into a replication-competent HxB2 backbone, it is possible to detect 
autologous NAbs and determine CMI.
3.2.2 Neutralisation patterns of HIV gpl20 from recently HIV-1 infected 
individuals
3.2.2.1 Description of the amplified gpl20
Sequential sera from seven recently infected individuals were used for this study. 
gpl20 sequences were amplified by nested PCR from genomic DNA of the first blood 
sample available from each patient. gpl20 DNA fragments were then cloned into the 
HxB2 replication-competent backbone expressing HxB2 gp41 as described by 
McKeating et al (McKeating et al., 1996). The resulting viruses were tested for 
infectivity and co-receptor usage. The results are shown in table 3.1 below.
NP2/CD4/CCR5 NP2/CD4/CXCR4 Co-receptor
tropism
MM4 5x 10s 8x 102 R5
MM8 106 2xl02 R5
MM19 5x10s 103 R5
MM22 104 <10 R5
MM23 3x104 <10 R5
MM27 2x104 <10 R5
MM28 7.6x106 5x10 3 R5
Table 3.1 Viral titres (ffu/ml) of the chimeric HIV-1 viruses expressing the early gpl20
from patients
For details o f each patient, see table 2.5 in Chapter 2
The CCR5 phenotype is strongly associated with the transmissibility of HIV-1 to 
new individuals (Moore et al., 2004) and, therefore, gpl20 sequences amplified 
during acute infection are expected to have primarily a R5-tropism. Some of them 
could also use CXCR4 but the titres were between 2.2 and 3.5 logs lower than the 
titres obtained on NP2/CD4 expressing CCR5. Dorns et al define dual tropic viruses
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virus isolates that can equally use, within a log difference in infectivity, CCR5 and 
CXCR4 (Doms et al., 1998). Therefore, all viruses were categorised as R5-tropic.
3.2.2.2 Detection of the anti-gpl20 Ab response
The detection of the specific anti-gpl20 Ig response from each patient was 
determined by ELISA using the monomeric recombinant gpl20 from IIIB. The results 
are shown in figure 3.4. For each patient, the detection of the anti-gpl20 Ig response 
followed an exponential curve to reach a plateau at around 300 days POS. Anti-gpl20 
Abs could be detected at days 35, 49, 25, 25, 15, 28 and 19 days POS for the viruses 
MM4, MM8, MM 19, MM22, MM23, MM27 and MM28 respectively.
3.2.2.3 Autologous neutralisation assays
The emergence of a specific anti-gpl20 Ig does not correlate with the 
development of NAbs in the case of HIV (Aasa-Chapman et al., 2004; Moore et al., 
1994a). Neutralisation assays were performed using heat-inactivated sequential sera 
from patients MM4, MM8, MM 19, MM22, MM23, MM27 and MM28 using the 
chimeric HIV-1 virus expressing autologous gpl20. The results are shown in table
3.2.
Patient sera Days POS 
90% 
neutralisation
MM4 206’
MM8 81*
MM19 519
MM22 NA
MM23 204
MM27 406
MM28 503
Table 3.2 Autologous neutralisation of chimeric viruses
The chimeric viruses were incubated with sequential autologous sera. The data represent the 
days POS, at which sera were harvested that neutralised autologous chimeric viruses by 90%. 
The percentage neutralisation was calculated from a viral input, represented by the incubation 
of the virus with HIV-negative serum, as described in 2.8.1 
from (Aasa-Chapman et al., 2004)
NA Not Applicable, as patient MM22 started anti-viral therapy 26 days POS
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Figure 3.4 Anti-gpl20 Ab detection in HIV-1 infected patients
Sequential sera on HIV-1 infected patients were diluted in 1/100 and were tested for the 
presence o f anti-gpl20 Abs by ELISA assay using monomeric recombinant gpl20 from IIIB. 
The values for each time point were calculated from the background value given by HIV 
seronegative serum incubated on gpl20 and by the absence o f serum or gp!20. Error bars 
represent the standard error from two experiments.
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The detection of autologous NAbs varied from individual to individual. Three 
patterns of neutralisation could be distinguished. The first pattern was unique to 
chimeric virus MM8 that was neutralised after less than three months POS. The 
second pattern was seen with the chimeric viruses MM4 and MM23, where 90% 
neutralisation was observed between six and seven months POS. The third pattern 
contained MM 19, MM27 and MM28, which were neutralised by 90% more than 
twelve months POS. For patient MM22, the NAb pattern could not be determined as 
this person underwent HAART treatment 26 days after onset of symptoms.
3.2.3.4 Heterologous neutralisation assays
The NAb pattern for each patient was determined using YU2 molecular clone. The 
results of the heterologous NAb patterns are shown in table 3.3.
Patient sera Days POS 
50% 
neutralisation
Days POS 
90% 
neutralisation
MM4 NDa NDa
MM8 333 608
MM19 889 >889b
MM22 NA NA
MM23 498 >63 lb
MM27 >685b >685b
MM28 >503b >503b
Table 3.3. Heterologous neutralisation of YU2
YU2 was incubated with sequential sera. The data represent the days POS, at which the sera 
were harvested, which neutralised the virus by 50% or 90%. The percentage neutralisation 
was calculated from a viral input, represented by the incubation o f the virus with HIV- 
negative serum as described in 2 . 8 . 1
* Not Done, not enough serum was available to perform the assay 
b 50 or 90% neutralisation was not achieved with the latest serum available from patients 
NA Not Applicable, as patient MM22 started anti-viral therapy 26 days POS
Neutralisation of YU2 was delayed compared to the autologous gpl20- expressing 
virus as already observed (Aasa-Chapman et al., 2004). YU2 was only neutralised by 
90% by sera from patient MM8, 20 months POS. None of the other sera neutralised 
YU2 by 90%. However, the virus could be neutralised by 50% by sera from patients 
MM 19 and MM23, 30 and 16 months POS, respectively. The sera available from the 
patients MM27 and MM28 did not neutralise YU2 even by 50%.
Complement can enhance neutralisation of some laboratory-adapted strains of 
HIV-1 by a maximum of 2-fold using cross-neutralising sera in our study (see sections
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3. 2. 1. 1). The effect of complement was next investigated using early neutralising 
sera (> 90 % neutralisation) and chimeric viruses expressing autologous gpl20.
3.2.3 CMI of viruses in the presence of autologous neutralising sera
The chimeric viruses were incubated with autologous neutralising sera in the 
absence and in the presence of complement. The assay was not performed using 
MM22 as neutralising sera were not available. The results are shown in figure 3.5.
In the absence of complement, the reciprocal serum dilution for achieving 90% 
neutralisation for chimeric viruses MM4, MM8, MM 19, MM23, MM27 and MM28 
were 20, 40, 20, 160, 40 and below 10 respectively. CMI enhanced by 2-fold the 90% 
neutralisation titres for viruses MM4, MM8, MM 19 and MM28 to 40, 80, 40 and 10. 
For these viruses, complement increased HIV neutralisation at Ab dilutions where 
90% neutralisation was not achieved. For viruses MM23 and MM27, CMI was not 
observed.
CMI was then tested using early non-neutralising sera, harvested during the first 
month POS, in combination with autologous viruses.
3.2.4 CMI of viruses in the presence of autologous non-neutralising sera
Viruses were tested in CMI assays in the presence of non-neutralising sera, 
harvested during the early phase of infection. The figure 3.6 shows results for each 
patient using non-neutralising sera from two time points, positive for the presence of 
anti-gp 120 Abs.
In the absence of complement, 90% neutralisation of the chimeric viruses was not 
achieved. The chimeric viruses MM4, MM8 and MM 19 were neutralised by 50% or 
less. The other chimeric viruses, MM22, MM23, MM27 and MM28 were not 
neutralised.
In the presence of complement, three patterns of CMI were observed. High CMI 
(90%) was observed for viruses MM4, MM8 and MM 19. A more modest increase 
(50-70%) was observed for viruses MM23 and MM28. For virus MM27, CMI was 
not detected in the presence of serum harvested at day 28 POS but was observed for 
day 39 POS.
For viruses MM 14, MM 19, MM23, MM27 and MM28, CMI was detected at low 
reciprocal serum dilutions, varying from 10 to 40. For MM8, however, CMI was 
observed for every serum dilution (up to 320). No CMI was observed for MM22.
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Figure 3.5 CMI of chimeric viruses with autologous neutralising sera
Viruses were incubated with serial dilutions of autologous neutralising sera in the presence 
(orange bars) or the absence (green bars) of complement. Percentage inactivation was 
calculated from viral inputs, represented by the incubation of virus with complement or heat- 
inactivated complement. Error bars represent the standard error from three independent 
experiments. The indicated star (*) represents a statistically significant difference (Mest, 
p<0.05) between data obtained in the presence and in the absence of complement under the 
experimental conditions used. The arrows span the dilutions where significant difference is 
observed
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Figure 3.6 CMI of chimeric viruses with autologous non-neutralising early sera
Viruses were incubated with serial dilutions o f autologous non-neutralising early sera in the 
presence (orange bars) or in the absence o f complement (green bars). Percentage inactivation 
was calculated from viral inputs, represented by the incubation o f  virus with com plem ent or 
heat-inactivated complement. Error bars represent the standard error from three independent 
experiments. The indicated star (*) represents a statistically significant difference (Mest, 
p<0.05) between data obtained in the presence and in the absence o f complement under the 
experimental conditions used. The arrows span the dilutions where significant difference is 
observed
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3.2.5 CMI of autologous viruses in the early course of infection
CMI assays were performed using autologous sera for each patient and for each 
time point. The results shown in figure 3.7 represent the inactivation curves when the 
autologous sera are diluted at the final concentration of 1/10.
CMI resulted in 70-90% inactivation for viruses MM4, MM8, MM 19 and MM28. 
Complement had a more moderate effect for virus MM23 and resulted in 40-50% 
inactivation. CMI was detected when tested in the presence of sera harvested at days 
32, 39, 53 and 109 POS for virus MM27. Complement, however, did not have any 
effect on virus MM22 and no inactivation was observed. For all viruses, CMI was not 
observed in the presence of 90% neutralising sera, like TCLA and PI viruses (see 
sections 3. 2. 1. 1 and 3. 2. 1.2 for details).
The breadth of CMI was tested using virus MM4 and the molecular clone YU2.
3.2.6 CMI of viruses in the presence of heterologous non-neutralising sera
3.2.6.1 Virus MM4
Sequential sera from patients MM 19, MM22, MM23, MM27 and MM28 were 
tested at the final dilution of 1/10 with virus MM4 for CMI. The sera from patient 
MM8 were tested in an alternative assay described in Chapter 4. The results are 
shown in figure 3.8.
In the absence of complement, the virus MM4 was not neutralised by the patients’ 
sera. CMI resulted in 50-90% inactivation using sera from patients MM 19, MM23 
and MM28. No CMI was observed using the serum harvested at day 9 POS for patient 
MM23 and all sera from patients MM22 and MM27. The breadth of inactivation was 
then tested using YU2.
3.2.6.2 YU2 virus
Sequential sera from all patients were tested at the final dilution of 1/10 with YU2 
for CMI. The results are shown in figure 3.9.
In the absence of complement, YU2 was 90% neutralised by none of the sera 
except sera from day 385 POS from patient MM4. CMI resulted in 65-95% 
inactivation for all patients except for patient MM27. CMI was not observed in the 
presence of neutralising sera from patient MM4 from day 385 POS.
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Figure 3.7 CMI of chimeric virus using sequential autologous sera.
Viruses were incubated with sequential autologous sera (at the final dilution o f 1/10) in the 
presence (orange bars) or the absence (green bars) o f complement. Percentage inactivation 
was calculated from viral inputs, represented by the incubation o f  virus with complement or 
heat-inactivated complement. Error bars represent the standard error from three independent 
experiments. The indicated star (*) represents a statistically significant difference (/-test, 
p<0.05) between data obtained in the presence and in the absence o f complement under the 
experimental conditions used. The arrows span the time points where significant difference is 
observed
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Figure 3.8 CMI of chimeric virus MM4 with sequential sera from recently infected patients
Virus MM4 was incubated with non-neutralising sera (at the final dilution o f 1/10) in the 
presence (orange bars) or the absence (green bars) o f complement. Percentage inactivation 
was calculated from viral inputs, represented by the incubation o f  virus with complement or 
heat-inactivated complement. Error bars represent the standard error from three independent 
experiments. The indicated star (*) represents a statistically significant difference (/-test, 
p<0.05) between data obtained in the presence and in the absence o f complement under the 
experimental conditions used. The arrows span the time points where significant difference is 
observed
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3.3 Discussion
Complement, in association with non-neutralising anti-HIV sera, in the early 
course of infection, can inactivate HIV-1 in vitro. CMI assays were performed using 
chimeric viruses expressing autologous gpl20 with sequential sera from patients. CMI 
was observed between day 6 and 28 POS in six out of seven patients, concomitantly 
with the detection of the CD8 T cell activity (Aasa-Chapman et al., 2005). In the 
absence of complement, neutralisation was detected generally between 6 and 12 
months POS in agreement with previous studies (Aasa-Chapman et al., 2004; 
Richman et al., 2003). Non-neutralising Abs, in association with complement, could 
play a role in the viral decline observed during acute infection, when NAbs are not 
detected.
CMI was weaker in association with neutralising sera and reached a maximum 2- 
fold under the experimental conditions used. The 2-fold increase was only observed 
for some isolates at dilutions that resulted in 50-70% neutralisation, and was lost at 
higher serum dilutions. No CMI was observed for serum dilutions that resulted in 
90% neutralisation (or above). This could suggest that complement cascades could be 
triggered by NAbs when they are only partially coating HIV. However, the presence 
of non-NAbs in neutralising sera, triggering complement, cannot be ruled out. CMI 
was not observed for all neutralising sera under the experimental conditions used. 
This is in agreement with a study by Spear et al (Spear et al., 1992). In their study, 
CMI could increase the neutralising titres up to 32-fold but CMI was sometimes 
absent in association with some sera, depending on the source of Abs.
The breadth of CMI was also tested on the heterologous viruses YU2 and MM4, 
which were not neutralised by sera alone, with the exception of MM8, where YU2 
was neutralised by 90% more than twenty months POS. The delay in the 
neutralisation of heterologous isolates was also reported by others (Aasa-Chapman et 
al., 2004; Albert et al., 1990). CMI of MM4 was detected between 60 and 90% using 
early sera harvested from patients MM 19, MM23 and MM28. No significant CMI of 
MM4 was, however, detected using sera from patients MM22 and MM27. CMI of 
YU2 was detected between 70 and 90% using sera from all but one patient (MM27).
HIV has previously been shown to activate complement in vitro (Saifuddin et al., 
2000; Spear et al., 1991b; Tacnet-Delorme et al., 1999) in the presence and the 
absence of anti-HIV Abs (Spear et al., 1992; Tacnet-Delorme et al., 1999). The Ab-
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independent complement activation against HIV might be triggered by natural IgM, 
present in all sera (Saarloos et al., 1995). In this study, all CMI values were calculated 
from viral inputs, determined after the incubation of the virus with fresh human serum 
containing natural Abs, as the complement source. CMI mediated by natural Abs was 
therefore excluded from the calculations.
Ab-dependent CMI can be triggered by Abs directed to cell protein complexes, 
particularly MHC class I and II (Spear et al., 2001; Spruth et al., 1999). Moreover, 
CMI against TCLA viruses was observed using sera from macaques containing anti- 
cellular Abs (Spear et al., 1993a). For patient MM22, CMI was not observed against 
chimeric autologous virus but was detected at 90% against YU2. For patient MM27, 
CMI was observed against the autologous virus (50% inactivation with some sera) but 
not against YU2. Since these two viruses are produced in the same cell line (293T) 
they express the same cellular protein complexes, it is therefore unlikely that CMI 
was triggered by Abs against MHC class I and II proteins, which could be present in 
the HIV-1 positive sera used in this study. Thus, CMI observed was likely to be due to 
the presence of anti-HIV Env Abs in the sera of patients.
Envs of the chimeric viruses, described in 3. 2. 2, consisted of gp41 from the 
TCLA strain HxB2 and gpl20 amplified from patient DNA. Anti-gp41 Abs are 
unlikely to be the main Abs involved in CMI, as sera from patient MM27 inactivated 
the autologous chimeric virus but not YU2. Therefore, it is likely that CMI was 
triggered by anti-gpl20 Abs.
Complement can activate the alternative pathway (Tacnet-Delorme et al., 1999), 
the MBL (Ying et al., 2004) and the classical pathway (Spear et al., 1992). As CMI, 
described in this chapter, was triggered by anti-gpl20 Abs, the classical pathway is 
likely to be the branch of complement involved. IgM and IgG can equally trigger 
complement and, therefore, the isotype of anti-gpl20 Abs should be determined. CMI 
could be dependent on the presence of epitope-specific Abs in sera. To address this 
issue, CMI will be tested with MAbs mapping to various regions of gpl20 and with 
sCD4-IgG2. The influence of the cell line in the modulation of CMI has to be studied. 
All these issued are addressed in Chapter 4.
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Chapter 4
Characterisation of complement-mediated inactivation of
HIV-1 in vitro
4.1 Introduction
Complement consists of more than 30 serum proteins and cell surface receptors, 
organised in three cascades: the classical pathway, the alternative pathway and the 
MBL pathway. The three complement cascades are schematised in figure 4.1. The 
serum proteins of complement are zymogens that are pro-enzymes requiring 
proteolytic cleavage to become active. All three cascades lead to the formation of the 
central component C3 and its cleavage triggers the late steps of complement 
activation, by the formation of the MAC.
The classical pathway (the first historically described) is triggered by Abs (IgM, 
IgGl, IgG3 and, less potently IgG2), by the interaction of C lq with the CH2 domain 
of IgG and the CH3 domain of IgM in a crab-like configuration. This subsequently 
leads to the rearrangement of Clq, which reveals interactions sites with two molecules 
ofC lr. C lr then interacts with two molecules of C ls and Clq, C lr and C ls form the 
Cl complex. The Cl complex then cleaves C4 into C4a and C4b via a Ca2+- 
dependent-mechanism. C4b then cleaves C2 into C2b and C2a and C4b2a form the 
C3 convertase that cleaves C3 into C3a and C3b, leading to the triggering of the late 
steps of complement cascades. C4b2a3b constitutes the C5 convertase and cleaves C5 
into C5a and C5b. C5b binds to C6 and C l and forms C5b67 that has hydrophobic 
properties and inserts into membranes. C8 subsequently inserts into the membrane, 
followed by polymerised C9 that generates the MAC.
The MBL pathway is activated by the recognition of Pathogen-Associated- 
Molecular-Pattems (PAMPs) characteristically repeats of Mannose and N-acetyl 
glucosamine or GlcNac (Carrol, Nat Immunol, 2004). MBL is structurally similar to 
Clq and associates with MASP1 and MASP2, which resemble C lr and Cls. The 
MBL cascade is identical to the classical pathway.
Unlike the classical and the MBL pathways, the alternative pathway is 
constitutively activated and is characterised by the spontaneous cleavage of an 
unstable thioester bond within C3 into C3a and C3b. C3b can bind to surface antigens. 
When bound on a surface, C3b binds to factor B that is subsequently cleaved by factor
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D and C3bBb is generated. This complex has a C3 convertase activity and can cleave 
more C3, amplifying the alternative pathway and triggering the late steps of 
complement described above.
MASP-1 MASP-2
Carbohydrates
Activator 
aggregated IgG. 
IgM-antigen complex 
polyanions. RNA DNj 
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Figure 4.1 Complement cascades
The classical pathway is triggered by IgG and IgM. The MBL pathway is triggered by 
mannose residues on pathogens and the alternative pathway is spontaneously activated and is 
mainly regulated by the presence o f complement regulatory proteins (CRP) at the surface of 
the cells. Adapted from biocarta.com
Complement is directly involved in fighting pathogens by the formation and the 
insertion o f the MAC into membranes, which leads to lysis. C3 also entirely coats the 
pathogens (known as opsonisation), which, sometimes, is sufficient for inactivation by 
steric hindrence (Spear et al., 2001). Opsonised antigens are presented to B cells via 
interactions with C3 degradation products, such as iC3b, C3d, C3dg, C3b and C4b,
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and CD35 (CR1) and CD21 (CR2) expressed on B cells and FDCs. These interactions 
lower the threshold for B cell stimulation and the uptake of antigens by FDCs. The 
maintenance of antigen presentation to FDCs results in the selection of high affinity 
antibody-secreting B cells (Boes, 2000; Carroll, 2004). Complement is also thought to 
play a role in the regulation of the T cell response, via uptake of opsonised antigens 
by APC and the modulation of release of some cytokines such as IL12 and IL10 
(Carroll, 2004). C3a and C5a also act as anaphylotoxins, which increase vascular 
permeability and recruit other components of the inflammatory response to the site of 
infection.
Complement can be potentially harmful to the self so it is tightly regulated by the 
expression of CRPs. CD59 inhibits the formation of the MAC. Decay accelarating 
factor (DAF or CD55) inhibits the binding of C2 to C4b (or accelerates the 
dissociation of C2a from C4b). Membrane co-factor protein (MCP or CD46) acts as a 
co-factor to promote the catabolism of C4b by factor I.
Complement is activated by many pathogens, like bacteria, fungi and also viruses. 
For example, human complement inactivates non-primate mammalian viruses via the 
binding of natural Abs against a-galactosidase motifs found on viral Envs (Takeuchi 
et al., 1996). Complement has also been shown to be activated by HIV in the presence 
of anti-HIV sera (Spear et al., 1992; Stoiber et al., 2001). HIV has also been shown to 
incorporate CRPs into its membrane, in order to prevent total inactivation (Montefiori 
etal., 1994; Saifuddin et al., 1994).
This chapter explores the mechanism of CMI described in Chapter 3. First of all, 
the pathway involved was elucidated, as HIV has been show to activate the classical, 
alternative and MBL pathways (Tacnet-Delorme et al., 1999). Then, the isotype of the 
anti-HIV Abs involved in CMI was investigated, particularly in the acute phase of 
infection, where anti-HIV IgG are barely detectable. CMI was tested using 
neutralising and non-neutralising MAbs, mapping to various regions of gpl20. CMI 
against HIV is modulated by the incorporation of CRPs in the viral membrane and 
therefore could depend on the HIV producing-cell line (Saifuddin et al., 1994). HIV 
viruses were grown in several cell lines and CMI was investigated.
131
4.2 Results
For each CMI assay, a Student /-test was used to evaluate if there was a significant 
difference between data obtained in the presence and in the absence of complement. 
For the complement titration experiment described in 4. 2. 2, the same test was used 
to evaluate if there was a significant difference between data obtained with 10% and 
20% of complement. The probability (p value) chosen was 0.05 in order to evaluate 
small differences as accurately as possible. Therefore, when the p value was above 
0.05, no statistically significant CMI (or no difference between 10 and 20% 
complement) was observed under the experimental conditions used.
For comparing the neutralisation profiles between the same isolate grown in two 
different cell types, the same statistical test was used. There was a significant 
difference between neutralisation data obtained in one cell type and the other cell type 
when the p value was below 0.05 under the experimental conditions used.
4.2.1 Involvement of complement
Burrer et al have reported that soluble factors in serum can inhibit HIV growth in 
vitro (Burrer et al., 2001). To formally involve complement in CMI described in 
Chapter 3, inactivation assays were carried out using Guinea pig purified complement.
4.2.1.1 Purified Guinea pig complement
Guinea pig complement has been shown to be activated by HIV (Spear et al., 
1991b). The chimeric virus MM4 was incubated with serum from day 49 POS from 
patient MM8 and purified Guinea pig complement. The results are shown in figure
4.2.
In the presence of heat-inactivated Guinea pig complement, MM4 was not 
neutralised. Purified Guinea pig complement inactivated the chimeric virus by 70% 
and 40% at the reciprocal dilutions of 10 and 20, respectively. This supports that the 
inactivation observed in Chapter 3, where whole seronegative human serum was used 
as a source of complement, is mainly due to the complement itself rather than some 
other heat labile compounds found in the serum.
The identity of the complement pathway involved in HIV inactivation was then 
investigated.
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4.2.1.2 EDTA/EGTA-treatment of complement
Complement consists of cascades of proteases. The first step of the classical 
pathway is the formation of the Cl complex, which requires Ca2+ ions. EGTA 
preferentially chelates Ca2+ ions whereas EDTA chelates all bivalent ions (Spear et 
al., 1991a). Therefore, EGTA inactivates the classical pathway alone whereas EDTA 
inactivates the three different pathways.
MM 19 was tested for CMI using complement, heat-inactivated complement, 
EDTA- and EGTA-treated fresh human serum with the autologous from day 65 POS. 
The results are shown in figure 4.3.
In the presence of EDTA-treated serum and EGTA-treated serum, no CMI was 
observed with MM 19 as observed in the presence of heat-inactivated complement. 
These results showed the involvement of the classical pathway in CMI.
Fresh snap-frozen sera from Clq- and C3- deficient individuals, kindly provided 
by Dr. Marina Botto from the Hammersmith hospital in London, were used for CMI 
assays to further confirm the role of the classical pathway.
4.2.1.3 Serum from Clq- and C3-deficient individuals as source of complement
CMI assays were performed using chimeric viruses MM8 and MM28 with 
autologous sera from day 12 and 6 POS in the presence of Clq- and C3-deficient sera. 
The results are shown in figure 4.4.
In the presence of C3- and C 1 q-deficient sera, no CMI was observed for either 
virus. The addition of recombinant C3, at a final concentration of 1.3 mg/ml, restored 
the inactivation of HIV for both viruses at 50 and 70%.
Results from 4.2.1 demonstrate that the classical pathway of complement, in 
association with anti-HIV Abs, is involved in CMI described in sections 3. 2. 5 and 3. 
2. 6.
4.2.2 Titration of complement
All assays performed in Chapter 3 and in 4. 2. 1 used complement at the final 
concentration of 10% as already described (Saifuddin et al., 1995). CMI assays were 
repeated using complement diluted at 20% to test whether an increased concentration 
of human complement could enhance CMI with neutralising and non-neutralising 
sera. The chimeric virus MM 19 was tested with early and late autologous sera. The 
results are shown in figure 4.5.
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Figure 4.2 CMI assay using purified complement from Guinea pig
MM4 was incubated with serial dilutions o f the heterologous serum from day 49 POS from 
patient MM 19 in the presence (orange bars) or the absence (green bars) o f  Guinea pig 
complement. Percentage inactivation was calculated from viral inputs, represented by the 
incubation o f  virus with complement or heat-inactivated complement. Error bars represent the 
standard error from three experiments. The indicated star (*) represents a statistically 
significant difference (/-test, p<0.05) between data obtained in the presence and the absence o f 
complement under the experimental conditions used. The arrows span the dilutions where 
significant difference is observed
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Figure 4.3 Inactivation of complement by EDTA/EGTA treatment
MM 19 was incubated with the autologous serum from day 65 POS (at the final dilution o f 
1/10), in the presence o f complement C, heat-inactivated human serum, fresh human serum 
treated with EDTA or EGTA at the final concentration o f 2.5mM. Percentage inactivation was 
calculated from viral inputs, represented by the incubation o f virus with complement, heat- 
inactivated complement, EDTA-treated or EGTA-treated complement. Error bars represent the 
standard error from three experiments. The indicated star (*) represents a statistically 
significant difference (/-test, p<0.05) between data obtained in the presence o f com plem ent and 
with inactivated complement under the experimental conditions used
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Complement inactivated the chimeric virus as efficiently regardless of the final 
concentration of complement. The amount of complement proteins in 10% serum is 
sufficient to mediate maximum CMI.
The classical pathway is activated by IgM or IgG. In the longitudinal study using 
sequential autologous sera, described in 3.2.5, the anti-gpl20 Ig response determined 
by ELISA was detected (see 3. 2. 2. 2) and the isotype of anti-gpl20 was not 
determined. Anti-HIV IgM or IgG could also be the triggering agents of CMI in the 
early phase of the infection.
4.2.3 Antibody isotypes involved in CMI
The IgG fractions were purified from sequential plasma harvested at days 13, 39, 
130, 519 and 701 POS from patient MM 19. Briefly, the plasma samples were 
centrifuged and supernatants were applied onto a protein G column. The Fall Through 
(FT) fractions were kept and, after washing, the IgG were eluted. CMI assays were 
performed using purified IgG and FT fractions. The results are shown in figure 4.6.
For the earliest time point, CMI was observed in the FT fraction at days 13 and 39 
POS (figure 4.6.A). With later time points, CMI was lost in FT fractions and was 
undetectable in time points 519 and 701. In parallel, no CMI was observed with the 
purified IgG from the earliest time point (day 13 POS) but developed with later time 
points (days 39 and 130 POS). At late time points (days 519 and 701 POS), no CMI 
was detected in both IgG and FT fractions. Furthermore, the additive potency of both 
fractions, for each time point, was comparable to the pattern obtained with whole 
serum (figure 4.6.B).
4.2.4 Monoclonal human antibodies and CMI
The classical pathway of complement is activated by one molecule of IgM in a 
“crab-like” conformation or by the agglomeration of IgG3, IgGl and, more weakly, 
IgG2. The IgG isotype in the anti-HIV Ab response is primarily constituted of IgGl 
(Khalife et al., 1988).
To identify if particular HIV epitopes were involved in CMI, a series of human 
anti-gpl20 MAbs (all with an IgGl isotype except IgG3 442-57D), mapped to the V3 
loop, the CD4BS, the V2 loop, the C5 region and to CD4-induced epitopes (binding 
to the co-receptor region) were tested individually for their properties in CMI of the
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Figure 4.4 CMI assays using fresh serum from Clq- and C3-deficient individuals as 
sources of complement
M M 8  and MM28 were incubated with autologous sera from days 12 and 6  POS (at the final 
dilution o f  1/10) in the presence o f  serum from C lq - and C3-deficient individuals. As a 
control, recombinant C3 was added at 1.3 mg/ml. Percentage inactivation was calculated from 
viral inputs, represented by the incubation o f the virus with complement, heat-inactivated 
complement, C l-deficient serum, C3-deficient serum and C3-deficient serum supplemented 
with C3. The indicated star (*) represents a statistically significant difference (/-test, p<0.05) 
between data obtained in the absence and in the presence o f  complement or in the presence o f 
C3-deficient serum and C3-deficient serum where C3 was added under the experimental 
conditions used
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Figure 4.5 Titration of complement in CMI
Virus MM 19 was incubated with autologous sera from day 65 and day 889 POS (at the final 
dilution o f  1 / 1 0 ) in the presence o f 1 0  and 2 0 % o f complement or heat-inactivated 
complement. Percentage inactivation was calculated from viral inputs, represented by the 
incubation o f virus with complement or heat-inactivated complement. The /-test statistical 
analysis (/-test, p<0.05) showed that there was no significant difference observed between 
CMI performed with 10% complement and 20% complement under the experimental 
conditions used
136
MM19
IgG FT
§
c#o
«—
-
«
G
>
EC
B
100
80
60
40
20
0
-20
i
i
13 39 130 519 701
Days POS
100 *
< ►
80 
60 
40 
20 
0 
-20 13 39 130 519 701
□
■
C’
HIC’
IgG + FT
—
13 39 130 519 701
120
100
80
Whole serum
20
13 39 130 519 701
Days POS
Figure 4.6 CMI of purified IgG and FT fractions of serial sera from patient MM19
A. The IgG and FT fractions from sera harvested on days 13, 39, 130, 519 and 701 POS from 
the patient MM 19 was tested for autologous CMI in the presence (orange bars) or in the 
absence (green bars) of complement. Percentage inactivation was calculated from viral inputs, 
represented by the incubation of virus with complement or heat-inactivated complement. For 
each time point, a background value obtained with IgG and FT fractions from HIV-negative 
serum was deducted. Error bars represent the standard error from three experiments. The 
indicated star (*) represents a statistically significant difference (f-test, p<0.05) between data 
obtained in the absence and in the presence of complement under the experimental conditions 
used. The arrows span the time points where significant difference is observed
B. The inactivation values (obtained for the IgG and the FT fractions of sequential sera from 
patient MM 19 in the presence or the absence of complement) were added and compared to 
the inactivation profile obtained with the whole sera as described in 3.2.6
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TCLA strain SF2 and the chimeric viruses MM 19 and MM27. The results are shown 
in table 4.1.
MM19 MM27 SF2
HIC C HIC C HIC C
442-5 7D§ 40±5 55±5 ISfl 54±3 72±51]
V3-loop MN215§ 80±5 90±3 NI ND ND
268-D§ Isfl NI 28±11 53±111
GP 68s NI NI ND ND
CD4 BS 654-D§ NI NI 76±6 80±9
b 12 90±5 90±5 NI 85±2 86±4
b6* NI NI NI NI
A32* NI ND ND ND
CD4-induced 17b* 90±5 90±2 NI 80±3 83±3
C5 670-D* NI NI 22±10 25±15
V2
697-D* NI NI NI NI
carbohydrate 2G12* NI 50±5 50±10 ND ND
Table 4.1 CMI assays using human MAbs
HIV viruses were incubated with MAbs mapped to various regions o f gpl20 in the presence 
or the absence o f complement. Inactivation percentage was calculated from the viral inputs, 
represented by the incubation o f viruses in the presence or the absence o f complement without 
the MAbs. Values are shown with the standard error (values±error). See section 2. 2. 3 for the 
description
N1 No Inactivation (<10%)
ND Not Done
§ The supernatant o f the hybridoma was tested and the Ab concentration was unknown. The 
supernatant was then tested at the final dilution of 1 / 1 0 .
* The MAb was tested at the final concentration o f 20 (ig/ml
1 Significant difference o f inactivation between complement and heat-inactivated complement 
(Mest, p<0.05)
CMI was detectable only in the presence of neutralising anti-V3 loops Abs with 
SF2. CMI was not detectable in the presence of any of the MAbs tested with MM 19 
and MM27. CMI was not detectable with neutralising MAbs that mapped to other 
regions on gp!20 or with non-neutralising MAbs.
138
4.2.5 Effect of complement in combination with sCD4-IgG2
sCD4-IgG2 (or immunoadhesin) is a hybrid molecule consisting of four copies of the 
D1-D2 immunoglobulin super family domains of CD4 fused to the Fc region of IgG2 
(Allaway et al., 1995). sCD4-IgG2 neutralises isolates of HIV in vitro, including Pis 
(Trkola et al., 1995), also protects hu-PBL SCID mice (Gauduin et al., 1998a) in vivo 
and reduces viral loads of infected patients in clinical trials (Jacobson et al., 2004; 
Shearer et al., 2000).
A previous form of immunoadhesin, where the N-terminal region of sCD4 was 
fused to the Fc region of IgGl, was tested for its effect in association with 
complement and the effect was dependent on the strain used (Spear et al., 1994a). The 
effect of complement on sCD4-IgG2 was investigated here by using SF162 and the 
chimeric virus MM 19. The results are shown in figure 4.7.
CMI enhanced inactivation of SF162 by 2-fold when sCD4-IgG2 was used at the 
concentration of 50 and 25 pg/ml, whereas no CMI was observed for MM 19, despite 
both viruses being neutralised.
4.2.6 Influence of cell lines in CMI
As described in Chapter 3, there was little difference observed in CMI of H9- and 
PBMCs-derived viruses in the presence of cross-neutralising sera. To assess if the 
producing cell has a major influence on CMI, the same HIV isolate was grown in two 
different cell types and CMI assays were performed.
PBMCs and macrophages were first compared, as they are likely to represent the 
main targets of HIV infection in vivo.
4.2.6.1 CMI comparison between macrophage- and PBMC-derived viruses
PBMCs and macrophages are the main targets of HIV infection and virus 
production. Viruses produced in macrophages acquire markers characteristic of late 
endosomal compartments (such as Lysosome-associated antigens LAMP-1 and 
CD63) and, do not seem to incorporate the CRP protein CD55 (Pelchen-Matthews et 
al., 2003) unlike PBMCs-derived viruses (Saifuddin et al., 1995). The virus BaL is a 
R5-tropic virus, that is particularly efficient at infecting primary macrophages 
(Simmons et al., 1996). The sensitivity to CMI of BaL was compared between BaL
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Figure 4.7 CMI using sCD4-IgG2
SF162 and MM 19 were incubated with serial concentrations o f  sCD4-IgG2 in the absence 
(green bars) or the presence (orange bars) o f  complement. Percentage inactivation was 
calculated from viral inputs, represented by the incubation o f  virus with complement or with 
heat-inactivated complement. Error bars represent the standard error o f  three independent 
experiments. The indicated star (*) represents a statistically significant difference (/-test, 
p<0.05) between data obtained in the presence o f complement and data obtained in the 
absence o f  complement. The arrows span the concentrations where significant difference is 
observed under the experimental conditions used
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Figure 4.8 Comparison of CMI between macrophage- and PBMC-derived BaL
Macrophage- or PBMC-derived BaL was incubated with serial dilutions o f  the heterologous 
neutralising sera QC 4 (A) and QC 6  (B) in the presence (orange bars) or the absence (green 
bars) o f  complement. Percentage inactivation was calculated from viral inputs, represented by 
the incubation o f  virus with complement or heat-inactivated complement. The indicated star 
(*) represents a statistically significant difference (/-test, p<0.05) between data obtained in the 
presence and in the absence o f complement. The arrows span the dilutions where significant 
difference is observed under the experimental conditions used. The symbol (—) represents a 
statistical difference between neutralisation under the experimental conditions used
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grown in macrophages or PBMCs using the heterologous neutralising QC sera 4 and 
6. The results are shown in figure 4.8.
BaL produced in macrophages was more sensitive to neutralisation by the QC 
serum 4, at the reciprocal dilution of 10.
The potency of CMI, however, did not vary and CMI resulted in a 2-fold increase 
of neutralisation regardless if BaL was grown in macrophages and PBMCs.
4.2.6.2 Comparison between H9- and PBMC-derived viruses
The PI macrophage-tropic 2044 uses CXCR4 as its main co-receptor (Simmons et 
al., 1996) and equally infects PBMCs and H9 cells. The 2044 strain, previously 
passaged in PBMCs, was grown twice in H9 cells. The two viruses were then tested 
for CMI with the QC serum 2. The results are shown in figure 4.9.
H9-derived 2044 was more sensitive to neutralisation by the QC serum 2, at the 
reciprocal dilution of 20 and 40. For PBMC-derived 2044, complement increased the 
neutralisation of the neutralisation of the QC serum 2 at the reciprocal dilution of 20. 
For H9-derived 2044, complement did not increase the neutralisation potency of the 
QC serum 2.
4.2.6.3 Comparison between 293T-and PBMC derived viruses
293T- and PBMC-produced virus YU2 was tested for its sensitivity to CMI in the 
presence of the QC serum 2. The results are shown in figure 4.10 A. Complement did 
enhance the neutralising potency of QC serum 2.
Thus, in our system, complement can only enhance by a maximum of 2-fold the 
neutralisation potency of neutralising sera. In studying the effect of complement on 
chimeric viruses expressing gpl20 isolated from patients (or heterologous gpl20) and 
their sequential sera, the effect of complement was greater, particularly early in the 
infection, when 90% neutralisation was not detected. YU2 was grown in PBMCs and 
was tested for CMI using sequential non-neutralising sera from patient MM 19. The 
results are shown in figure 4.10 B.
Surprisingly, the producing cell line seemed to have a more profound effect on the 
CMI using these early sera and YU2. In the presence of complement, 293T- derived 
YU2 was inactivated between 85 and 90%. When expressed in PBMCs, CMI was 
only observed in the presence of serum day 39 POS.
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Figure 4.9 C om parison  o f C M I betw een PB M C - and H 9-derived 2044
H9- or PBM C-derived 2044 virus was incubated with serial dilutions o f  the heterologous 
neutralising serum QC 2 in the presence (orange bars) or the absence (green bars) o f  
complement. Percentage inactivation was calculated from viral inputs, represented by the 
incubation o f  virus with complement or heat-inactivated complement. The indicated star (*) 
represents a statistically significant difference (Mest, p<0.05) between data obtained in the 
presence and in the absence o f  complement. The arrows span the dilutions where significant 
difference is observed under the experimental conditions used. The symbol (— ) represents 
statistical difference between neutralisation
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Figure 4.10 C om parison  o f C M I betw een 293T- and PB M C -derived YU2
A. 293T- or PBMC-derived YU2 was incubated with serial dilutions o f  the heterologous 
neutralising serum QC 2 in the presence (orange bars) or the absence (green bars) o f  
complement
B. 293T- or PBMC-derived YU2 was incubated with non-neutralising sera (at the final 
dilution o f  1/10) from patient MM 19 in the presence (orange bars) or the absence (green bars) 
o f  complement. Virus inactivation was calculated from viral inputs, represented by the 
incubation o f virus in the presence o f complement or heat-inactivated complement. The 
indicated star (*) represents a statistically significant difference (Mest, p<0.05) between data 
obtained in the presence and in the absence o f complement under the experimental conditions 
used. The arrows span the dilutions where significant difference is observed
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4.3 Discussion
The classical pathway is involved in CMI detected in the study reported in 
Chapter 3. CMI could be observed using purified Guinea pig complement. Moreover, 
CMI was not seen using fresh serum from C3-deficient individuals. The addition of 
recombinant C3 proteins at physiological concentrations restored CMI. EDTA, which 
chelates all bivalent ions, therefore inactivating all complement cascades, inhibited 
CMI. Furthermore EGTA, which chelates Ca2+ and prevents the formation of the Cl 
complex, totally inhibited CMI, similarly observed when serum from Clq-deficient 
individuals was used as a source of complement. These results suggest that the 
classical pathway is the main pathway involved in CMI observed in both Chapters 3 
and 4.
CMI, however, could be influenced by multiple factors.
The Ab isotype is involved in modulating CMI. CMI was not observed with 
purified IgG from the early sera (from the first month POS) from patient MM 19 but 
was detected in FT fractions, that are likely to contain IgM. IgM strongly activates the 
classical pathway as a single bound IgM can trigger complement and lyse a single red 
blood cell (Boes, 2000). IgM from early and late time points from patient MM 19 were 
purified but the elution buffer was toxic for the NP2 cells on which the CMI assays 
were performed (data not shown).
The specificity of the Abs present in sera could influence CMI. As observed in 
Chapter 3 (figure 3.8), CMI of virus MM4 resulted in 80-90% inactivation in the 
presence of sera from patient MM 19 but no CMI was observed in the presence of sera 
from patient MM27. Moreover, when tested in the presence of QC serum 2, CMI was 
only observed for IIIB and not SF2 or RF (figure 3.1). This suggests that CMI could 
be triggered by epitope-specific Abs, which was further supported when CMI assays 
were performed using MAbs mapping to various regions on gpl20. CMI was only 
detected in the presence of anti-V3 loop Abs, which is in agreement with a similar 
study by Spear et al, where only MAbs specific to the V3 loop of MN induced C3 
deposition on MN and IIIB (Spear et al., 1993b). Moreover, another study by Spear et 
al showed that CMI observed with MN and sera from HIV-infected patients could be 
abrogated by incubating the V3 loop peptide of MN with the tested sera (Spear et al., 
1994b). Therefore, the difference in CMI observed with MM4 could be due to the 
presence (or the absence) of anti-V3 loop Abs in the tested sera. However, the 
presence of Abs, capable of triggering CMI that do not bind to the V3 loop is also
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possible. A study by Trkola et al showed that 2G12 could also activate complement 
and reduce syncytia formation in MN-infected cells (Trkola et al., 1996b). In this 
study, CMI triggered by 2G12 was not observed. The effect of CMI on syncytia 
formation was not investigated. To verify if anti-V3 loop Abs are involved in CMI in 
this study, CMI could be performed in the presence of sera previously incubated with 
autologous and heterologous V3 loop peptides.
CMI could also be influenced by the modulation of CRP incorporation in the viral 
membrane. HIV incorporates CD55 and CD59 when produced in cell lines, such as 
H9 (Montefiori et al., 1994; Saifuddin et al., 1995) and in cell lines transfected for 
CD55, CD59 and CD46 (Saifuddin et al., 1997). CMI was observed for PBMC- 
derived 2044 in the presence of the QC serum 2 at the reciprocal dilution of 20 but not 
for H9-derived 2044. This in agreement with a previous study by Saifuddin et al that 
suggests that CMI could depend on the producing cell line, due to the possible 
difference in the incorporation of CRPs in the viral membrane (Saifuddin et al., 1994). 
To formally assess the effect of CRP in CMI, incorporation CMI assays could be 
performed in the presence of anti-CRP Abs that interfere with the inhibitory action of 
the CRPs against the MAC formation as described by Montefiori et al (Montefiori et 
al., 1994).
CMI could also be influenced by the nature of the virus. In the presence of non­
neutralising sera, CMI is detected for 293T-derived YU2 but not for PBMC-derived 
YU2. This could be due to fewer functional Env spikes on 293T-expressed YU2. 
Similarly, Ying et al recently described that MBL alone could inactivate some TCLA 
isolates but not Pis (Ying et al., 2004). They hypothesised, based on Poignard’s report 
(Poignard et al., 2003), that Pis tested contained more functional spikes than TCLA 
viruses (Poignard et al., 2003). Alternatively, PBMC-derived YU2 could be due a 
higher density of the glycosylation shield present on gpl20 (Wyatt et al., 1998).
The triggering of complement cascades can result in opsonisation or in lysis. 
Understanding the mechanism of CMI is important as it might determine the in vivo 
implications of complement in association with non-NAbs. Opsonised virions could 
enhance HIV infection of target cells. Studies have reported in vitro enhancement of 
HIV infection by complement on primary cells expressing CRs (Bajtay et al., 2004; 
Bouhlal et al., 2002; Kacani et al., 2001). Moreover, immune complexes containing 
HIV can bind to B cells and be transmitted to T cells via CR2 (Jakubik et al., 2000; 
Moir et al., 2000). Alternatively, complement could contribute to the viral clearance
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during primary viraemia. Complement enhanced the neutralising activity of an anti- 
HIV Ab in mice in vivo (Gauduin et al., 1998b). Sullivan et al have shown that HIV 
virions taken directly from plasma only incorporated CD59 and were more susceptible 
to lysis than viruses from producing cell lines (Sullivan et al., 1996). Schmitz et al 
have shown that complement depletion, by cobra venom, in monkeys lead to an 
increase in viral load during primary viraemia (Schmitz et al., 1999b). As CMI 
observed in this study could lead to lysis (Aasa-Chapman et al., 2005), CMI might 
play a role of viral decline, particularly in the acute phase, concomitantly with the 
CTL response (Borrow et al., 1994).
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Chapter 5
Isolation of llama non-classical Vhh specific for b l2 , a 
potent neutralising anti-HIV-1 antibody: a vaccine
approach
5.1 Introduction
The CTL and IgG responses against HIV are inefficient at eradicating the virus in 
vivo and no cure is currently available. Anti-HIV compounds are, however, available 
but they are not dispensed to patients in developing countries, where over 90% of the 
HIV cases are found. Moreover, they can be highly toxic when prescribed in the long 
term and they do not eradicate the infection. There is currently no sign of a decline in 
the number of transmissions worldwide. The high mutation rate of HIV facilitates the 
generation of escape mutants from both drugs and the anti-viral immune response. 
Thus an effective vaccine that protects against infection is urgently required.
Classical vaccine approaches against HIV have been, so far, unsuccessful and 
confer very little protection. Attenuated strains of SIV in monkeys can revert into 
their virulent state and, therefore, are not safe for clinical trials (Burton and Moore, 
1998). Alternative vaccine strategies have not lead to great success. Immunisation 
with recombinant monomeric gpl20 has failed to confer protection in clinical trials 
(Gilbert et al., 2005). An anti-HIV vaccine approach based on CTL, has so far failed 
to induce full protection, as escape mutants emerge rapidly (Barouch et al., 2002). The 
passive administration of NAbs can prevent HIV infection in macaques (Mascola et 
al., 2000; Veazey et al., 2003b). Therefore, it is likely that an efficient anti-HIV 
vaccine will involve the induction of cross-neutralising NAbs (Burton and Moore, 
1998).
NAbs target gpl20 and gp41 of HIV and inhibit the events of viral entry into host 
cells. Numerous neutralising epitopes have been identified on gpl20 including the 
CD4BS (Burton et al., 1991; McKeating et al., 1993; Trkola et al., 1995), the 
chemokine receptor binding site that is CD4 binding-induced (Fouts et al., 2002; 
Moulard et al., 2002; Thali et al., 1993; Wyatt et al., 1995), motifs on the V3 loop 
(Gomy et al., 1992; Javaherian et al., 1989), on the VI/V2 structure (Fung et al., 
1992; Gomy et al., 1994; Warrier et al., 1994) and on the carbohydrate motif 
recognised by 2G12 (Trkola et al., 1996b). Neutralising epitopes are also present on
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gp41, localised on the ectodomain (Muster et al., 1993; Zwick et al., 2001b). 
Although it is possible to generate a high titre neutralising Ab response against a 
particular virus strain, the neutralising response is generally weak against other 
isolates and does not confer protection (Parren et al., 1998; Weiss et al., 1985). HIV 
can escape the Ab pressure by several means. The virus can accommodate mutations 
within gpl20 and gp41 and, as a result, some Abs fail to recognise their targets. A 
glycosylation shield, present on the silent face of gpl20, prevents NAb access to the 
neutralising epitopes (Wyatt et al., 1998). The Abs might have a higher affinity in vivo 
for the shed monomeric gpl20 or uncleaved gpl60 rather than for the trimeric 
structures (Burton and Moore, 1998).
Despite the strain-specific nature of most anti-HIV NAbs, cross-neutralising NAbs 
have been elicited in vivo in some infected individuals. One of them is bl2, which has 
been isolated by phage display from the IgG repertoire of an HIV-1 positive man, 
asymptomatic for six years, using gpl20 of IIIB as a target (Burton et al., 1994). Its 
target epitope overlaps the CD4BS of HIV-1 and neutralises a broad range of isolates 
from different clades (Binley et al., 2004; Parren et al., 1998). It has an unusually long 
CDR H3 region (18 amino acid residues against 12 in general). The crystal structure 
of bl2 bound to gpl20 reveals that the unique ability of bl2 to bind directly to the 
deep CD4BS of gpl20, via the Trp residue at the apex of CDR H3 region, and to 
interact with the Phe residue present at the bottom of the pocket which is highly 
conserved among HIV isolates (Saphire et al., 2001b).
One possible strategy to trigger a protective NAb response in vivo could be to 
activate B cells to produce b 12-like Abs by stimulating them against a mimic of the 
binding site of bl2 on HIV-1. In other words, generating an anti-idiotype of bl2, 
which will bind to bl2 in the exact manner as bl2 binds to gpl20, would mimic an 
important HIV-1 neutralising epitope and its use for immunisation could lead to the 
generation of a high NAb response in vivo.
The anti-idiotype approach has been investigated before (Beverley et al., 1989). 
Previous attempts also included anti-CD4BS Abs. Although these Abs neutralised 
TCLA viruses, they did not cross-neutralise Pis and, very probably, did not target 
conserved residues within the CD4 binding pocket, like bl2. Furthermore, mouse Abs 
were used for the anti-idiotypic approach. Mice do not make Abs with long CDR 
regions, the average length for the CDR H3 is 8 amino acid residues, which could fail 
to mimic the deep pocket of the CD4BS of HIV-1.
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The approach described in this chapter involved non-classical llama IgG for 
mimicking conserved regions of CD4BS and bl2, a cross-neutralising Ab.
Llamas belong to the camelid family, which also includes camels, dromedaries 
and vicufias (small llamas). These animals have the unique characteristic of 
synthesising both classical and non-classical IgG (referred as Vhh) (Hamers- 
Casterman et al., 1993). V hh are formed by the association of two heavy chains. They 
lack the CHI domain, which is replaced by a hinge, and do not interact with light 
chains. The length of the hinge can vary and defines two sets of Vhh: the long-hinge 
Vhh and the short hinge V hh. The antigen-binding site of the V hh only consists of 
the CDR regions of the heavy chains, which show hydrophilic properties unlike 
classical IgG. The V hh CDR regions are generally longer than the CDR regions of the 
heavy chains of classical IgG, particularly the CDR region 3, which can contain up to 
22 amino acid residues compared to 12 amino acid residues in classical IgG. The 
unusual length of the CDR regions is thought to compensate for the loss of the light 
chain in the diversity of the Ab repertoire (for a review, see Muyldermans, 2001). As 
a result, the antigen binding sites of Vhh display, besides the classical canonical 
conformation, more flexible conformations (Decanniere et al., 1999), ideal for anti- 
idiotypic approaches (Muyldermans and Lauwereys, 1999).
Vhh fragments, therefore, could be used for isolating anti-idiotypes o f  b l2, as in 
this particular case, the anti-idiotypic mimic may need to have flexible loops to adopt 
the conformation o f the crevice formed by the CD4BS o f  HIV-1 that is recognised by 
bl2.
In this chapter, the isolation of five Vhh anti-idiotypes of b l2 is described. They 
were isolated from VHH libraries of a llama immunised with the Fab fragment of bl2. 
These five fragments inhibited the neutralising properties of bl2 against SF162 and 
IIIB in vitro. The Vhh fragments were conjugated to KLH and were injected into rats 
and rabbits. The sera of the immunised animals were assessed for their neutralising 
properties against HIV-1 in vitro.
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5.2 Results
5.2.1 Generation of the anti-bl2 libraries
This work was performed by Pim Hermans (Unilever, The Netherlands). The 
protocol followed was described by Dolk et al (Dolk et al., 2005). Purified Fab 
fragments of bl2, provided by Prof. D. R. Burton (Scripps, USA), was used to 
immunise a llama. After several boosts and verification of the specific immune 
response against bl2, 15 ml of blood was harvested, the PBMCs were isolated by 
ficoll gradient, the total RNA was extracted and cDNA was generated. Short- and 
long-hinge V hh encoding DNA was specifically amplified by PCR and cloned into a 
phagemid and transformed E. coli generating the long- and short-hinge V hh libraries. 
After estimation of the size of each library, the panning selections were undertaken.
5.2.2 Panning procedures of the libraries
In order to optimise the selection of Vhh fragments anti-idiotypic for b 12, purified 
phage were pre-incubated with total purified IgG fractions from a commercially 
available HIV-1 and HIV-2 seronegative human serum for 30 min. The phage 
encoding V hh fragments specific for conserved regions of Fab regions of IgGl 
would, therefore, bind to seronegative human IgG and not to bl2. The pre-incubation 
step was performed for each round of panning described below in 5. 2. 2. 1 and 5. 2. 
2. 2.
5.2.2.1 Panning of the libraries using bl2, total HIV-1 lysate and gpl40
The screening of both short- (07) and long-hinge (08) Vhh encoding libraries was 
undertaken using b l2 as a target for selection followed by non-specific TEA elution 
of the phage for the first round of panning in order to elute all the Vhh fragments 
binding to bl2. For the second and third rounds of panning, purified total viral lysate 
or purified gpl40 from IIIB were used to elute by competition Vhh fragments that 
interact with the epitope of bl2 involved in the binding of HIV. The panning 
selections are represented in diagram 5.1. Pim Hermans (Unilever, Vlaardingen, The 
Netherlands) collaborated with me for the first round of panning (5. 2. 2. 1. A) and I 
performed all the other selections described below at the Wohl Virion Centre.
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PANNING DIAGRAM S
RO
R1
R2
PAN 0: Short Hinge 
library (07)
PAN 0: Long Hinge 
library (08)
PAN 2: b 12 coated, viral 
lysate elution
PAN 1: b 12 coated TEA elution
: E N R I C H M E N T
PAN 1: b l2  coated TEA 
elution: E N R I C H M E N T
PAN 2: b 12 coated, 
g p l4 0  elution
E N R I C H M E N T
PAN 3: b 12 coated, gp 
140 elution:
E N R I C H M E N T
Enrichment is when, for each phage input, the 
number o f colonies representing phage 
rescued from the panning against b l2  was 
higher than the number o f colonies 
representing phage, for the same input, 
rescued from the panning against negative 
controls
R3
•  Screening of colonies
Diagram 5.1 Panning diagrams for the selection of anti-bl2 VHH fragments
5.2.2.1.1 First round of panning: non-specific elution
Both 07 and 08 libraries were used for the first round of selection. For each 
library, several phage inputs (107, 108, 109, 1010 and 1011 colony forming units or 
CFUs) were incubated against bl2 diluted at 10 and 1 pg/ml and against non-coated 
wells as negative controls. After incubation of the phage and extensive washes, the 
phage bound to b l2 and to the non-coated wells were eluted with TEA, which 
increases the pH and disrupts the bonds between the target and the Vhh expressed on 
the phage. The eluted phage were inoculated into an exponentially growing E. coli 
culture, serial dilutions of the bacterial culture were plated and colonies were counted. 
There was enrichment when, for each phage input, number of colonies representing 
phage rescued from the panning against bl2 was higher than the number of colonies 
representing phage, for the same input, rescued from the panning against non-coated 
wells. The results of the enrichments are shown in figure 5.1.
The selections performed for this first round of panning gave consistent 
enrichments compared to the negative controls and compared to the concentration of 
b 12 coated onto the plate. For example, the enrichment for each library for the 
panning against bl2 coated at 10 pg/ml is approximately ten times higher than the 
enrichment observed with the panning against b l2 coated at 1 pg/ml for the same 
phage input. These results suggest that the enrichments observed are highly specific, 
in accordance with the very low background of phage rescued from non-coated plates 
(data not shown). To obtain highly specific anti-bl2 VHH fragments, the phage input 
that yielded the highest enrichment was re-amplified in E. coli and used for further 
selections. The long-hinge library, amplified after the screening performed with the 
initial input of 1010 CFU/ml on bl2 coated at 1 pg/ml (designed as R l) was used for 
the second round of selection.
5.2.2.1.2 Second round of panning: specific elution with virus lysate
For the second round of panning, the stringency of the selections was increased in 
order to optimise the probability of eluting specific Vhh fragments mimicking the 
binding site of b l2 onto HIV-1 Env. In a first attempt to achieve this goal, selections 
for the second round of panning were performed on bl2 and elutions were performed 
using a purified virus lysate containing gpl20 and gpl40. The strain from which the 
lysate was obtained is a clone of IIIB. The virus lysate contains Env proteins,
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Figure 5. 1 Enrichment values obtained for the first round of panning
A. Enrichment values for the short-hinge library. Enrichment values of several inputs (108, 
109, 1010 and 1011 Colony Forming Units or CFU) of purified phage from the non-selected 
short-hinge library (07) against bl2 and eluted non-specifically with TEA. The enrichment 
values (in fold) are calculated from the number of phage rescued panned against non-coated 
wells performed with the same inputs of phage
B. Enrichment values for the long-hinge library Enrichment values of several inputs (107, 
108 109, 1010 and 1011 CFU) of purified phage the non-selected long-hinge (08) library against 
b 12 and eluted with TEA. The enrichment values are calculated as described for A
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w hich would specifically  com pete for the binding site o f  b l 2 w ith the V h h  fragm ents 
m im icking the CD4BS o f  b l2 .
Selections were performed on amplified and purified phage from the library 
rescued on R l. Several phage inputs (106, 107, 108, 109, 1010 and 1011 CFU) were 
incubated against b l2 diluted at 5 |ig/ml and, for negative controls, against HIV 
seronegative IgG diluted at the same concentration and against non-coated wells. 
After the incubation of the phage and extensive washing, the bound phage were eluted 
in two steps. First, the phage were incubated with viral lysate or PBS. Secondly, the 
phage, still bound to the targets, were eluted with TEA. Enrichment was when, for 
each phage input, the number of colonies representing phage rescued from the elution 
performed with the virus lysate was higher than the number of colonies representing 
phage, for the same input, rescued from the elution performed with PBS. The results 
of the enrichments are shown in figure 5.2.
The panning results show that the same number of phage were rescued with the 
elution performed with the virus lysate or with PBS (figure 5.2.A). To ensure that 
enrichment values represented actual enrichment and not inconsistency in the phage 
input on each well (due to experimental error), the rest of the phage was totally eluted 
with TEA (figure 5.2.B). There was no difference observed, showing no evidence of a 
discrepancy between the selection and the negative control.
The strategy of using partially purified HIV-1 lystate as a specific competitor to 
isolate Vhh fragments mimicking the neutralising epitope of HIV-1 was not 
successful. Using viral lysate as a specific eluate did not lead to the isolation of anti­
idiotypes of b l2, due maybe to the low concentration of Env proteins in the mix. 
Purified and more concentrated recombinant gpl40 was then used as a specific eluant.
5.2.2.1.3 Second and third rounds of panning: elution with gpl40
gpl40, lacking the cytoplasmic tail of gp41,was used as an alternative method of 
elution for a second round of panning performed on phage amplified from R l.
For the second round of panning, 107 and 108 CFU purified phage from Rl were 
incubated on b l2 or human IgG, as an indicator for background, both diluted at 5 
pg/ml. The elution was performed in two steps as described in 5. 2. 2. 1 .2  using 
gpl40 and TEA. The amount of gpl40 used for elution was used in excess compared 
to b l2 (around 10 molecules of gpl40 for 1 molecule of b 12) to maximise 
competition
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Figure 5.2 Enrichment values obtained for the second round of panning by specific 
elution with viral lysate
A. First step of elution: viral lysate. Enrichment values o f several inputs (107, 108, 109, 10,D 
and 1011 CFU) purified phage from R l and selected against b l2  and eluted with lOOpl o f non­
purified virus lysate. The enrichment values, in fold, are calculated from a non-specific 
elution with PBS performed with the same inputs o f phage
B. Second step of elution: TEA. Enrichment values o f the same phage inputs from Rl 
selected against b l 2 , previously eluted with viral lysate, and non-specifically eluted with 
TEA. The enrichment values are calculated from the number o f phage eluted with TEA after 
the non-specific elution with PBS performed with the same inputs o f phage
him
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between gpl40 and the V h h  fragments expressed on the phage. The enrichments 
were calculated by the number of phage incubated on bl2 and eluted with gpl40 
compared to the number of phage incubated on bl2 and eluted with PBS. The 
enrichments were also calculated for the TEA elution based on the same principle. 
The enrichments of the second round of panning are shown in figure 5.3.A.
The selections performed using gp 140 as a specific eluant show low enrichment 
values, between five and nine times. However, they are consistent, which could 
suggest some specific elution of anti-idiotypes of bl2.
If the enrichment values represent only background values, they are likely to be 
lost in a third round of panning using the same selection strategy. If they represent the 
elution of phage encoding Vhh fragments mimicking the CD4 neutralising site of 
HIV-1, then a third round of panning will allow the amplification of those clones, 
which will result in an increase in the enrichment values. A third round of selection 
was undertaken to confirm the relevance of the enrichments. The library, amplified 
after the screening performed with the initial input of 108 CFU on bl2 and eluted with 
gpl40 (designed as R2), was used for the third round of selection.
For the third round of panning, bl2 and human IgG were used at a final 
concentration of 3 pg/ml. The selections were performed as described as for the 
second round of panning. The enrichment values were calculated in the same manner 
and are shown in figure 5.3.B.
The selections show low values of enrichment, similar to the ones observed in the 
second round of panning between four and ten times. These values are low and could 
still represent background values. However, they could also reflect the elution of a 
small pool of phage encoding anti-idiotypes of bl2. Moreover, the selections 
performed against b l2 show high enrichment values compared to human IgG. The 
enrichment values of the selections against bl2 compared to IgG for the second and 
third rounds of panning using gp 140 as a specific eluant are shown in figure 5.3.C. 
Moreover, the elution performed with TEA after the elution with gpl40 showed 
negative enrichments, suggesting that more phage were eluted for gpl40 than with 
PBS and that the total number of incubated phage was equal for the selections and the 
negative controls, as shown in table 5.1.
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Figure 5.3 Enrichment values obtained for the second and third rounds of panning using 
gpl40
A. Second round of panning: elution with gpl40. Enrichment values of several inputs (107, 
10* and 1010 CFU) purified phage from Rl selected against bl2 and eluted with an excess of 
gpl40. The enrichment values, in fold, are calculated from a non-specific elution with PBS 
performed with the same inputs of phage
B. Third round of panning: elution with gpl40. Enrichment values of several inputs (10s, 
109 and 1010 CFU) purified phage from R2 selected against bl2 and eluted with an excess of 
gpl40. The enrichment values are calculated as described for the second round of panning
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Figure 5.3.C Enrichment values for the second and third rounds of panning between bl2 
and polyclonal IgG
Phage input Enrichment (fold) after 
TEA elution for the second 
round of panning 
performed with gpl40
Enrichment (fold) after 
TEA elution for the third 
round of panning 
performed with gpl40
10' -7 ND
10“ -5 -8
10y ND -4
10lu -6 -4
Table 5.1 Enrichment values obtained for the specific elution with gpl40 for the second 
and the third rounds of panning
Enrichment values o f  the same phage inputs from Rl and R2 selected against b l2 , previously 
eluted with gpl40, and non-specifically eluted with TEA. The enrichment values are 
calculated from the number o f phage eluted with TEA after the non-specific elution with PBS 
performed with the same inputs o f phage 
ND. Not Done
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Since the enrichment values calculated reflected the elution o f  anti-idiotypes, the 
isolation o f  specific V hh fragments was undertaken.
5.2.3 Isolation of specific anti-bl2 V hh clones
Libraries rescued from the second and third round of panning, using gpl40 as a 
specific eluant, were diluted in medium and plated to obtain separate colonies. 
Ninety-six clones were then picked and were grown in a 96-well V-bottom plate, 
which constituted the master plate. The colonies were screened for their properties to 
specifically bind to bl2.
5.2.3.1 Screening by phage ELISA
From the master plate, a duplicate plate was generated in which the phage 
production was induced. Phage ELISA was performed by testing the supernatant of 
these “mini-cultures” against bl2, human IgG and BSA, all diluted at 5 pg/ml. The 
detection was performed using an anti-p8 Ab (the major coat protein of the phage) 
directly conjugated to HRP. The results of the screening are shown in figure 5.4. All 
the tested clones bound strongly to bl2 and give background values on human IgG 
and BSA, suggesting that all the clones tested were anti-idiotypes of bl2. However, 
the picked clones were likely to show redundancy in their sequences. The restriction 
profile of the sequence of each of the 96 clones was then performed.
5.2.3.2 Restriction patterns
All the clones were tested for the coding sequence of the V hh fragment. The 
primers used for the amplification annealed within the Plac promotor for the 3’ primer 
(M13REV) and the coding sequence of the gene III for the 5’ primer (MPE25). The 
expected size of the amplified fragment is 600 base pairs in length. The PCR 
fragments were then digested using the restriction enzyme Hinfl. The restrictions were 
then loaded on agarose gel to identify the different profiles.
The restriction pattern shows some redundancy amongst the clones. The clones 
that had a different restriction pattern were further selected for sequencing.
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Figure 5.4 Screening o f VHH-encoded clones by phage ELISA
96 clones were randomly picked and screening by phage ELISA for their binding properties 
on b l2 , human IgG and BSA. A represents the screening o f the first 32 clones (from A l to H4 
from the master plate), B represents the screening o f the clones 33 to 64 (from A5 to H 8 ) and 
C represents the screening o f  the clones 65 to 96 (from A9 to HI 2)
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5.2.3.3 Sequencing of the Vhh fragments DNA
The sequencing of the V hh  fragments was performed in both directions. The 
amino acid translation of each clone was compared and aligned with the others using 
ClustalX. In order to rule out the differences due to the PCR incorporation or 
sequencing errors, the sequences were only selected if they differed by at least 3 
amino acid residues, which is significantly higher than the error of incorporation by 
the non-proof-reading Taq polymerase during the PCR reaction. The sequences of the 
clones are shown in table 5.2.
Redundancy was observed amongst the selected clones. Probably due to the 
approximate resolution of the agarose gel, the clones B4 and B12, C4, D9, D7 and E6 
had the same nucleotide sequence were picked although their restriction patterns 
looked dissimilar. Therefore, the clones B12, D9 and E6 were discarded. The other 
clones A3, A5, D3, DIO, El l ,  F10, G6 and G9 showed a unique sequence. Some 
sequences showed some similarity. They might bind to the same part of b l2 or the 
slight variation might be related to the affinity of the V hh  fragments for bl2. The 
CDR H3 length of the clones varies between 15 and 17 amino acids.
After the identification of all the individual clones by phage ELISA, restriction 
pattern and sequencing, the V hh fragments were expressed in E. coli for further 
characterisation.
5.2.4 Characterisation of anti-bl2 Vhh fragments
5.2.4.1 Expression of Vhh fragments
The initial screening by phage ELISA was performed by detecting the phage 
bound to the target. Phage have sticky properties and the signal detected by phage 
ELISA might lead to the isolation of false positive clones. To rule out this hypothesis, 
the fragments were expressed in the bacterial strain BL21. The VHH fragments were 
expressed with a 6-His and a Myc tag fused at their C-terminus.
V hh production was induced by IPTG (as the transcription of the VHH sequences 
is under PlacIq promotor) and was carried overnight. The cells were then lysed by 
osmotic shock and the V hh fragments were purified from the cell lysate using a Ni- 
NTA super low column via interaction with the 6-His tag. An irrelevant V hh
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CDR1 CDR2
s e q B 7 QVQLQESGGGLVQDGGSLRVSCAASG G T FSS-------- —Y S IS
s e q E 6 QVQLQESGGGLVQDGGSLRLSCAASG G T F S S -------- -Y S I S
se q D 7 QVQLQESGGGLVQDGGSLRLSCAASG G T FS S-------- -Y S I S
s e q G 9 ---------------GGGLVQAGGSLRLSCTTSA YTFDD-------- -Y P IG
s e q D 9 QVQLQESGGTLVQAGGSLRLSCAASG GTFSK-------- -YSM 3
s e q C 4 QVQLQESGGTLVQAGGSLRLSCAASG GTFSK-------- -Y  SMC
s e q A 3 QVQLQESGGGLMQAGGSLRLSCAASE H IF N T -------- -HVMA
s e q F l O QVQLQESGGGLMQAGGSLRLVCAASG R T F S S -------- -YVM3
s e q B 4 QVQLQESGGGLIQAGGSLRLSCAASG F T F S E -------- -YVMS
s e q B 1 2 QVQLQESGGGLIQAGGSLRLSCAASG F T F S E -------- -YVM3
se q A 5 QVQLQDSGGGLVQAGGSLRLSCAASG R TV SS-------- -YTMA
s e q D 3 QVQLQESGGGLVQAGGSLTLSCAASG R T F S S -------- -YHM3
s e q 2 G 8 QVQLQESGGGLVQPGGSLRLSCAASG S I F G I -------- -NAM3
s e q D IO QVQLQESGGGLVQPGVSLRLSCTASG G R F S I-------- -NDM3
s e q 2 C 1 2 QVQLQESGGGLVQTGHSLRLSCAASG RTFNG-------- -RTMA
s e q 2 C 9 QVQLQESGGGLVQPGDSLRLSCAASG RTFNG-------- -RTMA
s e q 2 G 6 QVQLQESGGGLVQPGGSLRLSCAASG RTFNGNPINGRTMA
s e q G 6 QVQLQESGGGLVQPGDSLRLSCAASG RTFNG-------- -RTMA
s e q E l l QVQLQESGGGLVQPGGSLRLSCAASG RTFNG-------- -RTMA
s e q 2 H 4 QVQLQESGGGLVQPGGSLRLSCAASG RTFNG-------- -RTMA
CDR3
s e q B 7  QMSRLRPEDTAVYHCAA IDSGNYYIPSDASVYDY
s e q E 6  QMSRLRPEDTAVYHCAA IDSGNYYIPSDASVYDY
s e q D 7  QMSRLRPEDTAVYHCAA IDSGNYYIPSDASVYDY
s e q G 9  QMSKLKPEDTAVYYCAF
s e q D 9  QMNSLKPEDTAVYYCAA
s e q C 4  QMNSLKPEDTAVYTCAA
s e q A 3  EMNSLKPEDTAVYYCAA
s e q F l O  EMSNLKPEDTAVYYCAA
s e q B 4  EMNSLKPEDTAVYYCAA
s e q B l 2  EMNSLKPEDTAVYYCAA
s e q D 3
s e q 2 G 8  
s e q D IO  
s e q 2 C 1 2  
s e q 2 C 9  
s e q 2 G 6  
s e q G 6  
s e q E l l  
s e q 2 H 4
WFRQAPGKER------------EFVAY ISWKRDGTYYADSVKGR FT I SRDN DKNTVYL
WFRQAPGKER------------EFVAY ISWKRDGTYYADSVKGRFTISRDNDKNTVYL
WFRQAPGKER------------EFVAY ISWKRDGTYYADSVKGRFTISRDNDKNTVYL
WFRQAPGKER------------EGVSC ISASDGITYYADFVKGRFTINSDNAKKTVYL
WFRQAPGNER------------EFVAA VSWRGGSTYYADFVKGRFTISRDNAKNTVYL
WFRQAPGNER------------EFVAA VSWRGGSTYYADFVKGR FT I  SRDNAKNTVYL
WFRQTSGKER------------ EFVAA ISW S-GSPLYAESVKGR FTISRNNAKNTVYL
WFRQTPGKER------------EFVAA ISWRRGSPLYADSVKGR FT I  SRDNAKNTVYL
WFRQAPGKER------------EFVAA ISWSGRNTNYADSVKGR F T I SRDNAKNTVYL
WFRQAPGKER------------EFVAA ISWSGRNTNYADSVKGR FT I SRDNAKNTVYL
WFRQPPGKER------------EFVAA ISWSGRNTNYADSVKGR F T I SRDNAKNTVYL
WFRQAPGKER------------EFVAA ISRSGGSTYYADSMKGRFTISRDNAKNTVTL
WYRQAPGKER------------ ELVAS ITSG-GTTNYADSVKGRFTISRDNVKNTVYL
WYRQVPGKQR------------ELVAE ITSG-GTKNYADSAKGRFTISRDNAKNTVYL
WFRQAPGKER------------EFVAL ITW SSGRTLYGDSVKGRFAISRDNTKKTLYL
WFRQAPGKEH------------EFVAL ITWSSGRILYGDSVKGRATISRDNTKKTVYL
WFRQAPGKER------------EFVAL ITWSSGRILYGDSVKGRFTISRDNTKKTLYL
WFRQAPGKEH------------EFVAL ITWSSGRILYGDSVKGRATISRDNTKKTVYL
WFRQAPGKER- EFGEFVAV ISWSGGRIDYGDSVKGRFTISRDNTKKTVYL
WFRQAPGKEREFEFSEFVAV ISWSGGRIDYGDSVKGRFTISRDNTKQTVYL
WGQGTQVTV SS-EPKTPKPQPAAAHHHHHH.
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQP
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTQVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTPVTVSS-AHHSEDPSSAAAHHHHH
WGQGTPVTVSS-AHHSEDPSSAAAHHHHHH
WGQGTPVTVSLRTQDTKTTTSRPPHHHHHH
WGQGTPVTVSS-EPKTPKPQPAAAHHHHHH
WGQGTPVTVSSEPKTPKPQPAAAHHHHHH
EMNSLKPEDTAVYYCAA 
EMNSLKPEDTAVYYCAA 
QMNSLKPEDTAVYYCNA 
QMNNLKPEDTAVYYCNA 
QMNSPRPE DTAVYYCAV 
QMNSSKPEDTAVYYCAI 
QMNSTRPEDTAVYYCAV 
QMNSSKPEDTAVYYCAI 
QMNNAKPEDTGVYYCAA 
QMNNAKPEDTGVYYCAA
SLC SN Y Y IT  HRLDD
QDTGLRVGPR— GPYDY 
QDTGLRVGPR— GPYDY 
GQAGDNYYRDY- SIYDY 
GQAGDNYYRDY-RlYDY 
GQAGDNYY TDY -M I YDY 
GQAGDNYYTDY -M I YDY 
GQAGDNYY TDY-MIYDY 
LFECGNS- PDL-CEYDY
I F P - P G S  W FTLD-
RGL-KYSDYDDRVGFDY 
LGDDTGDVSSY- TSYYY 
LGDDTGSVTHY- TSYYY 
LGDDTGDVS SY- TSYYY 
LGDDTGSVTHY- TSYYY 
LGDGAPSYSSA-TSYYY 
LGDGAPNYSSA-TSYYYW
Table 5.2 Amino acid sequences of the anti-bl2 VHH fragments isolated by phage display.
The sequences are aligned by Clustal X and distinct sequences are highlighted in different colours. The 
CDR regions of each VHH are in bold characters.
fragment, referred as OC (kindly provided by P Herman and Dr. H de Haard) was also 
expressed in the same manner.
The production and the purification of the fragments were successfully achieved 
and the concentration of each fragment was determined by comparing with the 
intensity of the BSA.
S.2.4.2 Binding properties of purified Vhh fragments
5.2.4.2.1 Binding properties against sCD4 and purified polyclonal human IgG
The clones A3, A5, C4, D3, D7, DIO, El 1 and F10 were tested by ELISA against 
bl 2 and purified polyclonal human IgG. Since bl2 overlaps the CD4BS of HIV-1, the 
anti-idiotype that mimics the b l2 binding site on HIV-1 could bind to CD4. To 
address this point, the Vhh fragments were also tested against sCD4 by ELISA. The 
ELISA results are shown in figure 5.5.A.
The clones A l, A5, DIO and El 1 weakly bind to b l2 and seem to cross-react with 
other human IgG. They probably bind to some conserved structures of human IgG and 
were therefore discarded from further studies. Interestingly, none of the clones 
showed relevant binding to sCD4. The clones A3, B4, D3, D7 and F10 showed 
specific and strong binding to bl2 and their properties were further characterised.
5.2.4.2.2 Binding properties against anti-HIV-1 human monoclonal antibodies
b l2 is an IgGl. Previously, the V h h  fragments were tested by ELISA against 
polyclonal human IgG, which includes all the isotypes of IgG. The IgGl isotype 
within the pool of IgG could be under-represented and any sign of cross-reactivity of 
the V h h  between b l2 and other human IgGl could have been undetected. The V hh  
fragments A3, B4, D3, D7, F10 and OC were then tested by ELISA against two other 
monoclonal IgGl Abs (17b and 2G12). The ELISA results are shown in figures 5.5.B 
and 5.5.C.
N one o f  the V hh  fragm ents show ed cross-reactivity w ith 17b or 2G 12, suggesting 
that all the isolated clones are highly specific to b l2 .
5.2.5 Inhibition properties of Vhh fragments in HIV-1 neutralisation mediated 
by bl2
b l2 neutralises strains of HIV by binding the CD4BS via its CDR regions, 
particularly the CDR H3. The specificity of the Vhh fragments against bl2
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Figure 5.5 ELISA assays of the purified anti-bl2 VHH fragments
A. ELISA assay o f anti-b l2  VHH fragments against b l2 , human IgG and sCD4
B. ELISA assay o f  anti-b l2  VHH fragments against b l2 , human IgG and 17b
C. ELISA assay o f  anti-b l2  VHH fragments against b l2 , human IgG and 2G12
For all assays, the proteins were coated at the concentration o f 5 pg/ml. The detection o f  the 
VHH fragments was performed using an anti-HIS conjugated to HRP. Soluble CD4 was 
detected by using a rabbit anti-CD4 antibody and by an anti-rabbit IgG-HRP. Human Mabs 
were detected by using an anti-human IgG conjugated to HRP
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was tested in an in vitro assay. True anti-idiotypes of b l2 should totally inhibit all 
neutralisation activity mediated by bl2.
The anti-bl2 Vhh fragments, as well as an irrelevant Vhh fragment (OC) were 
pre-incubated with bl2  (at the final concentration of 5 pg/ml) at different molecular 
ratios (10, 3, 1, 0.5, 0.1 and 0.01 fold in excess compared to bl2). Neutralisation was 
assessed when mixed with anti-bl2 Vhh fragment or the Vhh fragment OC on SF162 
and IIIB. The results of the assays are shown in figure 5.6 and in figure 5.7 for SF162 
and IIIB respectively.
b 12 neutralised IIIB and SF162 by 95% and 70% respectively. The Vhh OC, used 
as a negative control, did not affect neutralisation mediated by bl2 for either IIIB or 
SF162. In contrast, the five anti-bl2 Vhh fragments, at 10 and 3 times in excess, 
totally inhibited all bl2 neutralisation both for IIIB and SF162. At 0.1 and 0.01 times 
in excess, they did not affect bl2 neutralisation for both IIIB and SF162.
When the Vhh fragments were in equal molecular ratio, the Vhh fragments did 
not give the same results. The Vhh fragments A3 and D3 partially inhibited bl2 
neutralisation for IIIB for SF162. The Vhh fragments B4 and D7 still totally inhibited 
b l2 neutralisation for IIIB but not for SF162, where neutralisation was restored by 
40%. The Vhh fragment F10 did not inhibit bl2 neutralisation for IIIB but lost most 
of its inhibition for b l2  for SF162.
When one molecule of Vhh A3, D3 or F10 was present for two molecules of bl2 
(ratio 0.5), inhibition of bl 2 neutralisation was totally lost. The Vhh fragment B4 still 
inhibited bl2 for IIIB but not for SF162. The Vhh fragment D7 did inhibit bl2 for 
IIIB but not for IIIB.
These in vitro studies showed that each Vhh fragment isolated inhibited bl2- 
mediated neutralisation. Therefore, they are anti-idiotypes of bl2 and could 
potentially mimic the neutralising epitope of HIV-1. A true mimic of the neutralising 
epitope of HIV-1 could when injected into an animal, produce an anti-HIV 
neutralising response that could present the same properties than b!2.
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Figure 5.6 Inhibition of bl2-mediated neutralisation of SF162 with anti-bl2 VHH 
fragments
Neutralisation o f HIV-1 strain SF162 by b l2  is inhibited with specific anti-b l2  VHH 
fragments A3, B4, D3, D7 and F10 ( )  but not with a non-specific V hh fragment OC (-). The 
inhibition effect is dependent on the amount o f  VHH fragments incubated with b l 2. All the 
experiments were carried on IIIB with b l 2 diluted at the final concentration o f  5 pg/ml
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Figure 5.7 Inhibition of bl2-mediated neutralisation of IIIB with anti-bl2 VHH 
fragments
Neutralisation o f HIV-1 strain IIIB by b l2  is inhibited with specific anti-bl2 VHH fragments 
A3, B4, D3, D7 and F10 ( )  but not with a non-specific VHH fragment OC (-). The inhibition 
effect is dependant on the amount o f  VHH fragments incubated with b l2. All the experiments 
were carried on IIIB with b l2 diluted at the concentration o f 5 pg/ml.
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5.2.6 Anti-bl2 Vhh fragments used as immunogens for eliciting a neutralising 
antibody response against HIV-1
All experiments so far were performed with Vhh fragments partially purified (see 
5.2.4.1) with their C-terminus fused to a Myc and a 6-His tags. A Myc tag could be 
immuno-dominant when injected into an animal and should be removed. The tested 
fragments were therefore unsuitable for immunisation studies. The sequences of each 
fragment were sub-cloned into a new expression vector that allows the expression of 
the Vhh fragments without a Myc tag.
5.2.6.1 Sub-cloning and purification of the anti-bl2 Vhh fragments
The work described below in 5. 2. 6. 1 was carried out by Dr Hans de Haard and 
colleagues (The Netherlands). The glycerol clones obtained in 5. 2. 4. 2 were cultured 
and plasmid DNA was isolated. The Vhh fragments sequences were re-cloned into a 
new expression vector, expressing only the 6-His tag without the Myc tag.
After verification of the sequences, the production of the Vhh fragments was 
performed. The fragments were isolated, purified and re-tested against bl2 and 2G12 
(see appendices 2 and 3). The removal of the Myc tag did not alter the binding 
specificity of the Vhh fragments.
After purification, the five anti-bl2 Vhh fragments and the negative control were 
conjugated to KLH by Peter Delves and colleagues (UCL, London). For details of the 
KLH conjugation, refer to Chapter 2, section 2.15. The Vhh were then used for 
immunising rats and rabbits.
5.2.6.2 Neutralisation assays of HIV-1 with sera from the first boost of 
immunisation
Each Vhh fragment was injected in four rats and one rabbit. The protocols of 
conjugation and immunisation are described in Chapter 2. The references of the 
animals immunised for each Vhh are shown in table 5.3.
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Rats Rabbits
A3 5, 6, 7, 8 1
B4 17, 18, 19, 20 3
D3 21,22, 23, 24 3
D7 9, 10, 11, 12 4
F10 13, 14, 15, 16 5
OC 1,2,3, 4 6
Table 5.3 References of the animals immunised with each Vhh fragment
Each animal was immunised and then boosted with the same V hh . After the first 
boost, blood samples were harvested from each animal, serum was extracted and 
tested for neutralisation against HIV in vitro.
For each neutralisation assay, a Student /-test was used to evaluate if there was a 
significant difference between data obtained with sera from immunised animals and 
pre-bleed sera from the same animals. Similarly, for each CMI assay, a Student /-test 
was used to evaluate if there was a significant difference between data obtained in the 
presence of complement and in the absence of complement. The probability (p value) 
chosen was 0.05 in order to evaluate as accurately as possible small differences.
Therefore, when the p value was above 0.05, no neutralisation or CMI was 
observed under the experimental conditions used.
5.2.6.2.1 In the absence of complement
Each animal gave an immune response against the V h h  with which they were 
immunised (Peter Delves, personal communication). The sera from rabbit 2 gave a 
positive signal against gpl20 and gpl05 by ELISA (Peter Delves, personal 
communication).
The serum from each animal, as well as a pre-bleed serum, were tested for its 
neutralising properties on SF162 and IIIB. The neutralisation results for both IIIB and 
SF162 using sera from rats and rabbits are shown in figure 5.8.
None of the rabbit or the rat sera neutralised SF162 or IIIB compared to the pre­
bleed sera. The rat sera showed similar neutralising patterns.
The sera were collected and tested after the first boost of immunisation, b 12-like 
specific Abs could be present in the animal sera and could coat the virus particles but 
their affinity might be too weak to neutralise the virus alone. However, the coating of
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Figure 5.8 Neutralisation assays with sera from the first boost of immunisation
Neutralisation assays o f SF162 (A) and IIIB (B) with the sera from the 6  immunised rabbits.
C. Neutralisation assays o f SF162 and IIIB with the sera from the 19 immunised rats.
All assays were performed with sera diluted at 1/20. Neutralisation percentages were 
calculated from data obtained with pre-bleed sera from the same animal for each assay. For 
the decoding o f each animal, please refer to table 5.1. For all experiments, a neutralisation 
assay with b l2  diluted in a rat or rabbit serum at the final concentration o f 5 pg/ml was 
included as a positive control. The error bars represent the standard error from three 
experiments. The t-test statistical analysis (/-test, p<0.05) showed that there was no significant 
neutralisation by any o f the tested sera compared to the pre-bleed under the experimental 
conditions used
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the virus with the Ab might be sufficient to trigger the classical cascade of 
complement and inactivation of the virus might be observed as described in Chapters 
3 and 4.
5.2.6.2.2 In the presence of complement
The sera from the immunised rabbits were tested for neutralising IIIB and SF162 
in the absence or the presence of human complement. Too little sera from rats were 
available to perform the experiments. Sera were tested with 10% of snap-frozen 
human serum containing complement or with 10% heat-inactivated human serum. The 
inactivation data were calculated from the pre-bleed of the same animal in the 
presence or the absence of complement. The results are shown in figure 5.9. No CMI 
was observed with any of the sera.
The immunisation by anti-bl2 Vhh fragments did not lead to a potent neutralising 
anti-HIV-1 Ab response in rats or rabbits. This could be due to a weak affinity of the 
immune response against the Vhh fragments. The rabbits were boosted again and the 
rats were sacrificed.
5.2.6.3 CMI assays of HTV-1 with sera from the second boost of immunisation
After the second boost with Vhh fragments, the sera from the rabbits were tested 
again for neutralising IIIB. The neutralisation assay was set in the same conditions as 
described in 5. 2. 6. 2. b. The results are shown in figure 5.10.
No CMI was observed with IIIB in the presence of the rabbit sera. Rabbits 2 and 5 
were boosted again with their respective V h h  fragment.
5.2.6.4 CMI assays of HIV-1 with sera from the third boost immunisation
The sera of the rabbits 2 and 5 were tested again for CMI activity against IIIB in 
the absence or the presence of human complement, Guinea pig complement and rabbit 
complement. The results are shown in figure 5.11.
No CMI was observed with the sera. Immunising with gpl20, linked to KLH, 
could lead to the secretion of b 12-like Abs.
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Figure 5.9 CMI assays with rabbit sera from the first boost of immunisation
All assays were performed with sera diluted at 1/20. Inactivation percentages were calculated 
from the data obtained with pre-bleed sera from the same animal for each assay in the 
presence (orange bars) or in the absence (green bars) o f  complement. The positive control for 
complement was performed using M M 8  with serum day 49 POS in the presence o f  the same 
source o f  complement. Error bars represent the standard error from three experiments. The /- 
test statistical analysis (/-test, p<0.05) showed that there was no significant difference 
observed between data obtained in the presence and the absence o f complement under the 
experimental conditions used
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Figure 5.10 CMI assays with rabbit sera from the second boost of immunisation
All assays were performed with sera diluted at 1/20. Inactivation percentages were calculated 
from the data obtained with pre-bleed sera from the same animal for each assay in the 
presence (orange bars) or in the absence (green bars) o f  complement. The positive control for 
complement was performed using MM22 with serum day 31 POS in the presence o f  the same 
source o f  complement. Error bars represent the standard error from three experiments. The /- 
test statistical analysis (/-test, p<0.05) showed that there was no significant difference 
observed between data obtained in the presence and the absence o f complement under the 
experimental conditions used
171
Human complement
£
s
©
>‘S(j
93c
>
—B
100
80
60
40
20
0
-20
-40
rabbit 2 rabbit 5
B
£
c
’■S
93>%■*a
93s
>
£
100
80
60
40
20
0
-20
Guinea Pig complement
HIC’ IB
C’ □
rabbit 2 rabbit 5
Rabbit complement
£
c
'•C
93>
‘•*3u
93C
>  —<
S
100
80
60
40
20
0
-20 rabbit 2 rabbit 5
Figure 5.11 CMI with sera from the third boost of immunisation using human, Guinea 
pig and rabbit complement
All assays were performed with sera diluted at 1/20. Inactivation percentages were calculated 
from data obtained with pre-bleed sera from the same animal for each assay in the presence 
(green bars) or the absence (green bars) o f  complement from human (A), guinea pig (B) and 
rabbit (C) serum. Error bars represent the standard error from three experiments. The /-test 
statistical analysis (/-test, p<0.05) showed that there was no significant difference observed 
between data obtained in the presence and the absence o f complement under the experimental 
conditions used
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5.2.6.5 Neutralisation assays with sera from animals boosted with monomeric 
gpl20
The rabbits 1, 2 and 5 were boosted with gpl20 conjugated to KLH and were 
sacrificed. Serial dilutions o f sera (1/20, 1/40 and 1/80) were then assayed their ability 
to neutralise IIIB. For each dilution, the percentage of neutralisation was calculated 
from the virus incubated with the same dilution of the pre-bleed serum from the same 
animal. Results of the neutralisation assay are shown in figure 5.12.
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Figure 5.12 Neutralisation assays with sera of rabbits boosted with gpl20-KLH
All assays were performed with sera diluted at 1/20, 1/40 and 1/80. Neutralisation percentages 
were calculated from data obtained with pre-bleed sera from the same animal. As a positive 
control, b l2  was added in the pre-bleed serum o f  each animal at the final concentration o f  2.5 
pg/ml. The Student /-test statistical analysis (/-test p<0.05) showed that there was no 
significant neutralisation by any o f the tested sera under the conditions used.
All sera failed to significantly neutralise IIIB.
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5.3 Discussion
This chapter describes the isolation of five non-classical llama Vhh fragments 
(A3, B4, D3, D7 and F10) that are anti-idiotypic for bl2, a potent cross-neutralising 
anti-HIV-1 Ab. bl2 neutralises HIV-1 by binding to the CD4 pocket through 
interactions with its CDR regions, particularly the CDR H3 region (Saphire et al., 
2001b).
Anti-idiotypes have been generated in an attempt to mimic the antigen binding 
sites of NAbs against enterovirus 70 (Wiley et al., 1992), bovine herpesvirus 1 
(Hariharan et al., 1991), reovirus 3 (Bruck et al., 1986), hepatitis B (Thanavala et al., 
1986) and HIV-1 (Boudet et al., 1994; Dalgleish et al., 1987; Denisova et al., 1995; 
Denisova et al., 2000; Hohmann et al., 1993; Sutor et al., 1992; Zaghouani et al., 
1991). In all these studies, the anti-idiotypes could inhibit the antibody-antigen 
interaction and the subsequent immunisation with these anti-idiotypes induced a weak 
neutralising response in vitro.
The five V h h  fragments, specific to bl2, were isolated by screening a non- 
classical Ab library generated from the B cell repertoire of a llama immunised with 
the Fab fragment of bl2. The five V h h  fragments bound to b l2 as shown by ELISA 
and their specificity for the paratope was determined by their inability to bind MAbs 
of the same isotype, namely 17b and 2G12. Furthermore, all five V h h  fragments 
inhibited HIV neutralisation mediated by bl2 in a dose-dependent manner. They are 
therefore anti-idiotypes of bl2.
The five anti-idiotypes of bl2 were used to immunise rats and rabbits in an 
attempt to generate a b 12-like NAb response against HIV-1. After an initial 
immunisation and a further boost with V h h  conjugated to KLH, none of the sera from 
any of the rabbits or rats significantly neutralised IIIB or SF162, which are sensitive 
to bl2. We and others have reported that complement can be triggered by the binding 
of anti-HIV Abs on viruses (Aasa-Chapman et al., 2005; Spear et al., 1992). However, 
complement, in association with rabbit sera did not inactivate HIV. Further boosts of 
immunisations performed in rabbits did not lead to the generation of neutralising sera, 
even in the presence of Guinea pig or rabbit complement. Rabbits were challenged 
with gpl20 conjugated to KLH. The sera were subsequently tested with IIIB and did 
not neutralise this isolate under the experimental conditions used.
Other reports have shown the isolation of anti-idiotypes that induced a weak 
neutralising response against HIV-1. To generate an anti-idiotypic response, they used
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Abs for TCLA viruses such as IIIIB (Denisova et al., 1995; Sutor et al., 1992; 
Zaghouani et al., 1991), MN (Boudet et al., 1994; Kang et al., 1992), RF and SF2 
(Dalgleish et al., 1987)]. Such NAbs target the V3 loop (Denisova et al., 1995) the 
CD4BS (Kang et al., 1992) or CD4 itself (Dalgleish et al., 1987; Sutor et al., 1992). In 
these studies, the anti-HIV Abs were apparently type-specific, neutralising the 
specific strain recognised by the immunogen and were not tested for PI neutralisation. 
Because b l2  cross-neutralises a wide range o f TCLA and PI isolates (Parren et al., 
1998), it represented a good candidate to generate a mimic o f a conserved neutralising 
epitope o f HIV Env. Anti-idiotypic peptides for b l2  have been previously isolated 
(Zwick et al., 2001a) but their inoculation into mice and rabbits did not elicit NAbs. 
Muyldermans suggested that, because o f the extra flexibility o f the CDR regions, V h h  
fragments would be ideal for anti-idiotypic approaches (Muyldermans and 
Lauwereys, 1999). V h h  fragments were therefore chosen to generate anti-idiotypes to 
b l2 . Despite their flexible nature, the immunisation o f the anti-bl2 V h h  fragments in 
animals did not elicit a b 12-like NAb response, nor did the boost with gpl20 
conjugated to KLH. The experiments in this chapter did not determine whether the 
anti-V h h  Abs bound to HIV. To check if  they bind to HIV, cells expressing trimeric 
Envs on their surface could be incubated with the purified anti-V h h  IgG (and purified 
IgG from a non-immunised rabbit) and then analysed by FACS. However, the 
detection o f binding does not always correlate with neutralisation (Poignard et al., 
2003).
The lack o f induction o f neutralisation could be explained in several ways. Firstly, 
the internal image o f b l2  might have been isolated but the conjugation to KLH could 
have altered its conformation. However, this compound has been used successfully for 
the generation o f other anti-idiotypes (Hohmann et al., 1993; Zaghouani et al., 1991). 
Conjugation o f anti-idiotypes to ovalbumin has previously been used to generate Abs 
that bound to the V3 loop (Boudet et al., 1994). Perhaps using ovalbumin to conjugate 
the anti-bl2 V h h  fragments could lead to the induction of a NAb response in 
immunised animals. Further studies are needed to address this issue.
Secondly, the generation o f a neutralising anti-HIV-1 Ab response would require 
the induction of the internal image o f the b 12 antigen binding site. Anti-idiotypes can 
be categorised into four groups: anti-Ida, anti-Idp, anti-Idy and anti-Ide (Thanavala 
and Pride, 1994). Anti-Idy consist o f all the anti-idiotypes that recognise epitopes 
overlapping the CDR regions whereas anti-Idp are internal images (Thanavala and
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Pride, 1994). Anti-Idy and anti-Idp could inhibit bl2 neutralisation in vitro, but only 
immunisation with anti-Idp will trigger a neutralising response (Thanavala and Pride, 
1994). In this study, the five V hh  fragments might be anti-Idy and not anti-Idp and, 
therefore, might have failed to elicit any b 12-like Abs. The crystal structure of each 
VHH fragment in association with bl2 could detail the interactions and reveal if any of 
the V hh  fragment has the characteristics of the internal image of bl2.
Thirdly, the antigen binding site of bl2 might not be immunogenic in llamas and 
anti-Idp were not generated. The induction of classical IgG mimics of the CD4BS 
never occurs or does so very rarely (Beverley et al., 1989; Davis et al., 1992; 
Sattentau et al., 1989) and this also could be the case for V hh  fragments.
Finally, the isolation of a unique anti-id that exactly mimics a conserved epitope 
of HIV-1 might be too technically difficult. The internal image of bl2 could have 
been under-represented in the library against which the selections were performed. 
The library has a normal size for isolations of anti-bl2 V hh  fragments (109 CFU/ml, 
Dr. Hans de Haard, personal communication) but could have been too small to 
successfully isolate the anti-Idp of bl2.
Regardless, the five V hh  fragments generated in this study could be useful for 
screening sera from patients to evaluate the presence of b 12-like NAbs.
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Chapter 6 
Summary and general discussion
The overall focus of this thesis was to analyse humoral immunity to HIV-1.
In the first part of this thesis, the role of complement in HIV-1 inactivation using 
sera from patients with acute infection was investigated. In the absence of 
complement, NAbs were detected between 3 and 9 months POS. In the presence of 
complement, CMI was detected as soon as 9 days POS, for both autologous and 
heterologous viruses, concomitantly with the detection of CTL. Characterisation 
showed that the classical pathway, triggered by anti-gpl20 IgG and possibly anti- 
gpl20 IgM, was involved. Although CMI was tested with some MAbs, the nature of 
the epitopes involved in CMI has not been thoroughly investigated. If non-NAbs can 
inactivate HIV with complement in vivo, either directly or by stimulating phagocytes, 
the early humoral response could represent another immune pressure from which HIV 
has to escape. Hence, triggering an immune response against epitopes involved in 
CMI (if they are specific) could provide an alternative strategy to vaccine design 
against HIV. It will be equally important to rule out in vitro the possibility that non- 
NAbs with complement enhance HIV infection of FDCs or of phagocytes such as 
macrophages which express complement receptors at their surface. In vitro studies 
exploring the hypothesis of complement-mediated antibody-dependent enhancement 
of HIV early in infection might clarify if such phenomena could happen in vivo. Early 
non-NAbs, in association with complement, could play a more important role in HIV 
infection than initially thought.
The second part of this thesis explored the possibility of eliciting anti-HIV-1, bl2- 
like NAbs based on an anti-idiotypic approach. Non-classical llama V h h  fragments 
were selected by phage display against bl2 in order to isolate a mimic of the bl2 
epitope on HIV-1. The anti-bl2 V h h  fragments isolated were specific to bl2 as 
shown by ELISA and inhibited bl2 neutralisation in vitro but the immunisation of 
rabbits and rats with V h h  conjugated to KLH did not lead to the generation of a cross- 
neutralising bl2-like Ab response against HIV-1. These anti-bl2 V h h  fragments 
could be useful for screening of anti-HIV sera to investigate the presence and the 
occurence of b 12-like Abs against HIV in vivo.
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APPENDICES
C’ H IC’
Replicate 1 90 72
Replicate 2 70 96
Replicate 3 65 92
Replicate 4 90 60
Replicate 5 90 72
Replicate 6 73 70
Ex 478 460
n 6 6
~x 80 76
Ex' 38 654 36 548
(& 0' 230 400 211 600
(Ex)'/n 38 400 35 267
Ed'= E x '-  ((Ex)2/n) 254 1281
a2= E < //n-l 50.85 256.2
ad ' = a i'/n l + a22/n2 51.16
ad 7.15
t =(xi +X2)/ od 0.559
The t value for 6 degrees of freedom is 2.45 for a p value of 0.05. The t value found is 
0.559, below 2.45. Therefore, for this example, there is no significant difference 
between the data obtained in the presence (C) and the absence of complement (HIC).
Appendix 1. Example of the t- test calculations used for used for statistical 
analysis.
The data were obtained for patient MM27 in association with autologous serum at day 28 
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Logarithmic dilution of Vhh fragments
Appendix 2. Titration of purified VHH fragments against bl2 by ELISA.
Purified VHH fragments, lacking the Myc tag at their C-terminus, were serially diluted in PBS 
and were tested for binding to b l2  by ELISA. The VHH fragments were tested in uniplicate.
positive
Logarithmic dilution of Vhh fragments
Appendix 3. Titration of purified VHH fragments against 2G12 by ELISA
Purified VHH, lacking the Myg tag at their C-terminus, were serially diluted in PBS and were 
tested for binding to 2G12 by ELISA. The VHH fragments were tested in uniplicate. 2G12 
was detected by an anti-human IgG conjugated to HRP (positive control)
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